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Abstract
Burkitt’s lymphoma is a human B cell lymphoma which carries a characteristic 
translocation resulting in c-myc deregulation due to juxtaposition of an 
immunoglobulin locus. There is a strong association between endemic Burkitt’s 
lymphoma (eBL) and Epstein Barr virus (EBV). EBNA-1 is the only FRY 
latent antigen consistently expressed in eBL biopsies. Although tissue culture 
assays have not attributed any oncogenic activity to EBNA-1, two lines ofEp 
EBNA-1 transgenic mice succumb to monoclonal B cell lymphoma (Wilson 
and Levine, 1992, Wilson, Bell and Levine, 1996).
The experiments described in this thesis were designed to explore what 
cellular factors contribute to Ep EBNA-1 induced lymphomas.
The latency and penetrance of the phenotype are different between the t vo 
Ep EBNA-1 transgenic lines; 100% of line 26 mice succumb to lymphoma in
4-12months, 43% of line 59 mice succumb to lymphoma by 2 years of age. An 
analysis of the RNA expression of the transgene has identified compfex 
patterns of expression in both lines, with distinct differences between the 
lines.
EBNA-1 is a functionally pleiotropic protein. The DNA binding activity of 
EBNA-1 is required for its essential role in viral DNA replication during 
latency, and also for its activity as a transcriptional transactivator. EBNA-1 
DNA binding activity has been detected in line 26 tumour samples, but not in
1
line 59 spleens, although the level of protein detected by Western analysis is 
higher in line 59 samples than in line 26 samples (Wilson and Levine, 1992). 
This may indicate that the level of EBNA-1 DNA binding activity is an 
important determinant of oncogenicity.
Given that all the tumours in both lines are monoclonal, an attempt has been 
made to identify which oncogenes synergise with EBNA-1 in tumourigenesis. 
Several lines of evidence are strongly suggestive of a co-operation between 
EBNA-1 and deregulated c-myc in tumourigenesis, indicating that EBNA-1 
may play a direct role in the pathogenesis of Burkitt’s lymphoma.
2
Chapter 1
Introduction
1.1 Epstein Barr Virus and Human Disease
Epstein Barr Virus (EBV) is a human gamma herpes virus which is highly 
prevalent in all communities (for review see Epstein and Achong, 1986). The 
majority of people become infected before the age of 25. In children, initial 
infection is largely asymptomatic. Primary EBV infection begins in the pharyngeal 
epithelium, which is permissive for viral replication. From the epithelium the virus 
spreads to the subepithelial B lymphocytes where latent infection is established. 
After primary infection the virus persists for life within the host.
EBV causes a wide spectrum of acute and chronic infections in normal and 
immunocompromised individuals (Khanna et a l , 1995 and references therein) . 
Primary EBV infection is the usual cause of infectious mononucleosis (glandular 
fever). The virus is also tightly associated with a number of human malignancies 
including; endemic Burkitt’s lymphoma (eBL), nasopharyngeal carcinoma, and the 
lymphomas to which immunosuppressed individuals are prone. Recently it has 
become apparent that there is a strong association between EBV and nasal T cell 
lymphomas (Meijer et al., 1996). The potential involvement of the virus in a
3
number of other clinical syndromes has been proposed. These include Hodgkin’s 
disease, chronic mononucleosis, an X-linked lymphoproliferative syndrome 
(Duncan’s syndrome), oral hairy leukoplakia in AIDS patients and other epithelial 
malignanciesincludingcarcinomaof the parotid gland (Khanna et al., 1995).
The EBV genome is a double stranded DNA molecule of 172kbp, the B95-8 
prototype of which has been completely sequenced (Baer et a l , 1984). (Figure 
1.1). Although most of the early and late lytic infection genes show consistent 
homology in different herpes viruses, the latent genes and a few lytic infection 
genes show no homology to other herpes virus genes. During lytic infection a large 
number (more than 80) of virus specific RNA species are expressed.
Normal, resting human B-lymphocytes infected in vitro with EBV are transformed 
into permanent lymphoblastoid cell lines (LCLs). These cell lines provide 
evidence of the ability of EBV alone to induce indefinite B-cell proliferation and 
provide a model system for viral latency. The virus is maintained as a multicopy 
episome. By contrast to lytic infection, in latent infection only eight viral protein 
encoding genes are expressed (Kieff and Liebowitz, 1990). Six of these encode 
EBV nuclear antigens [EBNA-1, 2, 3A, 3B, 3C and Leader Protein (alternatively 
known as EBNA-1, 2, 3, 4, 6 and 5 respectively)]. The other two genes encode 
latent membrane proteins [LMP 1 and LMP 2 (A and B)(altematively known as 
LMP and TP (1 and 2) respectively)].
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1.1
In addition two small untranslated RNAs (EBER1 and EBER2) are expressed. An 
unusual set of 3’ coterminal spliced mRNAs transcribed through the BamHI A 
fragment of the virus were initially detected at high levels in nasopharyngeal 
carcinoma cells and subsequently found to be present at low levels in some 
latently infected B lymphocytes (Smith et aL, 1993). Recently these transcripts 
have been shown to encode one or more proteins that are expressed in latently 
infected cells and in tumour tissue (Fries etal., 1997).
However, different forms of EBV latency also exist (Klein, 1989). (Table 1.1). In 
biopsy samples from nasopharygeal carcinomas only EBNA-1, LMP1 and 2 and 
the EBERS are expressed (Brooks et al., 1992). Burkitt’s lymphoma biopsy cells 
can also be maintained in culture. In their initial state these cells express only 
EBNA-1 and the EBERs (Rowe et al., 1987). Certain stimuli can induce the 
expression of the other latent antigens, this is associated with a phenotypic change 
in the cells which become more like LCLs in appearance. An analysis of latent 
gene expression in peripheral blood lymphocytes has identified an EBNA-1 only 
pattern of latent gene expression like latency I (Qu and Rowe, 1992). A further 
EBV ‘latency program’ has been identified in vivo in resting Bcells, where 
LMP2A is the only latent antigendetectably expressed (Miyashita etal., 1997). 
EBNA 2 has been shown to play a central role in B cell transformation 
(Hammerschmidt and Sugden, 1989, Cohen ef a l, 1989, Kempkes et al., 1995). It 
is expressed together with EBNA 5 prior to the expression of other viral genes 
after infection of B cells, and acts as a transcriptional activator of latent viral and
7
cellular genes (eg CD21, CD23 and c-fgr) (Calendar et a l, 1987, Wang etal. 1987, 
Abbot et al. 1990, Cordier et a l, 1990, Fahraeus et a l 1990, Ghosh and Kieff, 
1990, Knutson, 1990, Sung etal. 1990, Woisetschlager et a l, 1991, Zimber-Strobl 
et al., 1991,1993, Jin and Speck, 1992, Ling et al., 1993, Laux et a l, 1994, 
Meitinger eta l, 1994). EBNA2 transactivation has been shown to be mediated via 
an interaction with a DNA binding protein called CBF1 or RBP-Jk which serves
to target EBNA2 to DNA (Zimber-Strobl et al., 1994). The similarities in 
mechanism and outcome between this interaction and the interaction of CBF1 and 
the intracellular domain of the receptor Notch 1, led to a model in which EBNA-2 
mimics constitutive Notch signaling (Hseih et a l, 1996, 1997). A number of 
tumours have been identified in which mutation of Notch family genes is thought 
to result in constitutive Notch signalling (reviewed in Wilson, 1997). By analogy 
EBNA-2 may have similar oncogenic action.
LMP 1 has potent transforming activity (Wang et a l , 1985, Baichwal and Sugden, 
1988, Wilson et al., 1990, Hu et al., 1993, Fishraeus et al., 1990). Expression of 
LMP 1 effects changes in expression of numerous cellular genes including 
upregulation of CD40, CD23 and cell adhesion molecules such as CD1 la, CD54 
and CD58, and downregulation of CD 10, CD77, insulin-like growth factor 
receptor type 1 and possibly also the recombination activating genes 1 and 2 
(RAG 1 and RAG 2) (Wang e ta l,  1988, Wang etal. 1990, Peng and Lundgren, 
1992, Fahraeus et al., 1992, Kriauciunas et a l , 1993, Kuhn-Hallek et a l, 1995).
8
LMP 1 expression may also induce the expression of Bcl-2 and this could be one 
mechanism by which the protein inhibits cell death (Henderson et a l, 1991, Finke 
et al. 1992). The mechanism of action of LMP 1 is beginning to be elucidated. 
Many of the actions of LMP 1 may be exerted through activation of the NF-kB
transcription factor (Laherty et a l, 1992, Hammerskjold and Simurda, 1992). 
Current evidence suggests that this effect is mediated by usurption of a cellular 
signalling pathway of the tumour necrosis factor (TNF) pathway (Mosialos et a l, 
1995, Sandbegef al, 1997).
Both EBNA 2 and LMP 1 act to upregulate cellular expression of Bel 2. In 
addition, it has also recently been shown that EBNA 4 can upregulate Bel 2 
expression (Silins and Sculley, 1995).
Whilst LMP 1 has demonstratable activity in several assays as an oncogene, this 
is not so for the other latent genes, even though some (EBNA-1, 2, 3, 6 and LMP- 
1) are required for transformation of B cells in culture by EBV (Hammerschmidt 
and Sugden, 1989, Mannick et a l, 1991, Swaminathan et a l, 1991, Allan et a l, 
1992, Tomkinsoneta l, 1993, Kaye e ta l,  1993, 1995). EBNA-1 particularly has 
not been reported to act as an oncogene in tissue culture assays. However, given 
that EBNA-1 is essential for viral DNA replication, its role in B cell 
transformation cannot be tested using the deletion/recombinant virus approach 
utilised in assessing the role of the other latent proteins. Nevertheless, the 
oncogenic potential of EBNA-1 has now been clearly revealed in vivo, since Ep
9
EBNA-1 transgenic mice are predisposed to B cell lymphoma (Wilson and Levine, 
1992, Wilson, e ta l, 1996).
1.2 Burkitt’s lymphoma
Burkitt’s lymphoma (BL) occurs throughout the world. It is one of the most 
frequent cancers in African children (endemic BL). In Europe and the USA it 
represents less than 3% of childhood cancers, but in all regions it represents a 
significant proportion of malignant non-Hodgkin’s lymphomas (30-40%). BL is a 
malignant lymphoma comprised of a clonal population of undifferentiated 
lymphoid cells.
Malaria is thought to be a contributing factor in endemic BL. The high incidence of 
BL occurs in regions where malaria is also prevalent (equatorial Africa and New 
Guinea). It has been proposed that the immunosuppression resulting from malarial 
infection increases the likelihood of BL development. There is a strong association 
between BL and EBV. More than 95% of endemic BLs are EBV genome positive 
(Lenoir and Bomkamm, 1986), although less than 1% of the patients’ total 
circulating B cell pool is detectably infected with EBV (Moss et a l, 1983). The 
association of the virus with sporadic BLs is less clear. Only approximately 15% 
of sporadic cases are EBV positive. However, integrated viral DNAs have been 
detected in some sporadic tumours possibly suggestive of a wider involvement of 
EBV in the onset of sBL than previously suspected (Razzouk e ta l , 1996).
10
Human (Burkitt's Lymphoma)
8
Mouse (Plasmacytoma)
15 12 t( 12; 15)
Figure 1.2
Diagram illustating the c-rayc/immunoglobulin heavy chain locus 
translocations common to human Burkitt’s lymphoma and murine 
plasmacytoma
Figure 
1.3
Diagram
 
of 
the 
breakpoints 
in 
the 
im
m
unoglobulin 
heavy 
chain 
and 
c-m
yc 
loci in 
hum
an 
B
urkitt’s 
lym
phom
a 
and 
m
urine 
plasm
acytom
a. Com
m
on 
breakpoints 
are 
indicated 
by 
arrow
s; red- endem
ic 
BL, blue- sporadic 
BL, green- 
m
urine 
plasm
acytom
a. T
he 
position 
of 
the 
IgH 
enhancer 
is 
indicated 
by 
the 
yellow 
circle.
3  |
=3 n
O © =r n 
GO
3o
C /3o
3a>
0°
3o
c"r ©o=r
O
3o
©
'Vi
'VI
03r
X}
ST
C/3
3sao
&©
3
S 3
K)
3 “ M
C 2
3 3
03
3
m•
c
o _ s
©
—s JQ
o
•—©
3 a *
o e .
C/3
o
3
CD
5 '
3 *
©
*——> os
c s
3 n
o sr
c ss
C/3
<T> 3
O tmm=r on
O G
3 C/3o
1 / 3o
3
n>
N >
U>
U>
i!
Characteristic of BL is a translocation involving the c-myc locus on chromosome 8 
and one of the three immunoglobulin loci (reviewed in Cory, 1986). The most 
common translocation involves the heavy chain locus (IgH) on chromosome 14. 
In 10% of cases either of the light chain loci on chromosomes 2 and 22 are 
involved. (Figure 1.2). All of the translocatons result in the deregulation of c-myc 
expression. However the precise location of the breakpoints in the more frequent 
t(8; 14) translocation differs between sporadic and endemic Bis. (Figure 1.3). In 
sporadic BL the breakpoint on chromosome 8 occurs in the region of exon or 
intron 1 of c-myc. Within this region are elements which regulate the normal 
expression of c-myc, and their disruption leads directly to the deregulation of c- 
myc expression. In these translocations the breakpoint on chromosome 14 is most 
often within one of the switch regions of the immunoglobulin gene. Murine 
plasmacytomas carry a c-myc translocation very similar in nature to that seen in 
sporadic BL, in the majority of tumours the immunoglobulin heavy chain enhancer 
on chromosome 12 becomes juxtaposed with a truncated c-myc gene on 
chromosome 15. In endemic BL, the breakpoint on chromosome 8 occurs at some 
distance (kilobases) 5’ to the c-myc gene and within the constant or joining region 
at the immunoglobulin locus, such that the immunoglobulin heavy chain enhancer 
is on the same chromosome as c-myc. The difference in the site of breakpoint 
within the IgH locus may reflect the different stage of the cells involved in each 
tumour. Sporadic BLs appear to derive from cells involved in immunoglobulin 
class switching. The translocation in endemic BL may occur at the time of V-D-J
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joining ie. in more immature B-cells. The fact that sporadic BL cells are more 
advanced along the differentiation pathway is supported by the observation that 
sporadic but not endemic BLs secrete IgM. The exact signifcance of the 
differences in the translocations and whether the presence of EBV is in any way 
related is unclear.
The precise role of EBV in the development of endemic BL is not known. It may 
be that the virus is directly involved in the transformation of B cells, or that 
through immortalization of B cells the virus produces a pool of cells more 
susceptible to further oncogenic changes. The known transforming capabilities of 
LMP1 may be important in the development of the disease. Other latent antigens 
may also play a role. However, in EBV positive Burkitt’s lymphoma biopsies 
consistently EBNA-1 is the only viral antigen detectably expressed. If EBV plays 
a role in the maintenance of the tumour phenotype then this can only be through 
the action of EBNA-1 and/or the EBERs. However, tissue culture assays have 
shown that the EBERs are dispensible for transformation of B cells (Swaminathan 
e ta l, 1991). It may also be that EBNA-1 performs a critical function in the onset 
or progression of Burkitt’s lymphoma tumours.
14
1.3 EBNA-1
a. Viral Regulation o f  EBNA-1 expression
EBV adopts more than one form of latency in different cellular environments 
(reviewed in introduction section 1.1). EBNA-1 expression is consistent in all 
forms of viral latency; expression of the protein is essential for maintenance of the 
viral episome (Yates et al 1984, Rawlins et a l, 1985). The use of different 
promoters is one mechanism by which the virus controls its gene expression. 
During the early stages of infection in B lymphocytes, transcription of six viral 
nuclear antigens ( EBNA-1-6) is initiated from an early promoter (Wp). This is 
followed by a switch to an upstream promoter (Cp) (Woisetschlager et a l , 1989, 
1990). In LCLs latent gene expression is from Wp or Cp. Wp and Cp are mutually 
exclusive promoters. The large transcripts are alternatively spliced to yield the 
individual EBNA mRNAs. Recent evidence suggests that the expression of 
EBNA-1 may be important in the switching from Wp to Cp (Schlager et a l, 
1996). Cp activity is regulated by EBNA-1 and EBNA2. EBNA-1 binding to the 
multiple EBNA-1 binding sites in the family of repeats (FR) region of oriP leads 
to the upregulation of expression from Cp (Reisman and Sugden, 1986, Yates et 
a l, 1984) and an EBNA2 dependent enhancer is located in in the proximal region 
upstream of Cp (Sung eta l, 1992, Woisetsclager et a l , 1991).In latency I cells and 
NPCs the expression of EBNA-1 is from a distinct promoter located in the Bam 
HI Q region of the virus, designated Qp (Schaefers a l, 1995). EBNA-1 again has
15
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a role in the regulation of this promoter, however EBNA-1 binding to a region 
within BAM HI Q leads to downregulation of expression (Sample et at, 1992). 
These binding sites are located within the transcribed sequences and it has been 
postulated that the downregulation may involve EBNA-1 RNA binding. Another 
promoter, Fp, located immediately upstream of Qp was originally identified as the 
active promoter for EBNA-1 expression in type 1 latency. However, this 
promoter has subsequently been shown to be an exclusively lytic promoter (Lear 
e ta l , 1992, Schaefer et a l , 1995).
b. EBNA-1 Structure and Function
In the B95-8 strain of EBV EBNA-1 is a 641 amino acid protein. The amino and 
carboxy terminal domains of the protein are separated by 235 amino acids of Gly- 
Gly-Ala repeats (figure 1.1) (Baer et a l , 1984). The number of these repeat 
regions varies between different strains of the virus, so the total size of the protein 
varies between ~69 to 94 kDa. This repeat region is thought to be important in 
the ability of EBNA-1 to evade recognition by the host’s immune system. 
Insertion of the repeat region into EBNA-4 led to inhibition of Tcell recognition of 
the protein through disruption of peptide processing and presentation (Levitskaya 
e ta l , 1995).
EBNA-1 has an established role in the replication and maintenance of the viral 
episome through the latent origin of replication ori P. EBNA-1 and oriP are the 
only viral contributions needed to mediate viral DNA replication in latently
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infected cells (Yates et a l, 1985). Ori P consists of two regions containing 
multiple EBNA-1 binding sites. The region of dyad symmetry (DS) contains four 
EBNA-1 binding sites at which latent replication is initiated. Upstream of this is a 
repeat region, family of repeats (FR), containing 20 copies of the EBNA-1 binding 
site. In addition to its role in replication of the virus FR can act as a transcriptional 
enhancer in the presence of EBNA-1 (Reisman and Sugden, 1986). EBNA-1 binds 
to DNA as a homodimer, and this is essential for its activity both in replication 
and as a transcriptional transactivator (Polvino-Bodnar and Schaffer, 1992, 
Goldsmith eta l, 1993, Frappier eta l, 1994). Mutation and deletion analysis have 
determined that the portion of the protein required for these activities lies between 
aa460 and 607 (Figure 1.4). Crystallization of this region of EBNA-1 both bound 
and unbound to DNA has indicated that the DNA binding region is composed of 
two regions. The C-terminal core domain, comprising residues 504-604, is 
virtually identical in structure to the DNA binding and dimerization domain of the 
E2 protein of bovine papilloma virus, despite no sequence similarities. Residues 
461-504 comprise an N-terminal flanking domain (Barwell et a l, 1996, Bocharev 
e ta l, 1996).
Within the amino terminal region of the protein are a number of ‘RGG’ motifs 
which are thought to be important in RNA binding. EBNA-1 has been 
demonstrated to bind RNA in vitro although no specificity of binding is apparent 
(Snudden eta l, 1994).
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No enzymatic activities have been attributed to EBNA-1. A number of regions of 
the protein have been shown to be important for transactivation (figure 1.4) 
(Polvino-Bodnar et a l, 1988, Yates and Camiolo, 1988, Polvino-Bodnar and 
Scaffer, 1992).
EBNA-1 is phosphorylated on serine(s) in its carboxy terminal domain, but 
effects of phosphorylation on the protein’s activities have not been reported 
(Hearing and Levine, 1985, Frappier and O’Donnell, 1991).
An additional activity of EBNA-1 which is likely to be important particularly in 
replication is the ability to link regions of DNA to which it binds specifically 
(figure 1.4). Three separate regions of the protein can independently link DNA to 
which they are bound (Mackey eta l, 1995). Electron microscopy has shown that 
EBNA-1 bound to oriP links DS (region of dyad symmetry) and FR(family of 
repeats) looping out the intervening DNA (Yates e ta l,  1985).
Cellular factors have been identified which can bind to oriP in vitro (Wen et a l, 
1990, Zhang and Nonoyama, 1994). By analogy, there may exist sites in the host 
genome to which EBNA-1 can bind in vivo.
The combination of DNA and RNA binding activities with the transactivation 
and repression capabilities provide EBNA-1 with great potential to disrupt 
cellular gene regulation.
19
1.4 Tumourigenesis and Transgenic Mouse M odels
It is now generally accepted that cancers arise as the result of a number of genetic 
or epigenetic changes (reviewed in Hunter, 1991). The progression from normal to 
cancerous cell involves a series of events which allow the cell to evade the usual 
controls on proliferation. The specific nature of the changes involved varies 
greatly between different tumours. However the effects of the changes fall into 
classes common to the majority of tumours: acquisition of growth factor 
independence, ability to ignore restraining signals, escape from immunological 
surveillance, induction of angiogenesis, breach of surrounding tissues and 
metastatic invasion. Genes identified as having oncogenic potential encode 
proteins of widely varying function, from cell surface receptors and cytokines to 
nuclear transcription factors. The stages in the development of different cancers 
are similar (figure 1.5). Haemopoietic neoplasms may require fewer steps given 
that the cells are inherently migratory.
Transgenic systems provide a powerful tool for the analysis of the effects of 
specific genetic changes in vivo. The ability to investigate pre-neoplastic changes 
in cells allows the investigation of the process of tumourigenesis in discrete stages. 
This is an advantage over analysis of human tumour biopsies or cell lines where 
only the end point is available.
The inactivation of specific genes by homologous recombination can be used to 
assess candidate tumour suppressor genes. Introduction of mutated or 
inappropriately expressed genes allows assesment of their oncogenic potential.
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Transgenic mouse models for many types of cancer now exist. Of specific 
relevance to this work are a number of models of haemopoietic malignancies 
(reviewed in Adams and Cory, 1991).
Characteristic of human Burkitt’s lymphoma is a translocation in which the c-myc 
gene is linked to an immunoglobulin locus (reviewed in introduction section 1.2). 
Transgenic mice enabled direct testing of the hypothesis that deregulated c-myc 
expression is oncogenic (Adams et a l, 1985). E\i-c-myc transgenic mice (the
transgene consists of the immunuglobulin heavy chain enhancer, Ep, linked to the
c-myc gene) develop monoclonal, nodal pre-B or B cell lymphomas. However, it is 
clear that the structure of the transgene has a strong bearing on the accuracy o f the 
disease model (reviewed in Wilson, 1997). A transgenic model even closer to BL in 
phenotype has been generated through the introduction of a large (220kb) IgH/o 
myc translocation region carried on a yeast artificial chromosome (YAC) (Butzler 
et al , 1997). These mice also succumb to monoclonal B-cell lymphoma at an 
early age, but the tumours in these mice arise at non-nodal sites and consist of 
sIgM+ B cells.
In the assessment of the oncogenic potential of genes, the ability to direct 
transgene expression in specific cell types or developmental stages is important. A 
given gene may be highly oncogenic in one cell type, but have little observable 
effect in another.
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In developing a disease model it is critical that the gene of interest is linked to 
appropriate expression control sequences. The immunoglobulin heavy chain 
enhancer (Ep) has been used to direct the expression of a number of genes in both
B and T cells. Whilst Ep-c-myc mice develop B cell lymphomas (Adams et
a l, 1985), Ep N ras mice succumb to T cell lymphomas (Harris et a l, 1988) and
Ep H ras mice do not develop lymphomas but do develop lung adenocarcinomas
(Sudaeta l, 1987), presumably due to some sequence within H ras which directs 
expression in lung tissue. Varying the regulatory sequences attached to a transgene 
allows the investigation of effects of expression in different cell types, however 
cellular sequences flanking the transgene insertion point can modify the pattern of 
expression.
In addition, in transgenic models the strain background of the animals can have a 
significant bearing on the observed phenotype. On a C57BL/6, SLJ or BALB/c 
background Ep-c-myc transgenes provoke B lymphoid tumours almost
exclusively. However, in C3H/HeJ mice the transgene provokes predominantly T 
lymphomas (Yukawa et a l, 1989). The strain difference may reflect varying 
stromal environment.
Analysis of the pre-neoplastic state of transgenic tissues can yield information 
about the mechanism of action of an oncogene. In pre-tumourous Ep-c-myc mice
there are greatly elevated numbers of cycling early B lymphocytes (Adams and 
Cory, 1991, Morgenbesser and DePinho, 1994). This observation suggested that
23
c-myc expression favours proliferation over differentiation. Support for this 
theory is provided by the recent observation that Myc protein induces the 
expression of a key regulator of G1 cell cycle progression (Galaktionov et a l, 
1996) and represses the expression of a growth arrest gene(Marhin etal., 1997). 
Transgenic models of neoplasms have provided support for the multistep model 
of tumourigenesis. The tumours which develop in E\i-c-myc transgenic mice are all
monoclonal and arise in a stochastic fashion. The E\i-c-myc transgene is expressed
before birth in the vast majority of B lineage cells. Calculation from the rate of 
tumour onset suggests that a tumourigenic clone typically arises after 1010 
divisions o fB  lymphoid cells (Harris e ta l,  1988). Given this low frequency at 
least one precise, or more likely several, additional genetic changes are required to 
take a B lymphoid cell aberrantly expressing c-myc on to becoming tumourigenic. 
One of the greatest advantages of the use of transgenics in the study of 
oncogenesis is the ability to begin to address the sequence of genetic changes 
required for the development of a tumour (described in section 1.6).
1.5 Ep EBNA-1 Transgenic mice
A number of Ep EBNA-1 transgenic mouse lines have been generated by Joanna
Wilson (Wilson and Levine, 1992, Wilson, et al., 1996). The transgene contains 
the EBNA-1 coding region linked to the polyomavirus early promoter and the
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mouse immunoglobulin heavy chain enhancer (Wilson et al, 1990), designed to 
enhance expression in B lymphocytes (figure 1.6). Mice of two Ep, EBNA-1
transgenic lines (designated line 26 and line 59) succumb to monoclonal B cell 
lymphoma, demonstrating that EBNA-1 is oncogenic in vivo.
In both line 26 and line 59 there are one or two copies of the transgene, and 
EBNA-1 protein is detectably expressed within lymphoid cells. Two other Ep
EBNA-1 transgenic lines are also relevant to this study, designated line 60 and line 
61. Line 60 harbours a single rearranged transgene in which the EBNA-1 coding 
region is interrupted. Line 61 harbours multiple copies of the transgene (~ 10), 
with an inheritance pattern indicative of integration on the Y chromosome. There 
is no detectable expression of EBNA-1 protein in the spleens of animals of line 60 
or 61, and neither line displays any pathological phenotype (summarized in table 
1.2).
Although mice of both line 26 and line 59 succumb to monoclonal B cell 
lymphoma, the penetrance and latency of the disease is very different in each line. 
Whilst 100% of line 26 mice succumb to lymphoma between the ages 4-12 
months, 43% of line 59 mice sampled at 2 years of age had neoplastic lesions in 
the spleen. This may be related to the different expression pattern of the transgene 
in each line (table 1.2 and chapter 3) or may be due to differences in the 
oncogenicity of the protein expressed in each of the lines (chapter 5). It may be 
that there are particular forms of EBNA-1 which are more oncogenic. In most
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normal peripheral blood cells 2-3 subtypes of EBV are detected which have 
sequence differences in EBNA-1. In BL only a single subtype has been observed 
in each tumour and one specific subtype (V-leu) was found only in BL cells 
(Bhatia e ta l, 1996).
Expression of EBNA-1 is not sufficient for tumourigenesis; the lymphomas in Ep
EBNA-1 transgenic mice are monoclonal. Identification of the cellular factors 
which co-operate with EBNA-1 may elucidate the mechanism by which EBNA-1 
acts as an oncogene and provide an insight into the development of EBV 
associated lymphomas (chapter 6).
1.6 Identification of Synergising oncogenes in Tumourigenesis in 
Transgenic mice
a.Genomic rearrangements
Consistent DNA rearrangements in tumours in a number of transgenic mice may 
indicate co-operation with the transgene in the tumourigenic process. M ost 
plasmacytomas in E\i-abl transgenic mice carry a c-myc rearrangement
(Rosenbaum eta l, 1990), as do many of the lymphomas arising in E\i-bcl-2 mice
(McDonnell e ta l, 1989, Strasser e ta l, 1993) indicative of the ability of c-myc to 
synergise with a number of other oncogenes.
Rearrangements at the chromosomal level; translocations, deletions, duplications, 
can be detected through karyotyping. Southern blotting can be used to detect
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rearrangements at the gene level. Single stranded conformational polymorphism 
(SSCP) analysis can be used to screen for point mutations within a specific locus 
of interest. Whilst this approach can be used to identify common genetic 
alterations within tumours, one cannot then assess what role these alterations play 
in the process of tumourigenesis.
b.Transgenic Cross Breeding
Synergy between two candidate oncogenes can be assessed directly by cross 
breeding transgenic lines. Changes in the rate of onset, penetrance or nature of 
tumours which develop are indicative of a co-operation between the transgenes in 
oncogenesis. This approach has demonstrated the synergy between c-myc and bcl- 
2 (Strasser etal., 1990, introduction section 1.8) and between c-myc andpim-1 in 
oncogenesis(Verbeeke^al, 1991, introduction section 1.8).
c.Proviral insertional mutagenesis
The Anton Bems laboratory has developed a powerful technique for the 
identification of synergising oncogenes (Bems, 1988). On post-natal infection in 
the mouse, Moloney murine leukaemia virus (MoML V) proviral insertions occur 
relatively randomly throughout the genome. Some insertions may confer a growth 
or survival advantage to a cell through the (in)activation of cellular genes. The 
viral presence also serves to “tag” the gene. Using MoMLV infection of mice
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transgenic for one oncogene allows identification of genes which synergise with 
the transgene in tumourigenesis. Such an approach further demonstrated the strong 
synergy between pim-J and myc family members in oncogenesis (reviewed in 
Bems et a l, 1994). Infection of Ep pirn-1 mice greatly accelerated T lymphoma
onset and every tumour bore a vims near the c-myc or N-myc genes.
This approach can also be used to identify candidate genes involved in later stages 
of tumour progression, such as angiogensis and metastatic potential, by comparing 
genetic alterations in primary and secondary tumours, for example two genes 
{tiam-1 and frat-1) have been identified which seem to be involved in progression 
in T-cell lymphomas (Habets e ta l , 1994, Jonkers e ta l , 1997).
d.Chemical induction o f  tumours
Chemicals can be used to induce tumours. In susceptible strains of mice 
intraperitoneal injection of the mineral oil pristane induces plasmacytomas 
(Anderson and Potter, 1969). Although E[i-c-myc transgenic mice do not develop
spontaneous plasmacytomas, young E\i-c-myc mice treated with pristane develop 
plasma cell tumours as well as lymphoma (Harris et a l , 1988). Plasmacytomas 
arose much faster in E\i-c-myc transgenic mice than in pristane primed BALB/c or
NZB mice suggesting that the rate limiting step in tumourigenesis in the latter 
strains is the chance occurrence of a myc translocation. IL-6 is produced by 
macrophages in response to pristane (Van Snick et al., 1988) and is required for
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plasmacytoma growth. The macrophage ridden, IL-6 enriched granuloma induced 
by injection of the mineral oil may nurture the nascent plasmacytoma cell.
The incidence of T lymphomas in Eix pim-1 mice is dramatically enhanced if the
mice are treated with the carcinogen N-ethyl-N-nitrosourea (ENU) (Breuer et al.,
1989). ENU is a mutagen, all ENU induced tumours expressed high levels of c-myc 
RNA, although no evidence of myc mutation was found.
A clear disadvantage of this approach over viral insertional mutagenesis is that the 
precise mechanisms of the chemical induction are not known.
1.7 Mechanism of Action of EBNA-1 as an Oncogene
The role of EBNA-1 in the regulation of viral RNA expression and in viral DNA 
replication are well established, however the effects of the protein on the cellular 
machinery are less clearly defined. EBNA-1 may exert its oncogenic effect through 
binding to cellular DNA sequences and modifying transcription, through effecting 
the stability or translation of mRNAs through RNA binding, through protein- 
protein interactions or through a combination of activities. It may be that there are 
particular forms of EBNA-1 which are more oncogenic (Bhatia et al., 1996, 
discussed in introduction section 1.5).
If EBNA-1 plays a role in Burkitt’s lymphoma, it could act in a number of 
different ways;
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i. EBNA-1 may act through deregulated c-myc expression  
EBNA-1 could exert its oncogenic action through affecting the rate at which 
translocations occur, or through exerting influence over the expression of a 
translocated c-myc gene. The nature of the translocations detected in endemic and 
sporadic BL are different (discussed in section 1.2), EBNA-1 may be a factor in 
this. In this work some potential targets of EBNA-1 have been identified which 
might affect the process of translocation in B-cells;
• 1. RAG 1 and 2
The recombination activating genes 1 and 2 (RAG land 2) are the only lymphoid 
specific genes required for V(D)J recombination of immunoglobulin loci (Oettinger 
etal., 1990). Usually these genes are expressed in a narrow window of precursor 
lymphocyte development. However, EBNA-1 expression induces the expression 
of RAG 1 and 2 in cell lines (Srinivas and Sixbey, 1995). Identification of 
heptamer-nonamer recombination signal sequences at the breakpoint regions of 
several 8; 14 translocations in BL cells have led to the speculation that the 
translocations arise due to aberrant recombination (Haluska et al., 1987). The 
inappropriate expression of RAG1 and 2 induced by EBNA-1 could lead to a 
greater incidence of aberrant translocations.
• 2. LR1
LR1 is a sequence specific DNA binding protein, identified as a potential regulator 
of immunoglobulin isotype switch recombination in activated B lymphocytes 
(Williams and Maizels,1991). There are multiple binding sites for the protein 
within the heavy chain intronic enhancer (Ep) and also in the G rich switch
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regions. In addition there are a number of binding sites for LR1 close to and within 
the c-myc gene. In vitro analysis has indicated that at least one of these sites has a 
role to play in c-myc expression (Brys and Maizels, 1994). Mutation of one site 
close to the PI promoter of c-myc led to a 5.5-fold decrease in reporter gene 
expression in the EBV positive BL cell line Raji, and a 3.8-fold decrease in 
reporter gene expression in the EBV negative B cell lymphoma cell line BJAB. 
This evidence has led to the speculation that LR1 may have a dual role to play in 
transcription and recombination. Coupled with the distribution of LR1 sites 
within the immunoglobulin and c-myc loci it is tempting to postulate a role for 
LR1 in the aberrant translocations and deregulated c-myc expression in BL.
LR1 contains two polypeptides, one of 106kDa and one of 45kDa. The 106kDa 
component has recently been identified as nucleolin (Hanakahi et al., 1997), an 
abundant protein found in nucleoli, the N terminus of which is homologous to 
histone HI. Nucleolin is thought to play a role in determining the architecture of 
the DNA within the nucleolus and may play an analogous role as a component of 
LR1 inB cells.
LR1 has been identified as a key regulator of transcription from the Fp promoter 
of EBV (Bulfone-Paus et al., 1995). It follows that enhanced LR1 activity in B 
cells might be beneficial to the virus. One action of EBNA-1 may be to increase 
the levels of active LR1 within B cells, thus both enhancing viral transcription and 
contributing to c-myc deregulation.
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ii. EBNA-1 may co-operate with deregulated c-myc expression.
Identification of which oncogenes synergise with EBNA-1 in tumourigenesis could 
be important in determining whether EBNA-1 acts through or in conjuction with 
c-myc in tumourigenesis (section 1.8). If EBNA-1 acts through c-myc, then it 
might be expected to co-operate with oncogenes with which c-myc synergizes. If 
the action of EBNA-1 is through some other mechanism then it might be expected 
to co-operate with deregulated c-myc.
1.8 Potential co-operating factors in EBNA-1 induced tumourigenesis
a. c-myc
The c-myc gene has an established role in lymphoid tumourigenesis. Of particular 
relevance to this study, the characteristic translocations of human BL link the gene 
to an immunoglobulin locus. Given the strong association between EBV and BL , 
c-myc is a likely candidate for co-operation with EBNA-1 in tumourigenesis.
Myc protein is a nuclear transcription factor, the expression of which is tightly 
regulated in normal cells. To exert its effects Myc protein must form a 
heterodimeric complex with Max, like Myc another basic region helix-loop-helix 
leucine zipper protein (Amati et al., 1993). Deregulated c-myc expression is 
common in multiple tumour types. The potency of this oncogene is likely to be 
associated with its role in the progression of the cell cycle (reviewed in 
Henriksson and Liischer, 1996). However, the role of Myc extends beyond the
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induction of the cell cycle, Myc expression is maintained in proliferating cells and 
down regulated as cells become differentiated. In addition, where there is a block 
to cellular proliferation, deregulated c-myc expression is a potent inducer of 
programmed cell death (apoptosis) (Evan etal., 1992). Few transcriptional targets 
of Myc have been identified. However one, the cell cycle phosphatase cdc-25A, 
may be an important effector of c-myc oncogenic activity (Galaktionov et a l , 
1996). Cdc-25A is essential for the transition from G1 to S phase of the cell cycle 
(Jinno et a l, 1994, Hoffman et al., 1994). cdc-25A expression is stimulated by 
Myc, through My c/Max binding to elements in the cdc-25A gene. cdc-25A is itself 
a protooncogene, which like c-myc co-operates with Ha-ras in transformation of 
normal rodent fibroblasts (Galaktionov et al., 1995). In addition, Cdc-25A and 
Myc share the ability to induce p53-dependent apoptosis, and Myc driven 
apoptosis is inhibited by cdc-25A antisense oligonucleotides (Galaktionov et a l, 
1996). Myc dependent inhibtion of growth cycle arrest may be mediated through 
the repression of the growth arrest gene gadd45 (Marhin et a l, 1997). This may 
well contribute to the tumourigenic potential of transformed cells, through 
precluding their entering a growth arrested state.
c-myc is a member of a family of homologous genes. Two other members were 
identified through their involvement in human tumourigenesis (reviewed in Marcu 
e ta l, 1992). N-myc is commonly amplified in neuroblastomas, and L-myc in small 
cell lung carcinomas. All three genes elicit tumours when overexpressed in 
transgenic mice (reviewed in Morgenbesser and DePinho, 1994). The ability of the
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genes to induce lymphomas differs, with c-myc the most potent, then N-myc and 
then L-myc. c-myc expression is in part self regulated; Myc protein feeds back to 
down regulate its own expression (reviewed in Marcu et al ,1992). In tumours 
generated in Ep N- or L-myc mice, no expression of endogenous c-myc was
observed (reviewed in Adams and Cory, 1991). This may indicate that negative 
crossregulation is operating and that N- and L-myc can substitute for c-myc 
function in vivo.
It may be that EBNA-1 acts through c-myc in lymphomagenesis by contributing 
to deregulation of its expression. The phenotype of line 26 bears a strong 
resemblance to that of ^E\n-c-myc transgenic mice (Adams et a l, 1985). As a
transcriptional transactivator it is conceivable that EBNA-1 may transactivate the 
c-myc gene, a regulator of the c-myc gene or a translocated c-myc gene. The exact 
nature of the translocations in EBV associated BL and sporadic BL are different 
(reviewed in section 1.2). EBNA-1 may have a causal role to play in the process 
of translocation, or the presence of EBNA-1 may allow for the selection for 
translocations which would not otherwise be oncogenic.
Although highly oncogenic, the deregulated expression of Myc proteins is 
insufficient to cause tumourigenesis. Indeed, no one oncogene has been found to be 
sufficient for a one step tumourigenic conversion of a normal cell. A number of 
oncogenes which co-operate with myc genes in tumourigenesis have been 
identified (discussed in section 1.8b-d). If the oncogenic action of EBNA-1 is
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through deregulation of c-myc expression then factors which co-operate with c- 
myc in tumourigenesis should also co-operate with EBNA-1. If EBNA-1 co­
operates with c-myc then some factors which would otherwise synergise with 
deregulated myc expression in tumourigenesis may be redundant where EBNA-1 
is expressed.
b. bcl-2
The most common human lymphoma, follicular lymphoma, characteristically has 
a t(14;18) translocation, in which the bcl-2 gene and immunoglobulin locus are 
juxtaposed, leading to an upregulation of bcl-2 expression. Eji -bcl-2 transgenic 
mice display a polyclonal hyperplasia of non cycling follicular centre B- 
lymphocytes, which can progress to give rise to a long latency monoclonal 
malignant lymphoma (McDonnell eta l, 1989, 1990, 1991, Strasser e ta l, 1991). 
Overexpression of bcl-2 has been shown to promote cell survival and inhibit 
programmed cell death (apoptosis). bcl2 protein is localized mostly to the outer 
mitochondrial membrane, but also is found in other membranes. There is evidence 
that bcl-2 prevents apoptosis through acting in an antioxidant pathway 
(Hockenberry e ta l , 1993). bcl-2 belongs to a family of genes. Other members of 
the gene family play important roles in both positive and negative regulation of 
programmed cell death. The members of the Bcl-2 family can form homo and 
heterodimers. The pro-apoptic member Bad can dimerize with Bcl-2 and Bcl-xL, 
and if  overexpressed can counter their survival promoting effects. Similarly Bax 
can form heterodimers with both Bcl-2 and Bcl-xL. In transfected cells an excess of
Bax results in cell death, where Bcl-2 overexpression promotes cell survival. It is 
thought that the relative ratio of anti-apoptic dimers versus pro-apoptic dimers is 
important in determining the resistance of a cell to apoptosis. Post translational 
modifications also have a role to play in determining the effect of family members 
(reviewed in Gajewski and Thompson, 1996).
Transgenic cross breeding experiments have indicated a strong co-operation 
between c-myc and bcl-2 in tumourigenesis (Strasser et a l, 1990). Bitransgenic 
mice develop rapid onset tumours of a primitive haematopoietic cell type. If the 
oncogenic action of EBNA-1 is through deregulation of c-myc expression, then an 
equally strong co-operation between EBNA-1 and Bcl-2 might be predicted.
c. Pim-1
The pim-1 proto-oncogene was first implicated in T cell lymphomagenesis 
through its frequent activation by proviral insertion in murine MoML V induced T 
cell lymphomas (Cuypers e ta l,  1984). Although it has not yet been shown to 
have a clear role in human lymphomagenesis, over expression of pim-1 in Ep pim- 
1 transgenic mice induces T cell lymphomas in a dose dependent manner. Existing 
transgenic lines have relatively long tumour latencies, but the rate of 
tumourigenesis is greatly enhanced by mutagens able to activate collaborating 
oncogenes. Pim-1 is a cytoplasmic serine threonine kinase, but as yet it is not 
known in which signal transduction pathway it functions. There is evidence that 
Pim-1 may inhibit apoptosis and impair the differentiation of cells in which it is
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expressed. Pim-1 belongs to a family of genes, pim2 and pim 3 are highly 
homologous (reviewed in Allen and Bems, 1996).
Crossbreeding of E\i-c-myc and Ep pim-1 transgenic mice demonstrates a dramatic
synergy between these two oncogenes. Foetuses which express both transgenes 
succumb perinatally to lymphoblastic leukaemia(Verbeek etal., 1991). This co­
operation is further supported by proviral tagging experiments; pim-1 is 
frequently activated by MuMLV in Ep myc transgenic mice (Haupt et a l, 1991,
van Lohuizen et a l, 1991), and in Ep pim-1 transgenic mice in nearly all of the
tumours either c-myc or N-myc is activated by the integrated virus (van Lohuizen 
etal., 1989). This synergy with c-myc makes pim-1 a possible candidate for co­
operation with EBNA-1 in tumourigenesis
d. Other potential factors
The factors discussed in 1.7a-c above represent areas where this study has 
focussed, however this does not represent an exhaustive investigation of potential 
co-operating factors in EBNA-1 induced tumours.
Proviral tagging of Ep myc mice has identified a number of factors which co­
operate with myc in tumourigenesis, and therefore may also co-operate with 
EBNA-1. In addition to /?zm-/(discussed above), two other loci, bmi- l(or bla-1), 
and pal-1, are frequently activated by proviral insertion (Haupt et a l, 1991, van 
Lohuizen e ta l, 1991).
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Proviral insertions in bmi-1 lead to the overexpression of the gene. The bmi-1 gene 
encodes a protein with zinc finger structures which belongs to the polycomb 
family and which seems to be important in regulating the proliferation of a number 
of haematopoeitic cells throughout pre and postnatal life (reviewed in Bems et al, 
1994).
The pal-1 locus spans a region of about 50kb and contains a number of genes 
(Scheijene/a/., 1997). Most proviral insertions in the pal-1 locus lead to the high 
expression of one of these genes, gfi-1 (Schmidt et a l, 1996). gfi-l encodes a 
protein which functions as a transcriptional repressor, one target of which is the 
Bax gene, a ‘pro-death’ member of the bcl-2 family. In an IL2 dependent T cell 
line, IL2 withdrawal leads to an increase in Bax levels and subsequent apoptosis. 
However, if gfi-1 is overexpressed Bax transcription is repressed and cell death is 
retarded(Zom igelal, 1996, Grimes, To e ta l, 1996, Grimes, Gilks e ta l, 1996). 
Further in vivo oncogenic partners of c-myc have been identified through the use 
of transgenic cross breeding experiments. Yl-ras, K-ras and N-ras encode 
cytoplasmic G proteins which are involved in the relaying of stimulatoiy signals 
from the cell surface to the nucleus. Mutations o f K-ras are frequently involved in 
lung, ovarian, colon and pancreatic cancers. Mutations of N-ras are involved in 
leukaemias. Although Ep N -ras mice do not develop B lymphoid tumours,
myc/ras bitransgenic mice rapidly succumb to B lymphomas predominantly of 
early differentiation stages (Harris eta l, 1988).
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The abl gene encodes a tyrosine kinase, mutation of which is associated with a 
number of haematologic malignancies (reviewed in Konopka and Witte, 1985, De 
Klein eta l, 1988). Abelson murine leukaemia virus expresses a fusion protein (v- 
abl) which lacks the N terminal portion of the normal cellular abl gene product and 
has heightened tyrosine kinase activity. Ep v-abl transgenic mice develop 
plasmacytomas, the majority of which harbour a rearranged c-myc gene. 
Crossbreeding of Ep v-abl mice with Ep-c-myc mice results in rapid development
of oligoclonal plasmacytomas in the bitransgenic progeny (Rosenbaum et al.,
1990).
Translocation of the cyclin D1 (bcl 1) gene to an immunoglobulin locus is 
associated with some human lymphoid neoplasias. Cyclins and cyclin dependent 
kinases regulate the progression of the cell cycle. Ep cyclin D1 transgenic mice do
not develop lymphoid neoplasia. Only subtle alterations in the cycling behavior of 
B-cell populations are detected in the bone marrow of transgenic mice compared 
to normal. However, cross breeding of Ep cyclin-D1 mice with Ep N-myc or Ep L- 
myc transgenic mice demonstrates a high level of co-operation between cyclin D1 
and Myc in tumourigenesis (Lovec et al., 1994).
Mutations of the tumour suppressor gene p53 are common in a wide range of 
human cancers. In normal cells DNA damage and other cellular stresses activate 
the transcription factor p53 resulting in growth arrest or apoptosis. Loss of p53 
allows cells with unstable genomes (due to DNA damage) or in an abnormal
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environment (ie located in a place with limited survival factors) to evade p53 
induced apoptosis (reveiwed in Hall and Lane, 1997, Levine 1997). Homologous 
recombination has been used to generate mice that lack one or both copies of 
endogenous p53. Nullizygous mice all succumb to tumours of various types by 
the age of lOmonths. Heterozygous mice have a 50% incidence of cancer by the 
age of 18months; the cancers are predominantly lymphomas and sarcomas 
(Donehower et al., 1993). Mutations of p53 have been observed in a number of 
BL derived cell lines of both endemic and sporadic origin (Farrell et al., 1991). p53 
loss synergises with c-myc in T-cell tumourigenesis in CD2-myc transgenic mice 
(Blyth etal., 1995). Mutation or loss ofp53 could therefore have a role to play in 
EBNA-1 induced lymphomas.
Other EBV antigens could interact with EBNA-1 in tumourigenesis. Both LMP1 
and EBNA2 have been demonstrated to have oncogenic properties (reviewed in 
introduction section 1.1). Although EBNA-1 is the only EBV latent antigen whose 
expression is known to be consistently maintained in BL, other viral proteins may 
play a role in the initiation of tumourigenesis.
It is also concievable that the oncogenic action of EBNA-1 requires interaction 
with some completely novel proto-oncogene or tumour suppressor gene.
1.9 Complementation Groups of Synergizing Oncogenes in 
lymphomagenesis
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Combination of the results of a number of studies of oncogene synergy in 
lymphomagenesis suggests that there are three complementation groups of 
oncogenes involved in the initial stages of tumour development (Wilson, 1997) 
(figure 1.7). One group contains the myc family members, at least one major 
function of which in oncogenesis is to drive cells towards proliferation. The 
second group contains the pirn family genes, the exact function of which is not yet 
clear. The third group contains a number of genes which act to inhibit apoptosis, 
cell differentiation or senesence. For example, in MuMLV induced tumours in 
Ep-pim-1 transgenic mice deregulated c-myc and gfi-1 expression may be
concurrent in one tumour. However, c-myc and N-myc genes are never found to be 
co-activated in the same tumour cell clone and therefore these two genes constitute 
a complementation group. Similarly, simultaneous activation of gfi-1 and bmi-1 is 
rare(Bems e ta l , 1994, Schm idts a l, 1996, Scheijen e ta l, 1997).
MoML V falls into the third group because recent evidence suggests that the virus 
can promote cell survival through some other mechanism in addition to proto­
oncogene insertional activation (Pak and Faller, 1996). In addition viral infection 
does not show an appreciable tumour acceleration in either Ep blc2 mice or p53
null mice (Acton et a l, 1992, Baxter et a l, 1996). The placing of genes within a 
particular group does not necessarily represent functional redundancy of the 
members of that group (although this may be true of myc family members). 
Rather the genes within one grouping act in parallel pathways or at different
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Group 1 Group 2
N-myc
c-myc pim-2
pim-3L-myc
Group 3
Figure 1.7
Com plem entation groups in lym phom agenesis. Several oncogenes, p53 loss and M oM LV 
have been grouped according to their ability to synergise in lym phom agenesis in vivo  
(reviewed in introduction section 1.6, 1.8-9). For exam ple m yc  fam ily m em bers can synergise 
with p im - 1 or b c l-2 , but p53 loss and bcl-2  do not synergise. Not all com binations have been 
analysed. This work (chapter 6) was designed to address which com plem entation group, if any 
of these, EBNA-1 falls into. (Adapted fom W ilson, 1997).
points on the same signal transduction pathway. For example, some evidence 
suggests that p52> and bcl-2 serve as an effector and repressor function 
respectively of a common cell death pathway (Marin e ta l , 1994).
The mechanisms of co-operation between different groups are beginning to 
become apparent. Myc family members induce cellular proliferation, but in a non 
permissive environment can also induce apoptosis. Bcl-2 inhibits apoptosis, thus 
the inappropriate expression of both of these oncogenes could give rise to a cell 
which does not die in response to normal signals and is driven to proliferate. Both 
in vivo and in vitro experimentation have demonstrated the co-operation between 
c-myc and bcl-2 in cell transformation (Strasser et a l, 1990, Faniidi et a l, 1992, 
Wagner eta l, 1993). However the combination of these two oncogenes is still not 
sufficient for tumourigenesis as the tumours which develop are mono or 
oligoclonal.
Analysis of the co-operation of EBNA-1 with other oncogenes may shed light on 
the mechanism by which it acts in tumourigenesis.
1.10 Aims of this research
This research project has involved the analysis of Ep EBNA-1 transgenic mice to
elucidate how EBNA-1 acts as an oncogene.
Approaches:
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Chapter 3 Expression o f EBNA-1 in Ep EBNA1 Transgenic Mice 
A number of techniques have been used to analyse the expression of the Ep
EBNA-1 transgene at the RNA level. The aim was to assess whether the 
regulation of transgene expression is a contributing factor in the different latency 
and penetrance of the transgenic phenotype between line 26 and line 59.
Chapter 4 Cell Culture from Ep EBNA-1 Induced Lymphomas
Attempts have been made to generate cell lines from tumours in Ep EBNA-1
transgenic mice. This approach allows a more in depth analysis of the nature of 
the tumours. Through the down regulation of EBNA-1 expression in cell lines in 
vitro it may be possible to assess whether continuous EBNA-1 expression is 
required for the maintenance of tumour phenotype. Analysis of genetic changes in 
cell lines in vitro (for example through karyotyping) allows investigation of 
potential secondary factors in tumourigenesis.
Chapter 5 Protein DNA Binding Activity o f  EBNA-1 and LR1 in Ep 
EBNA-1 Transgenic Mice
EBNA-1 is a pleiotropic protein and it is not clear what functions of the protein 
are oncogenic. DNA binding is required for the action of EBNA-1 in both DNA 
replication and transcriptional transactivation. Given this, an investigation of the 
DNA binding activity detectable in line 26 and line 59 was undertaken to address 
whether the differences in phenotype between the lines reflected different protein 
DNA binding activities.
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LR1 was identified as a potential collaborator with EBNA-1 in tumourigenesis 
through its ability to contribute to c-myc deregulation and its implied role in c-myc 
translocations. However, at the time of this study the identity of the genes 
encoding LR1 were not known. To address whether LR1 plays a role in EBNA-1 
induced tumourigenesis, it was attempted to compare the DNA binding activities 
of LR1 protein in line 26 and line 59 samples.
Chapter 6 Co-operating Cellular Factors in Efi EBNA-1 Induced 
Lym phom as
Since EBNA-1 expression is insufficient to induce tumourigenesis in transgenic 
mice, a number of approaches have been used to identify synergising oncogenes. 
Particular emphasis has been placed on the role of Myc family members. 
Experimental approaches include: analysis of RNA expression patterns, screening 
for genomic rearrangements, plasmacytoma induction using pristane and transgenic 
cross breeding.
Chapter 2
Materials and Methods
2.1 Oligonucleotides
The oligonucleotides listed in table 2.1 were synthesised on an Applied 
Biosystems PCR Mate (departmental service). Oligonucleotides were removed 
from the column matrix and deprotected using the following protocol. The 
column was opened and the glass bead packing material poured into a Nunc 
2ml tube. 1ml of 30% aqueous ammonia was added and the tube incubated at 
room temperature for 1 hour. The tube was then vortexed, briefly centrifuged 
and the supernatant removed to a fresh Nunc tube. A further 1ml of 30% 
aqueous ammonia was added and the tube incubated at 50°C overnight. 
Ammonia stocks were stored at -20°C. As required aliquots of 
oligonucleotides were precipitated with one fifth volume of 10M ammonium 
acetate and 2 volumes of absolute ethanol. The precipitate was washed with 
70% ethanol and resuspended in distilled H20 or TE as required.
The oligonucleotides listed in table 2.2 were ordered from commercial 
suppliers as shown.
EBNA-1 sequence nucleotide numbers indicated are with reference to the 
sequence of the BamHI K fragment of Epstein Barr virus, which has a total 
size of 5055bps. The sequence nucleotide numbers for the immunoglobulin
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Oligonucleotide Oligonucleotide sequence (5 - 3 ) Description
EB1 A CCCTTCCTCACCCTCATCTCC EBNA-1 coding sequence 
nucleotides 2281-2301 (reference in 
text)
EB1 B GCTCTCCTGGCTAGGAGTCACG EBNA-1 coding sequence 
nucleotides 1843-1864 (reference in 
text)
EB1 C CCCCTCGTCAGACATGATTC EBNA-1 coding sequence 
nucleotides 380-400 (antisense) 
(reference in text)
EB1 D GAAT CAT GT CT G ACGAGGGG EBNA-1 coding sequence 
nucleotides 380-400 (sense) (reference 
in text)
EB1 E CTTAAATTCACCTAAGAATG EBNA-1 3’ sequence nucleotides 
2581-2600 (referencein text)
Py ORIF CTTTTTCTCCAGAGTAAGC Polyoma origin sequence nucleotides 
16-34 (referencein text)
Myc2 5’A ATGCCCCTCAACGTGAACTTC Murine c-myc exon 2 5’ primer 1 for 
SSCP (Bhatiae t a l ,  1993)
Myc2 5’B TTCCCTTGGGGAGAAGGACGT Murine c-myc exon 2 5’ primer 2 for 
SSCP (Bhatia et a l ,  1993)
Myc2 3’C AGTGAGGATATCTGGAAG Murine c-myc exon 2 3’ primer 1 for 
SSCP (Bhatia et a l ,  1993)
Myc2 3’D GGTCTCGTCGTCAGGATC Murine c-myc exon 2 3’ primer 2 for 
SSCP (Bhatia et a l ,  1993)
Myc3 5’E G A AATT GAT GT GGT GT C T Murine c-myc exon 3 5’ primer 1 for 
SSCP (Bhatia et a l ,  1993)
Myc3 5’F CTGCTTCAGGACCCTGCC Murine c-myc exon 3 5’ primer 2 for 
SSCP (Bhatiae t a l ,  1993)
Table 2.1
heavy chain enhancer are as described (Baneiji et a l, 1983). Polyoma 
sequence nucleotide numbers are as described for the polyoma origin region 
(Tooze, 1981).
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Oligonucleotide Oligonucleotide sequence (5 ’-3) Description/supplier
EB1 F CCCCTCGTCAGACATG EBNA-1 coding sequence nucleotides 
384-400 (antisense) (referencein text) 
Cruachem
EB1 G CATGTCTGACGAGGGG EBNA-1 coding sequence nucleotides 
384-400 (sense) (referencein text) 
Cruachem
EB1 H TTCCAGGTCCTGTACC EBNA-1 coding sequence nucleotides 
404-418 (antisense) (referencein text) 
Cruachem
EB1 L GGT AC AGGACCTGGAA EBNA-1 coding sequence nucleotides 
404-418 (sense) (referencein text) 
Cruachem
EB1 I GTTCCACCGTGGGTCC EBNA-1 coding sequence nucleotides 
634-650 (referencein text)
Cruachem
EB1 J CTTTGCAGCCAATGCAACTTG EBNA-1 coding sequence nucleotides 
614-634 (referencein text)
Cruachem
EB1 K GGGGTCTCCGGACACCATC EBNA-1 coding sequence nucleotides 
586-604 (referencein text)
Cruachem
Anchor primer CUACUACUACUAGGCCACGCGTCG 5’ RACE anchor primer
ACT AGT ACGGGIIGGGIIGGGIIG Gibco BRL
UAP CUACUACUACUAGGCCACGCGTCG Universal Amplification Primer
ACTAGTAC Gibco BRL
Myc 1 GAGCTGCCTTCTTAGGTCG
Ig H l CCAATAATCATAGAGCTC IgH enhancer 4398-4415 (reference in 
text)
EBlbindA GATCTAGGATAGCATATGCTACCC EBNA-1 DNA binding site sequence
CGGGG (Polvino-Bodnar and Scaffer, 1992) 
Cruachem
EBlbindB GAT CCCCCGGGGT AGC AT ATGCT A EBNA-1 DNA binding site sequence
TCCTA (Polvino-Bodnar and Scaffer, 1992) 
Cruachem
LRlbindA GATCCTCCTGGGTCAAGGCTGAAT LR1 DNA binding site sequence
AGACGC (Williams and Maizels, 1991) 
Cruachem
LRlbindB GATCTCCCCTGCGTCTATTCAGCC LR1 DNA binding site sequence
TTGACCC (Williams and Maizels, 1991) 
Cruachem
Splbind Duplex oligonucleotide containing Spl 
consensus DNA binding site 
Promega
Table 2.2
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2.2 DNA Probe Fragments
Table 2.3 lists the DNA fragments routinely used to make labelled probes in 
the following work. Enzymatic digestion of plasmid DNA and subsequent 
purification of probe fragments was carried out according to standard 
protocols listed later in this chapter. The EB13’ probe was derived from the 
plasmid pE|i-EBNA-l as described (Wilson and Levine, 1992). The EB15’
probe was derived from plasmid pPy5’EB-l as described (Wilson, et al., 
1996).
Probe Fragment Name Description
EB1 3’ Contains 3’ region o f EBNA-1 transgene (lkb) including EBNA-1 coding
sequence (1645-2308) (referencein text)
EB1 5’ Contains Polyoma promoter sequences from EBNA-1 transgene (1-190) and 5’
EBNA-1 coding sequence (365-554) (referencein text)
IgHl Xbal- EcoRI fragment (682bps) from the murine immunoglobulin heavy chain
enhancer
IgH2 BamHl- Xbal fragment (1.3kb) from the murine immunoglobulin heavy chain
enhancer
mmycl PstI fragment (420bps) from murine c-myc exon 2
mmyc2 Xbal fragment (3 .lkb) containing murine genomic c-myc exon 2, intron 2 and
exon 3
mbcl Hindlll-EcoRI fragment (865bps) containing murine bcl2 cDNA
mpim BamHl fragment (lkb) containing murine genomic piml exon 5, intron 5 and
exon 6
hbcl Sacl fragment (550bps) containing human genomic bcl2 exon 1 3’ region
mp53 murine p53 cDNA
mcycDl murine cyclin D1 cDNA
Table 2.3
2.3 Protein Reagants
DNA restriction and modification enzymes and RNA modification enzymes
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were obtained from a number of suppliers; BRL, Boehringer Mannheim, 
Promega, Pharmacia, Ambion.
Foetal calf serum was supplied by Sigma.
Anti EBNA-1 antibodies; monoclonal Aza2E8 was used as a direct tissue 
culture supernatant prepared by Joanna Wilson. The cells were grown as 
described (Hearing et a l , 1985). When the cells were confluent, supernatants 
were collected The cells were spun down and the supernatant stored at -70°C 
in aliquots until use then at 4°C once defrosted. Anti EBNA-1 reactive human 
sera AM and WS were supplied by human donors A.M and W.S and stored at 
4°C. Different dilutions of these antisera were used according to the 
application.
All secondary antibodies used in cell staining experiments were supplied by 
Sigma
2.4 Chemicals
CHEMICAL SOURCE
General chemicals, biochemicals and organic solvents BDH, May and Baker, Sigma
Media Difco, Oxoid
Agarose BRL
X-gal, IPTG BRL
Radiochemicals NEN, ICN
lOx Restriction enzyme buffers BRL, Boehringer Mannheim, Promega
Nucleotides Boehringer Mannheim
Antibiotics Sigma
Table 2.4
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2.5 Bacterial Culture Media
L Broth: lOg tryptone, 5g yeast extract and 5g NaCl made up to 1 litre in 
distilled water and adjusted to pH 7.5 with NaOH.
L Agar: as L Broth with the addition of 15g per litre of agar.
2.6 Sterilisation (Departmental service)
All growth media were sterilised at 120°C for 15 minutes. Supplements and 
buffer solutions at 108°C for 10 minutes and CaCl2 at 114°C for 10 minutes. 
Solutions for use in RNA work were autoclaved for at least 30 minutes.
2.7 Bacterial Growth Conditions
Liquid cultures for transformation, or DNA preparations were routinely 
grown in L broth at 37°C with vigorous shaking. For plates L agar was used 
with antibiotic supplements as required. Plates were generally incubated 
overnight at 37°C. Bacterial strains were stored in 50% L broth, 20% glycerol 
and 1% peptone at -70°C.
2 .8  Indicators
X-gal (5-bromo-4-chloro-3-indolyl-B-D-galactoside) was used in conjuction 
with TA cloning kit (InVitrogen) according to the manufacturer’s instructions. 
Use of this indicator acts as a screen for plasmids with inserts in the 
polylinker region. Clones containing inserts were generally white (due to the 
disruption of the (3-galactosidase gene), clones lacking inserts were blue. X-gal
(40pg/mlinDMF) was stored at -20°C.
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2.9  Buffer Solutions
Stock Solution Components
10X TBE 109g Tris base, 55g Boric Acid, 9.3g Na2EDTA.2H20, made up 
to 1 litre in distilled water
50X TAE For 1L; 242g Tris base, 57.1ml glacial acetic acid, 100ml 0.5M  
EDTA pH8, made up to 1L with distilled water
10X gel loading dye (agarose 20% ficoll, 0.25% bromophenol blue, xylene cyanol 0.25%, Tris
gels) HC1 pH7.5 lOmM, EDTA ImM
10X restriction enzyme buffers various as supplied by BRL, Boehringer Mannheim, Promega
TE buffer lOmM Tris/HCl, ImM EDTA, pH 8.0
TE / 0 .1%SDS lOmM Tris/HCl, ImM EDTA 0.1% SDS
20X SSC 3M NaCl, 0.3M trisodium citrate
0.5M EDTA pH8 EDTA plus distilled water titrated to pH8 with 10M NaOH
Church Buffer 28g SDS, 4g B S A  0.8ml 0.5M EDTA pH8, made up to 300mls 
with distilled water, then add lOOmls 1M Na2HP0 4
‘2FC’ (buffered phenol 50mls o f phenol and 50mls o f chloroform are mixed, then 1ml cf
chloroform) isoamyl alcohol and 0. lg  o f hydroxyquinolene are added. The 
mixture is saturated and buffered with 1M Tris pH8.
Buffered phenol Water saturated buffered phenol pH7.5 was supplied by Fisons
Tail Solution 50mM Tris pH8, lOOmM EDTA pH8, lOOmM NaCl, 1% SDS
STE buffer lOOmM NaCl, 20mM Tris HC1 pH7.5, lOmM EDTA
RNA loading buffer 12.5pl deionized formamide, 2.5pl 10 x MOPs buffer, 4pi 37% 
formaldehyde solution
RNA loading dye 50% glycerol, 0.1% bromophenol blue, 0.1% xylene cyanol, 50pM  
EDTA
10% Buffered Neutral Formalin For 2.5L; sodium dihydrogen phosphate(anhydrous) 8.75g, 
disodium hydrogen phopsate(anhydrous) 16.25g, 
formaldehyde 250ml, made up to 2.5L with distilled water
Table 2.5
2 .1 0  Plasmid DNA isolation
Medium Scale DNA Preparation 1 (basically as Birboim et al., 
1979)
Solutions:
I. 50mM glucose, 25mM Tris/HCl pH8.0, lOmM EDTA.
II. 0.2M NaOH, 1% SDS (made fresh)
III. 5M Potassium acetate pH4.8; mix equal volumes of 3M CH3COOK and
i
| 2M CH3COOH
j
|
ii11
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Method:
100ml cultures of stationary phase plasmid containing cells were harvested by 
centrifugation (12,400g, lOminat 4°C). The pellet was resuspended in 4ml of 
solution I. 8ml of solution II was added and the mixture left on ice for 5 
minutes. 6ml of solution III was then added, gently mixed and the cell debris 
and chromosomal DNA removed by centrifugation (39,200g, 30min at 4°C). 
The plasmid DNA was precipitated from the supernatant with 12ml 
isopropanol for 15minutes at room temperature. The DNA was pelleted by 
centrifugation (27,200g, 15min at 20°C), rinsed with 70% ethanol and then 
further purified by banding on a CsCl/EtBr gradient. The DNA was 
resuspended in 2.1ml of TE buffer and added to 270pl of a 15mg/ml ethidium
bromide solution. 5g of CsCl was dissolved in 3ml of water and added to the 
DNA/EtBr solution. The gradients were centrifuged in a Beckman Ti70.1 fixed 
angle rotor at 200 OOOg for 16 hours at 20°C. Where two bands were visible; a 
lower supercoiled plasmid band and an upper nicked DNA band, the lower 
band was removed using a 1ml syringe. The ethidium bromide was removed by 
repeated butanol extractions and the DNA recovered by ethanol precipitation. 
The DNA was washed in 70% ethanol and resuspended in 500pl TE.
Medium Scale DNA Preparation 2.
This was carried out using Qiagen Medium Scale Preparation kits for plasmid 
DNA, according to the manufacturer’s instructions using 20mls of stationary 
phase plasmid containing cells.
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Small Scale DNA Preparation .
The Bimboim, Doly (1979) miniprep method was used for small scale 
preparation of plasmid DNA as follows.
1.5ml of a stationary culture was harvested by centrifugation in an Eppendorf 
tube (12,000g, 30sec) and resuspended in lOOpl of solution I (as described for
large scale preparation above). 200pl of solution II was added and mixed by 
gentle inversion of the eppendorf tube. Following a 5 minute incubation on ice, 
150pl of solution III was added and mixed by vortexing at the lowest setting of
a Vortex Genie-2 (Scientific Instruments) for 10 seconds. Following a further 3 
minutes on ice, the tube was centrifuged (12,100g, 5 min). The supernatant 
was collected and extracted against 400pl of 1:1 phenol: chloroform. Following 
centrifugation (12,000g, 5min) the supernatant was added to 2 volumes of 
ethanol. After a 5 minute incubation at room temperature and centrifugation 
(12,100g, 5min) the supernatant was carefully removed and the pellet washed 
with 70% ethanol, air dried and resuspended in 50ml TE buffer. 1 pi of a 
1 mg/ml RNase A solution was added.
2.11 Isolation of Chromosomal DNA from Mouse Tissues
Preparation o f  DNA From Mouse Tail Samples
This was carried out basically as described in Wilson et al. 1990. Tissue 
samples were either taken fresh or stored at -70°C prior to DNA preparation. 
700pl of Tail solution (table 2.5) was added to the tail sample plus 35pl of a
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lOmg/ml solution of proteinase K. Digestion of the tissues was allowed to 
progress overnight at 55°C. It is possible to store the samples at 4°C following 
complete digestion with proteinase K for DNA purification at a later time 
point. To purify the DNA, the digested tail sample was subjected to 
sequential phenol, phenol/chloroform extractions. 700pl of phenol was added
to the sample and mixed by hand. The sample was then centrifuged at 
approximately 9000rpm in an Eppendorf benchtop centrifuge for 15 minutes. 
The upper phase was removed to a fresh tube, 700pl of 2FC added, mixed and
the centrifugation repeated. This step was then repeated. After a final 
centrifugation the upper aqueous phase was removed to a fresh tube and 1 
volume of ice cold absolute ethanol and lOOpl of 10M ammonim acetate
added. Following gentle mixing by hand the sample was centrifuged briefly 
(2mins, 8000g 2mins). The supernatant was removed and the pellet washed 
with 70% ethanol, then air dried briefly and resuspended in TE. The majority 
of tail DNA samples were diluted to a final concentration of V3 to V2 pg per 
ml.
Preparation o f Mouse Chromosomal DNA From Other Mouse 
T issues
Basically the same protocol as above was used to prepare DNA from spleen, 
liver, lymph node and other tissues. Where necessary the tissue samples were 
physically mashed or cut to aid the initial digestion with proteinase K. Where 
the tissue sample was large, preparation solution volumes were increased 
accordingly.
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2.12 Transformation of E.coli with plasmid DNA
This was carried out as described (Current Protocols). An overnight culture of 
the recipient strain (usually DH5) was diluted 1 in 100 into 20ml L broth and 
grown to a density of 2xl08 cells/ml (about 90mins).
The cells were harvested (21,100g, lmin, 4°C) and resuspended in 10ml of 
50mM CaCl2. The cells were pelleted again, resuspended in 0.5ml ice cold 
50mM CaCl2 and kept on ice until use. lOOpl aliquots of competent cells were 
added to DNA in TE buffer and, after gentle mixing left on ice for 15 minutes. 
400pl of pre warmed L broth was added to the cell suspension and incubated 
at 37°C for 90 minutes to allow expression of plasmid genes. lOOpl aliquots of 
the transformation mixture were spread on to selective plates.
2.13 Restriction of DNA
For restriction of plasmid DNA 4-5 units of enzyme were used per pg of
DNA. The appropriate restriction buffer was included and the reactions 
allowed to proceed for 1-3 hours at 37°C ( or the appropriate temperature 
according to the manufacturer’s instructions).
The majority of mouse chromosomal DNA digests included 5pg of DNA in a 
total reaction volume of 20pl. An initial overnight incubation at 37°C with 4-5 
units of enzyme per pg DNA was followed by the addition of an extra 1-2 
units of enzyme and a further 1-2 hour incubation at 37°C.
The enzymes were inactivated by the addition of DNA loading buffer and 
heating to 70°C. Alternatively, where subsequent manipulation of the DNA
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was to be undertaken phenol extraction followed by ethanol precipitation was 
used to purify the DNA from the enzyme(s).
2.14 Ethanol Precipitation of DNA
For precipitation of small DNA fragments; Vjq volume of 3MNaOAc and 2 
volumes of absolute ethanol were added to the DNA solution. After mixing, 
the DNA was precipitated at -20°C for at least 30 minutes and pelleted for 15 
minutes at 4°C. The pellet was washed with 70% ethanol and dried 
Chromosomal DNA was precipitated with V5 volume of 10M Ammonium 
Acetate and 1 volume of cold absolute ethanol. After mixing the pellet was 
spun down at room temperature for 2 minutes and washed with 70% ethanol.
2.15 Ligation of DNA Fragments
Restriction fragments were ligated in reaction volumes of 10-20pl containing
lx ligation buffer and 0.5 units of T4 DNA ligase. Generally a 3:1 insert to 
vector ratio of fragments was used (10:1 for blunt end ligations). The reactions 
were incubated at 16°C overnight. Aliquots of the ligation mix were used to 
transform competent cells.
2.16 Gel Electrophoresis of DNA
Agarose gels
0.8%-2% agarose gels were used. Agarose powder was dissolved in 0.5-lx 
TAE at 100°C and then cooled to 55°C before use. For some applications lpl 
of lOmg/mlethidium bromide was added to the gel prior to use. Otherwise the
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gels were bathed in a 0.6mg/ml ethidium bromide solution after electrophoresis 
and then rinsed in water.
IBI gel kits were used. Running buffer was TAE at the same concentration as 
in the gel.
Visualisation of DNA was on a254nm wavelength UV transilluminator except 
where the DNA was to be isolated from the gel, then a 365nm wavelength 
transilluminator was used.
Polyacrylamide G els
• 1. Sequencing Gels (and gels for RNase Protection Assays)
The gel kit used was made by IBI. A pre-made sequencing gel solution (6% 
polyacrylamide/8M urea) was used to pour the gels according to the 
manufacturer’s instructions (Scotlab, Anachem). Gels were allowed to set for 
at least one hour and often left overnight. Gels were run in IX TBE. Gels were 
pre-run for at least 45 minutes and run for 2-6 hours at 65W. After 
electrophoresis gels were either fixed in 10% acetic acid/ 10% methanol for 15 
minutes and then dried, or dried directly. Gels were dried onto Whatman 
3MM chromatography paper under vacuum at 80°C and then 
autoradiographed.
* 2. Non-denaturing gels for single stranded conformational analysis
Various different conditions were used for gels for SSCP analysis (section 
2.24). Gels were run on IBI sequencing gel apparatus. All the gels contained 
TBE at 0.5-IX and TBE was the running buffer. Both 30:1 and 19:1 
acrylamideto bis-acrylamide ratios were used to optimise resolution of DNA
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strands. In addition for some gels Hydrolink-MDE acrylamide solution was 
used (Hoeffer).
Gels were not pre run. Gels were run very slowly overnight (12-14hrs) either 
at room temperature with a fan to cool the gel, or at 4°C. Gels were dried 
under vacuum at 80°C and then autoradiographed.
• 3. Non-denaturing polyacrylamide gels
These gels were used to separate protein-DNA complexes. Various 
concentrations of acrylamide were used according to the experimental 
requirements (section 2.31). All gels were made and run in IX TBE buffer. Gel 
mixes were made according to a basic recipe (table 2.6).
Component Volume
30% acrylamide / 0.8% bisacrylamide (w/v) solution (Biorad) xml
lOxTBE 5ml
10% APS (w/v) 200pl
TEMED 20 pi
Made up to final volume of50mls with distilled water xmls
Table 2.6
A Biorad vertical gel electrophoresis apparatus was used. All gels were 
allowed to set for approximately 45 minutes and then pre-run for at least 45 
minutes. Gels were run for variable lengths of time at room temperature at 
approximately 200V depending on the application.
2 .17 Isolation of DNA Fragments after gel Electrophoresis
Isolation o f DNA from Agarose gels
DNA fragments were cut from ethidium bromide stained gels and purified by 
one of two methods.
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a. Spin X tubes (Costar) were used as recommended by the manufacturer. The 
Spin X tube contains a 0.22pC cellulose acetate filter. On centrifugation the
DNA in solution flows through the filter into the collection tube, the agarose 
particles remain above the filter.
b.QiaexII gel extraction kit (Qiagen) was used according to the manufacturer’s 
instructions. The agarose is solubilised using a high concentration of a 
chaotropic salt which disrupts the hydrogen bonds between the sugars in the 
agarose. 40bp-50kb DNA fragments are adsorbed to QiaexII silica particles in 
the presence of high salt. Impurities are removed by washing. The pure DNA 
is eluted from the matrix in water or TE (low salt/basic conditions).
Isolation o f DNA from  Low Melting Point Agarose gels
The band containing the DNA of interest was cut directly from ethidium 
bromide stained gels, mashed and TE or distilled water added to dilute the 
agarose. Prior to use the DNA was heated to 70°C to melt the agarose and 
mixed thoroughly.
Isolation o f DNA from  Polyacrylamide gels
The 32P labelled DNA of interest was identified using autoradiography and cut 
from the gel. The gel fragment was mashed and 0.5ml of elution buffer (0.5M 
ammonium acetate/ ImM EDTA/ lOmM TRIS pH8) added. After an 
overnight incubation at 65°C the DNA was ethanol precipitated and washed.
2.18  Southern Blotting of DNA
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The method used was as described in the handbook for Pall Biodyne 
Membrane. Briefly, after electrophoresis gels were denatured in a solution of 
1M sodium hydroxide/1.5M sodium citrate for 30 minutes. Capillary blotting 
was used to transfer the DNA from the gel to the membrane. 20 x SSC was 
used as the transfer solution. Transfer was allowed to occur overnight. Where 
the DNA fragments to be transferred were of large size an acid hydrolysis step 
(15 minutes in 0.25M hydrochloric acid) was included prior to denaturation to 
partially break down the fragments. On occasion Hybond N (Amersham) 
membrane was used, it was then necessary to include a neutralisation step 
after denaturation (15 minutes in 0.5MTris pH 7.4/1.5M sodium chloride). 
After complete transfer the membrane was baked for 1 hour at 80°C and UV 
crosslinked.
2.19 Slot Blot Analysis of DNA
A vacuum slot blot apparatus (Schleicher and Schuell Minifold II) was used 
for the direct application of DNA to nylon membranes. To 5jig of DNA in
120pl, 40pl of 1M sodium hydroxide was added and the mixture vigorously
vortexed to denature the DNA. After 10 minutes at room temperature 160fil
of 10 x TAE buffer was added. The samples were vortexed, briefly spun down 
(2mins Eppendorf bench centirfuge, 14 OOOrpm) and put on ice. The 
membrane was pre soaked in 1 x TAE buffer. The samples were loaded 
without the vacuum. Vacuum was applied once all of the samples had been 
loaded. When the samples were through, a drop of 5 x TAE buffer was added
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to each well. After complete transfer the membrane was baked for 1 hour at 
80°C and UV crosslinked.
2 .20 Polymerase Chain Reaction (PCR)
The exact conditions used for PCR reactions varied depending on the 
application. Reaction cycles followed the format:
Cycle Description Number o f Cycles
Denaturation; 5minute, 95°C 1
Denaturation; 1 minute, 95°C
Anneal; 1 minute, various 30-35
Extension; l-3minutes, 72°C
Extension; lOminutes, 72°C 1
Table 2.7
Reactions were carried out in volumes of 30-50pl. Exact ingredients varied 
with the application, but the basic reaction mix was as follows:
Reaction Component Concentration
DNA (in H20 or TE) various, approximately 0.1-0.5fxg
lOx reaction buffer (BRL or Promega) Vio total reaction volume
Magnesium Chloride solution various, usually 2.5mM
dNTP mix (ATP, CTP,GTP,TTP) various, usually 0.2mM
Primer oligonucleotide 1 various, usually 0.2pM
Primer oligonucleotide 2 various, usually 0.2pM
Taq DNA polymerase (BRL or Promega) various, usually 0.4 units per reaction
Table 2.8
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Thermal cyclers used were a Perkin Elmer Thermal Cycler and a Crocodile II 
(Appligene).
2 .21 Cloning of DNA fragments
PCR products were cloned using the InVitrogen TA cloning system, basically 
according to the manufacturers instructions. This system utilises the 
overhanging thymidine nucleotide added to the end of PCR products generated 
by Taq polymerase. DNA products were visualised on ethidium bromide 
stained agarose gels and cut out as individual bands. The DNA was purified 
from the agarose using Qiaex II gel extraction kit (Qiagen) according to the 
manufacturer’s instructions. Purified DNA was used directly in ligation 
reactions to the T- vector (InVitrogen). Transformation of the ligated DNA 
into competent E.coli was as described (section 2.12). The vector contains a 
copy of the p galactosidase gene at the polylinker site, expression of which is 
disrupted by the presence of an insert. This allowed for selection of colonies 
containing inserts (section 2.8). Several of the colonies obtained were picked, 
grown up in 1.5ml L broth and DNA prepared from them using the miniprep 
method (section 2.10). Plasmid DNA was subjected to an EcoRI digest, this 
enzyme cuts on either side of the poly linker and releases the cloned insert, and 
analysed by electrophoresis. Where the insert was of the expected size, the 
plasmid was subjected to further analysis eg restriction mapping and 
sequencing.
2 .22  Sequencing of Plasmid DNA.
Two different protocols were used for the sequencing of miniprepped DNA.
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Taq Terminator Sequencing (on ABI373A) at the CRC Beatson 
Institute fo r  Cancer Research
Reactions were carried out using lpg of double stranded plasmid DNA with 
3.2pmoles of primer. The reaction mix and enzyme were supplied by 
Promega. The PCR reaction cycle was as follows; (96°C 15 secs, 50°C 1 sec, 
60°C 4mins) x 25 cyles (Perkin Elmer 9600 Thermal Cycler). Reactions were 
then extracted twice with phenol/chloroform, precipitated, dried and 
resupended in loading buffer. Reactions were carried out and gels run with the 
assistance of Rob McFaralane at the Beatson Institute.
Sequenase Quick Denature Sequencing K it (USB)
Sequencing reactions were carried out with 1 pg of double stranded plasmid
DNA and 0.5pmoles of primer according to the manufacturers instructions. 
Samples were heated to 80°C for 2 minutes prior to loading on 6% sequencing 
gels.
2 .23 Probing of Southern, Northern and Slot Blots with Labelled 
DNA fragments.
25ngof appropriate DNA fragments were labelled using 32PdATP or 32PdCTP 
and the Primelt II (Stratagene) DNA labelling kit according to the 
manufacturer’s instructions. This kit utilises Klenow DNA polymerase 
lacking the 3’ exonuclease. Polymerisation reactions are primed from denatured 
template to which random nonamer oligonucleotides are annealed. Labelling 
reactions were allowed to proceed for 10 minutes to 1 hour, the reaction 
stopped and then unincorporated nucleotides separated from the probe
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fragment using a Stratagene Nuctrap Push Column according to the 
manufacturer’s instructions.
Prior to the addition of the labelled probe the membrane underwent a pre­
hybridisation step.
Both pre-hybridisation and hybridisation were carried out in plastic tubes in a 
rotatory hybridisation oven. For the pre-hybridisation the membrane was 
soaked in Church Buffer at 65°C for at least lhour. Hybridisation was carried 
out in Church Buffer (approximately 8-15mls depending on the size of the 
membrane) at 65-68°C for 12-16 hours. The labelled DNA probe fragment was 
denatured at 95°C for 5 minutes prior to addition to the pre-warmed Church 
Buffer. This mixture was then added to the membrane (after removal of the 
pre-hybridisation mixture). Where extremely stringent hybridisation 
conditions were required, up to 20% formamide was included in the Church 
Buffer.
After hybridisation, membranes were washed for 20-60 minutes at room 
temperature in 2 x SSC, 0.1% SDS and then for 20-60 minutes at 68°C in 0.1 x 
SSC, 0.1% SDS (stringent conditions).
Washed membranes were sealed in plastic bags and visualised by 
autoradiography.
2.24  Single Stranded Conformational Analysis of DNA
SSCP analysis of the c-myc gene in transgenic tumour DNA was carried out 
using the protocols of Bhatia et al., 1993. A selection of different genomic 
DNAs (tumour and non-tumour) from both positive and negative transgenic
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mice were screened for mutations in c-myc exon 2. Each set of PCR reactions 
was electrophoresed on a range of different gels; 6% polyacrylamide (19:1 
acrylamide to bis-acrylamide ratio) at room temperature and 4°C, 6% 
polyacrylamide (30:1 acrylamide to bis-acrylamide ratio) at room temperature 
and at 4°C, or Hydrolink-MDE (Hoeffer) at room temperature. All gels were 
run for 12-15 hours.
2.25 Preparation of RNA from Mouse T issues
This was carried out essentially according to the method of Chomcznski and 
Sacchi (1987). Total RNA was prepared from snap frozen tissues by acid 
guanidinium thiocyanate-phenol-chloroform extraction using RNAsolB 
(Biogenesis) according to the manufacturer’s instructions. The tissues were 
lysed using a poltron directly in a solution which denatures proteins and 
degrades DNA. Subsequent phenol/chloroform extraction is used to remove 
proteins and the RNA is precipitated with isopropanol or absolute ethanol. 
RNA was stored at -70°C in 1 volume TE/0.1% SDS, and 2V2 volumes 
absolute ethanol. Prior to use in any assay RNA was precipitated with V10 
volume of 3M sodium acetate and washed with 70% ethanol. For RNase 
Protection assays and 5’RACE PCR any trace DNA was removed from the 
RNA by two further precipitations with lithium chloride: the RNA was 
resuspended in TE, 0.1% SDS and lithium chloride was added to a final 
concentration of 2.5M. The sample was mixed and incubated at -20°C for 
30minutes and then spun down at 4°C for 30minutes. The precipitated RNA 
was then washed with 70% ethanol.
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2.26 Northern Blotting of RNA
For Northern blots 10 or 20pg aliquots of RNA were run on 1% agarose gels
containing V5 volume formaldehyde and lxMOPS E buffer. RNA samples 
were prepared in a formamide loading buffer and denatured at 65°C for 
5minutes prior to loading. Gels were electrophoresed for 5 hours at 150V at 
4°C. The gels were stained in ethidium bromide solution and visualised with 
UV irradiation. Transfer of the RNA to Pall Biodyne membrane was carried 
out by capillary blotting as described in the manufacturer’s instructions 
(essentially as for Southerns section 2.18).
Subsequent probing of northern blots was as described (section 2.23).
2 .27 RNA Slot Blot
Loading Buffer;
Component Volume
Formamide 1ml
Formaldehyde (37% solution) 324pl
10 xMOPs buffer 200pi
Table 2.9
20 pg aliquots of lithium chloride precipitated RNA were resuspended in 40pl
of TE/0.1%SDS. 120pl of loading buffer was added (table 2.9) and the sample
incubated at 65°C for 5 minutes then placed on ice. 40pl of cold 20 x SSC was
added and then the samples loaded onto the slot blot apparatus. 5pg of RNA
was loaded on to each membrane (50pl of sample). Pre soaked (10 x SSC)
Hybond-N membrane (Amersham) was used. After application of the samples 
the membranes were baked at 80°C for 1 hour and UV crosslinked.
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2 .28 RNase Protection Analysis
DNA fragments for riboprobe preparation were prepared from DNA purified 
by caesium chloride banding (section 2.10). Each plasmid was cut with the 
relevant enzyme to give a defined end point to the transcribed riboprobe. 
Digestion was allowed to proceed for three hours then additional enzyme was 
added for a further hour to ensure that the reaction had gone to completion. 
Proteinase K was added to the sample for 30 minutes at 37°C to remove any 
contaminating RNase. Phenol/ chloroform extraction followed by ethanol 
precipitation ensured that the DNA was clean (RNase free)for use as a 
template in synthesis of the riboprobe.
Riboprobes were synthesised using a Maxiscript RNA polymerase 
transcription kit (AMBION) according to the manufacturer’s instructions. All 
probes were labelled with 32P UTP.
Riboprobe Plasmid/Source Digestion/RNA polymerase
EBNA-1 5 ’ pPy5’E B -l EcoRI/T3
Polyoma/IgH 1 plgHPy PvuII/T3
Polyoma/IgH 2 plgHPy Xbal/T3
GAPDH Ambion Ddel/T7
Table 2.10
The riboprobes used are illustrated in figure 2.1.
Unincorporated labelled UTP was purified from the riboprobe using 
StratageneNuctrap Push Columns. The riboprobe was treated with RNase 
free DNase (BRL) and purified by phenol/chloroform extraction and 
subsequent ethanol precipitation. The probe was washed in 70% ethanol and 
resuspended in RNase Protection hybridisation buffer (Ambion).
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Hybridisation reactions and RNase digestion were carried out using reagents 
supplied with Ambion’s RNase Protection Kit. The protocol was basically as 
described in the manufacturer’s handbook as follows.
40-80pg samples of lithium chloride treated RNA were precipitated, washed
and resuspended in hybridisation buffer containing 2xl05cpm of riboprobe per 
sample. Where a loading control was required, the GAPDH probe was added 
to the mixture in addition. In order to prevent the GAPDH signal from 
overwhelming the signal of interest, the riboprobe was sythesised with a 
greater concentration of unlabelled UTP( ratio of unlabelled to labelled UTP 
for GAPDH was 2:1, and for other probes was 3:5) such that the specific 
activity of the GAPDH probe was lower than that of the riboprobe of 
interest. After mixing the samples were heated to 95°C and allowed to cool 
slowly to 65°C. Hybridisation was allowed to proceed overnight at 65°C. 
Samples were digested with RNaseA and RNaseTl to remove single stranded 
RNA (Ambion, 1:50 dilution). After inactivation of the RNases and ethanol 
precipitation the samples were resuspended in 80% formamide loading buffer, 
denatured at 95°C and separated on 6% polyacrylamide/urea gels. For probe 
alone samples 2xl02 cpm undigested probe was loaded. Protected fragments 
detected in RNase protection experiments were quanitified using 
phosphorimager analysis.
2.29  5 ’RACE PCR
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5’ RACE PCR reactions were carried out using a kit supplied by GIBCO BRL 
as depicted in figure 2.2.
All the RNA samples analysed with this technique had been twice 
precipitated with lithium chloride to remove any trace DNA. V3 pg of each
RNA was used in the initial cDNA synthesis. A gene specific primer 
(oligonucleotide EB11 section 2.1, table 2.2) was used in all cDNA synthesis 
reactions. Following purification of the cDNA from the primer, the DNA was 
tailed with poly dC using terminal transferase. PCR amplification of the 
products was carried out using a second gene specific primer (oligonucleotide 
EB1 J, section 2.1, table 2.2) and the anchor primer (section 2.1, table 2.2) 
supplied with the kit. 50 pi reactions contained each primer at 0.2pM, dNTPs
at 0.2mM, magnesium chloride at 1.5mM, lxPCR reaction buffer(BRL) and
0.5 units per reaction of Taq DNA polymerase (BRL). Reactions denatured at 
95°C and then cooled to 80°C prior to the addition of Taq polymerase. 30 
cycles of amplification were performed with an annealing temperature of 60°C 
and an extension time of 1 minute. 20pl aliquots of PCR reactions were
electrophoresed in 2% agarose gels containing ethidium bromide. Gels were 
Southern blotted onto Pall Biodyne membrane (section 2.18) and probed with 
either probe EB1 5’ containing 5’ EBNA-1 and polyoma sequences, or probe 
IgHl containing Ep enhancer sequences.
For secondary amplification of PCR products a number of different protocols 
were used. In initial experiments, the primary PCR reaction was diluted 1:50 
and 5 pi used in a secondary PCR reaction using the same gene specific primer
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(oligonucleotide EB1 J section 2.1, table 2.2) as the primary reactipn and the 
Universal Amplification Primer (section 2.1, table 2.2). The samp reaction 
conditions as for the primary reaction were applied. Subsequently, the 
primary PCR reactions were amplified ip a second round of PCR using one of 
two different nested gene specific priipers, either oligonucleotide EB1 F 
(section 2.1, table 2.2). or oligonucleotide EB1 H (section 2.1, table 2.2) in 
order to increase the specificity of products obtained. Ultimately, because thp 
yield of products was low from either of thp above apprpaches rather than 
dilute the primary PCR reaction it was purified using a Qiagen PCR clean up 
kit to remove any free primers. 5 pi (V 10) pf the resultant products were used
in a secondary amplification using q nested gene specific primer 
(oligonucleotide EB1 K, section 2.1, tabje 2.2) and the Universal 
Amplification Primer. 20pl aliquots of products from secondary amplification
reactions were electrophoresed on 2% agarose gels and Southern blotted and 
probed as above. The 5’ RACE procedure is diagrammed in figure 2.2.
It was attempted to clone and sequence 5’ RACE products from line 26 and 
line 59 samples. After two rounds of PCR using gene specific primer EB1 J, 
products from two 50 pi reactions for each line were pooled, precipitated and
resuspended in 20pl then separated by electrophoresis in a 2% agarose gel. 
Fragments were cut from the gel and labelled according to size. Subsequent 
purification of the DNA fragments, cloning and sequencing was as described 
(sections 2.17,2.21,2.22).
2.30  Preparation of Nuclear Protein Extracts from Mouse T issues
75
The protocol used to prepare protein extracts from mouse spleens was 
essentially as described below. Tissues were snap frozen in liquid nitrogen and 
then stored at -70°C. Tissues were pulverised in liquid nitrogen in a mortar 
and pestle and then resuspended in a hypotonic lysis buffer (0.6% NP40, 
150mM NaCl, lOmM HEPES pH7.9, ImM EDTA, 0.5mM PMSF). The cell 
suspensions were subjected to 5 strokes in a Dounce homogeniser (pestle B). 
After removal of tissue debris by centrifugation (30 secs at 2000rpm in a 15ml 
tube), the supernatant was incubated on ice for 5 mins. The nuclei were 
pelleted by centrifugation (5mins at 5000rpm) and then resuspended in 100- 
500pl of a buffer supplemented with a protease inhibitor cocktail (20mM 
HEPES pH7.9, 0.42M NaCl, 1.2mM MgC12, 0.2mM EDTA, 0.5mM DTT, 
25% glycerol, 0.5mM PMSF and 5pg/ml each of aprotinin, leupeptin,
pepstatin A and 2mM benzamidine). The resuspended nuclei were incubated 
on ice for 20 mins for high salt extraction. The lysed nuclei were transferred to 
a microcentrifuge tube and cellular debris pelleted by a 15 secs centrifugation. 
The supernatant containing the DNA binding proteins was aliquoted in 30ml 
fractions, frozen in liquid nitrogen and stored at -70°C. Protein concentrations 
were calculated using a Biorad assay.
2.31 Gel Retardation Assays for Protein DNA Binding Activity
1. EBNA-1 Gel Retardation Assays
The protocol used was essentially as described (Polvino-Bodnar and Schaffer, 
1992). Complementary oligonucleotides EBlbindA and EBlbindB (section 
2.1, table 2.2) were mixed in equimolar amounts, heated to 95°C to denature
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completely and then allowed to cool slowly to room temperature to anneal. A 
short non-complementary 5’ extension (GATC) was included in each 
oligonucleotide to allow for labelling. Duplex oligonucleotide was labelled with 
a 32P dATP by filling in with Klenow. Labelled oligonucleotide was separated
from unincorporated 32P dATP using a Stratagene Nuctrap Push Column. To 
ensure that only duplex probe was used, the probe was purified by 
electrophoresis on a polyacrylamide gel and excision (section 2.17).
For the comparison of the binding activity of various protein extracts a master 
reaction mix was made containing the labelled oligonucleotide (lpmole per 
reaction), the binding buffer (150mM NaCl, 20mM HEPES, 10% glycerol, 
ImM Mg Cl2, ImM p ME) and poly dl dC (lpg  per reaction, Boehringer
Mannheim). 25pl of reaction mix was added to 2pg of each protein of interest
in a total volume of 5 pi. The binding reaction was incubated for 20 minutes at
room temperature prior to loading onto a 4% non denaturing polyacrylamide 
gel. Gels were run for 2V2-3hours at 200V.
For the determination of specificity of binding a reaction master mix was made 
as above, however for this experiment the mix contained the protein of 
interest. Labelled probe and the appropriate competitor were mixed and then 
the reaction mix added to them and incubated for 20minutes, as above the total 
reaction volume was 30pl.
Two different types of supershift experiment were performed. In the first the 
binding reactions were set up exactly as for the comparison experiment 
described above. After the initial 20 minute incubation lpl of the appropriate
antibody (monoclonal Aza2E8, polyclonal human serum AM, or polyclonal 
human serum WS) was added to the reaction and incubation at room 
temperature continued for a further 20 minutes.
In the second type of binding reaction the protein was not pre-incubated with 
the probe prior to antibody addition, instead antibody and protein were added 
simultaneously and the reaction incubated for 40 minutes at room temperature.
2. LR1 Gel Retardation Assays.
The reaction conditions used for these experiments were as described 
previously (Williams and Maziels, 1991). Complementary oligonucleotides 
LRlbindA and LRlbindB (section 2.1, table 2.2) were mixed in equimolar 
amounts, annealed to form duplex and labelled with a 32P dATP as described 
above (section2.31.1).
Both comparison of protein activity experiments and specificity experiments 
were set up as described above. However the binding buffer used differed in 
composition (8mM HEPES, 60mM Kcl, 0.1% NP40, 10% glycerol) and the 
reactions were separated on 6% polyacrylamide gels.
3. SP1 Gel retardation assays.
Duplex oligonucleotide for use as a binding site probe was supplied by 
Promega, table 2.2. This was labelled with y32P dATP using T4 polynucleotide
kinase and the probe separated on a StratageneNuctrap Push Column.
As described (section 2.31.1) binding reactions were set up in a volume of 
30pl. The SP1 binding buffer used was (4mM MgCl2, 0.6mM EDTA, 15mM
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HEPES, 10% glycerol). Reactions were incubated at room temperature for 20 
minutes and then separated by electrophoresis on either 4 or 6% 
polyacrylamide gels at 200V for 2-3hours.
2 .32 Tissue Culture
Maintenance o f lymphocyte cell cultures
All cell lines were maintained in lymphocyte medium (RPMI 1640 medium 
(BRL), supplemented with 10-20% foetal calf serum (FCS), 4mM glutamine, 
Penstrep (BRL), 10"5M p Mercaptoethanol and 7pg/mldextran sulphate).
With the exception of primary lymphocyte cell lines all other cell lines were 
obtained through the ECACC catalogue.
Derivation o f primary cell lines from  transgenic spleen and lymph 
nodes
Spleen and lymph node tissue samples from mice were mashed in a small 
quantity of lymphocyte medium to yield a cell suspension. This was briefly 
spun down and the pelleted cells resuspended to a final concentration of 
> lx l08 cells per ml in lymphocyte medium containing 20% FCS.
Where aliquots of cells were frozen, the freezing medium contained up to 50% 
FCS and 10% DMSO (dimethyl sulphoxide). Frozen cells were maintained in 
liquid nitrogen.
In attempts to derive cell lines from transgenic tissues the concentrated cell 
suspensions were monitored every day and gradually diluted by the addition 
of fresh medium to a concentration of lxlO6 cells per ml. Cell viability was 
addressed using trypan blue staining (Sigma) as directed by the manufacturer.
This dye is excluded by viable cells, but stains dead cells. Cells were counted 
using a haemocytometer.
Monitoring the effect o f oligonucleotide addition to cell lines.
A number of different sense and antisense EBNA-1 oligonucleotides (EB1 C, 
EB1 D in table 2.1, EB1 F, EB1 G, EB1 H, EB1 L in table 2.2) were added to 
cell lines. 2 xlO5 cells of each type were aliquoted at the start of the 
experiment. 30pg of the appropriate oligonucleotide was added to the cells on
day 1. At each interval of 24 hours an additional 5pg of oligonucleotide was 
added. After 72 hours 40pg additional oligonucleotide was added. From day 1, 
aliquots of cells were taken at 24 hourly intervals, stained with trypan blue 
and a count made of both viable and dead cells. At least 8 counts were made 
for each sample.
2 .33 Maintenance of Transgenic Mouse Lines
All animal work was carried out under Home Office Licence.
The transgenic mouse colony was monitored at least twice weekly, according 
to Home office requirements, for evidence of tumours or ill health. Routinely, 
samples of spleen, liver, lymph node, thymus and any abnormal looking 
tissues were collected in buffered formalin solution (table 2.10) for 
pathological examination. All pathological analysis was carried out by Dr. 
Sarah Toth at Glasgow University Veterinary Pathology Department. In 
addition samples of tissues were routinely snap frozen and stored at -70°C for 
subsequent preparation of DNA, RNA and protein. For tissue culture,
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samples were collected and rinsed briefly with 70% ethanol then immersed in 
FCS and taken directly into culture.
Monitoring o f transgene status and transgenic lines
Tail genomic DNA was prepared as described in section 2.11.
Ep EBNA-1 transgenic lines 26, 59, 60, 61, 26B and 59B were routinely
screened by slot blot analysis and Southern blotting for transgene status 
(described in Wilson and Levine, 1992). For cross breeding experiments and 
pristane induction, Southern blotting was the method of choice to determine 
transgene status using probe EB1 3’ (table 2.3). In addition a PCR approach 
was developed to screen tail DNA for the EBNA-1 transgene. 
Oligonucleotides EB1 A and EB1 B (table 2.1) were used as primers. The 
standard reaction used approximately V3pg of DNA in a 50pl reaction 
containing lx PCR reaction buffer (Promega), 2.5mM magnesium chloride, 
0.2pM dNTPs, 0.2pM of each primer and 0.4units per ml Taq DNA
polymerase (Promega). 30 amplification cyles were performed with an 
annealing temperature of 60°C and an extension time of 1 minute. The 
combination of these two primers yields a 500bp product from transgenically 
positive DNA and no product from transgenically negative DNA.
Bcl2-Ig transgenic mice were imported from the laboratory of S. Korsmeyer 
(McDonnell et al., 1989) and designated line 85. Tail DNA from these mice 
was screened by Southern analysis as described previously (McDonnell et a l , 
1989). In addition slot blot analysis was used in some cases, but extreme
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stringency was required in hybridisation (church buffer containing 20% 
formamide) and washing (70°C, 0.1xSSC/0.1%SDS, 60minutes) to prevent 
cross hybridisation between the probe containing human Bcl2 sequences 
(probe hbcl, table 2.3) and the mouse genomic Bcl2.
Ep-piml transgenic mice were imported from the laboratory of A. Bems (van
Lohuizen et a l , 1989), designated line 87, and screened by Southern analysis 
as described ( van Lohuizen eta l, 1989) using probe mpim (table 2.3).
Ep myc transgenic mice were imported from the laboratory of A. Bems. The
transgenic line was generated in that laboratory using the same constructs as 
described by Adams et al (Adams et a l , 1985). The line was designated line 
86. It was attempted to assess transgenic mice as described previously. It was 
not possible to determine the transgene status of these mice accurately. 
Definitively positive mice in this line were never obtained.
All mouse importations were overseen by the University Biological Services 
adhering to appropriate UK quarantine regulations according to licencing by 
the Home Office and Ministry of Agriculture.
Pristane Induction o f Plasmacytomas.
Certain substrains of BalbC mice (including BalbCAnn) are susceptible to the 
induction of plasmacytomas by intraperitoneal injection of the mineral oil 
pristane (Anderson and Potter 1969). Both line 26 and line 59 (C57B16 strain 
background) were backcrossed to the BalbCAnn strain of mice. The new lines 
were called 26B and 59B respectively. After the second backcross to 
BalbCAnn all young mice in both line 26B and line 59B were injected with
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0.5mls of pristane into the peritoneal cavity. This injection was repeated after 
2months and again after four months. From the time of the first injection all 
mice were closely monitored for any outward appearance of lymphoma, 
plasmacytoma, or general ill health and euthanased on presentation of any of 
these symptoms according to Home Office guidelines.
2.34. Immunostaining of Transgenic Mouse Tissues for EBN A -1.
A number of different protocols were used to attempt to stain EBNA-1 
protein in both frozen and paraffin embedded tissue sections.
Staining o f Frozen tissue Sections
• 1. ExtrAvidin Peroxidase Staining with anti EBNA-1 antibodies
The ExtrAvidin Peroxidase Staining Kit was supplied by Sigma. Endogenous 
peroxidase activity was blocked by a 5 minute incubation of the slides with 
3% hydrogen peroxide. Slides were then washed in 1 xPBS buffer. Slides were 
incubated for 15 minutes with a 5% goat serum solution and then again washed 
with 1 x PBS. The anti EBNA-1 antibody was diluted for use in 1 x PBS 
containing 5% goat serum and 1% BSA. A number of different dilutions of 
both the human serum AM and the monoclonal Aza2E8 were used in attempts 
at staining. Where the monclonal Aza2E8 was used the slides were first 
incubated in a solution of anti mouse immunoglobulin antibodies to block the 
endogenous mouse immnuoglobulins present within the tissues used. The 
slides were incubated with the anti EBNA-1 antibody for 60 minutes and then 
washed with 1 xPBS. The biotinylated antibody was diluted 1:20 in 1 x PBS 
containing 1% BSA. When the human serum AM was used the secondary
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antibody was biotinylated goat anti human immunoglobulin, when the 
monoclonal Aza2E8 was used the secondary antibody was biotinylated goat 
anti mouse immunoglobulin. The secondary antibodies were incubated on the 
tissues for 40 minutes and then the slides were washed with 1 x PBS. The 
ExtrAvidin peroxidase was diluted 1:20 in 1 x PBS containing 1% BSA and 
added to the slides for 30 minutes. Slides were then washed for 5 minutes in 1 
x PBS. Staining of the slides was carried out using A.E.C substrate supplied 
by Sigma according to the manufacturer’s instructions. Slides were 
counterstained with Mayer’s hematoxylin (Sigma)and mounted using glycerol 
gelatin.
* 2. ExtrAvidin Alkaline Phosphatase Staining with anti EBNA-1 
antibodies
Essentially the protocol used was as above with the following exceptions.
a. After the addition of the ExtrAvidin Alkaline Phosphatse all washes of the 
slides were carried out in 1 xTBS (Sigma) rather then PBS buffer.
b. Staining of the slides was carried out using the Fast Red staining system 
(Sigma) according to the manufacturer’s instructions.
Staining o f Formalin Fixed Paraffin Embedded Tissues
Both of the peroxidase and phosphatase staining of tissues was attempted.
The techniques were basically as described above with the addition of several
steps.
• Removal of Paraffin and Rehydration
Slides were heated to 58°C for 15 minutes and then transferred to a xylene 
bath for 5 minutes. The slides were removed to a fresh bath of xylene for a
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further 5 minutes and then placed into fresh absolute ethanol for 3 minutes. 
The slides were removed to a fresh bath of absolute ethanol for a further 3 
minutes and then placed into 90% ethanol for 3 minutes, then into 80% 
ethanol for 3 minutes and then rinsed gently with tap water.
• Antigen “ Unmasking” Techniques
A number of different techniques were used to attempt to make the EBNA-1 
protein more available for staining.
I. Trypsin digestion
After removal of paraffin the slides were incubated with a solution of 0.1% 
trypsin for 15 minutes at 37°C and then rinsed with 1 xPBS.
II. Pressure Cooking
After removal of paraffin and blocking of endogenous peroxidase the slides are 
placed in citrate buffer (lOmM sodium citrate buffer, pH6 Sigma) and cooked 
for 15 minutes at 15 psi. The slides are rinsed in 1 xPBS prior to staining.
In addition to the two anti EBNA-1 antibodies listed above attempts were also 
made to stain tissue sections using two antibodies supplied by Jaap 
Middeldorp, Organon Tekninka BV, The Netherlands. One antibody was a 
rabbit polyclonal, the other a mouse monoclonal. The protocols used were 
supplied by Jaap Middeldorp, but were basically as described above for 
frozen tissues and for formalin fixed tissues including a pressure cooking step 
as described.
No specific staining of the sections used was detected, however only 
transgenic tissues were used therefore the experiment did not contain a 
positive control.
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Chapter 3
Expression of EBNA-1 in Ep-EBNA-l Transgenics 
3 .1 Introduction
The similarity in the nature of the tumours which develop in both line 26 and 
line 59 is strongly suggestive of a role in tumourigenesis for EBNA-1. 
However, the significant difference in the latency and penetrance of the 
phenotype between the two lines could be indicative of different expression 
patterns of the transgene. Indeed, previous work has confirmed that the 
detectable levels of EBNA-1 protein vary considerably between line 26 and 
line 59. Surprisingly, by Western analysis the detectable level of EBNA-1 
protein is much higher in line 59 than in line 26 (Wilson and Levine, 1992).
In the following section I will present results from a number of experiments 
designed to analyse the nature of transgene transcription comparing the two 
lines.
3 .2  Northern Analysis
Figure 3.1 shows a Northern blot of total RNAs from a selection of tissues of 
mice from both transgenic lines, from two control lines 60 and 61 which 
contain the Ep-EBNA-l transgene but have no phenotype and no detectable
expression, and from some negative controls. The blot was probed with two 
EBNA-1 probes covering 55 and 3’ EBNA-1 transcribed sequences to enhance 
the signal.
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Figure 3.1
20pg  o f  total tissue RNAs Northren blotted and probed w ith EBNA-1 (probes EB1 5' and EB1 3') 
as described in M aterials and M ethod .M -m arker, sizes indicated in base pairs T - m ouse had
lym phom a. 5 9 ^ 5 9 ^  - splenic RNA from 2 different line 59 mice. 26^/26^/26^ - RNA from 3 
different line 26 mice (spleen and lymph node). 60/61/ ° - Control RN A s from  lines 60, 61
and transgenically negative m ice respectively. Splenocytes- RNA prepared from cultured line 26 
splenocytes.
Large EBNA-1 transcripts detected in line 26 sam ples are indicated by plain arrow , 2kb EBNA-1 
transcript is indicated by dashed arrow I, truncated EBNA-1 transcript is indicated by dashed 
arrow II.
Only in the line 26 samples are any EBNA-1 containing transcripts detectable. 
This confirms original results using just the 3’ probe (Wilson and Levine, 1992, 
Wilson, et al., 1996). A large transcript is evident in the spleen and in the 
lymph nodes of line 26 samples (indicated by an arrow, figure 3.1). At greater 
than 9.5kb in size, this transcript is considerably larger than that predicted 
from transgene sequences. The inserted transgene sequences are completely 
contained within a 8.5kb Bell fragment detected by Southern blotting and 
therefore the transcript must contain cellular sequences in addition to those 
derived from the transgene. The size of the predicted product using the 
transgene RNA start site and polyadenylation sequences would be 2.1 kb. A 
faint band is evident in the three line 26 lymph node samples at approximately 
2kb in size (figure 3.1, lanes 14-16, band indicated by dashed arrow).
Lane 9 contains splenic RNA and lane 15 contains lymph node RNA from the 
same animal, 26.85, which had a malignant lymphoma. The large EBNA-1 
containing transcript is evident in both samples, although more readily 
detectable in the lymph node sample. By ethidium bromide staining the levels 
of these two RNAs appears similar. In addition an abundant second transcript 
is detected in the lymph node sample which is not evident in the spleen 
sample (dashed arrow on figure 3.1). At less than 2kb this transcript is smaller 
than expected from the intact transgene. This smaller transcript has not been 
detected in any other line 26 samples and therefore its relevance to the 
progression of line 26 tumours in general is not clear, although its expression 
may have been involved in tumour development in this one animal. The DNA
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from this lymph node was not analysed, therefore it is not known if this 
unique transcript is the product of a transgene rearrangement in these cells.
By this assay there is no detectable expression of EBNA-1 in any of the line 
59 samples, nor predictably in the control samples from lines 60 and 61.
3 .3 RNase Pro tection
As Northern analysis is not sensitive enough to detect low level expression, 
line 59 RNA samples were analysed further with more sensitive techniques. 
RNase protection is a more sensitive technique and also affords the ability to 
address transcript boundaries, such as initiation sites. The latter is of 
particular interest given that the line 26 transcripts detected by Northern 
analysis are not of the predicted size.
In initial experiments, a riboprobe containing the 5’ region of EBNA-1 and the 
polyoma promoter sequences used in the transgene (figure 3.2) was used in 
protection experiments with total RNA from line 26, line 59 and transgenically 
negative spleen or lymph node samples. As had been previously shown 
(Wilson and Levine, 1992), in line 26 two major RNA products are protected 
with this probe of approximately 359 and 240 nucleotides in size. The larger 
product represents protection of the entire EBNA-1 and polyoma sequences 
in the probe and provides evidence that transcriptional initiation is occurring 
upstream of the predicted start site within the polyoma promoter of the 
transgene. It is not possible to determine from this experiment whether 
transcriptional initiation is occurring upstream of the probe, but within 
transgene sequences, or further upstream within cellular sequences. The
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smaller product (approximately 240 nucleotides) represents protection of the 
entire EBNA-1 sequences and approximately 50 nucleotides of polyoma 
(within the promoter region, mapping close to the TATA box).
In the experiment shown in figure 3.3a, two different line 59 samples were 
compared with line 26 samples. In line 59, as in line 26, two major products 
are detected. The larger is identical in size to that detected in line 26 samples 
and correlates with protection of all the EBNA-1 and polyoma sequences 
contained within the probe. The smaller product is slightly shorter than that 
detected in line 26 (approximately 220 nucleotides), but is likely to correlate 
with the major viral start site within the polyoma promoter. Mouse 59.44 had 
a lymphoma which had greatly invaded the spleen. The spleen of mouse 59.58 
was histologically normal. In order to determine the relative levels of 
expression between line 26 and line 59 samples, signals resulting from RNase 
protection analysis were normalised against GAPDH expression. Relative 
transcript levels (against GAPDH) are presented in table 3.1. It would appear 
from this analysis that there is little difference between total levels o f 5’ 
EBNA-1 containing transcripts in line 26 and line 59 samples, in contrast to 
the observations by Northern blotting. It is clear, however, that the relative 
usage of transcription initiation sites is different between the two lines (but 
consistent within lines).
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In the experiment shown in figure 3.3a, in addition to the two major products 
in line 26 and in sample 59.44 there are a series of other minor products of 
varying size. There are a number of potential explanations for these products. 
One is that there is extensive start site heterogeneity in the transcripts 
expressed. Another might be that the digestion of hybridised RNAs has not 
gone to completion. The fact that on a long exposure some undigested intact 
probe can still de detected suggests that this might be contributing to the 
banding pattern. It is also possible that the integrity of the RNA has been 
compromised at some stage in the experiment and that other than the two 
major bands, the majority of detected bands are due to partially degraded 
RNAs hybridising to the probe. The majority of the RNA in each sample was 
intact at the start of the experiment, evidenced by the clearly visible 28S RNA 
band on an ethidium stained gel. It is likely that all three of the above factors 
contribute to the pattern of products detected. The presence of a series of 
minor bands is a common observation in this type of assay.
To further characterise the larger 5’ protected product detected in both lines, 
the RNase protection experiment conducted included two additional 5’ 
extended probes, illustrated in figure 3.2. The results from this experiment can 
be seen in figure 3.3b. The probes were designed to protect sequences derived 
from the transgene, each probe extending differing degrees into the Ep 
enhancer. Each probe was hybridised to splenic RNA from either line 26, line 
59 (59.44), or a transgenically negative control. A number of products specific
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GAPDH
EBNA-1
1 (start 
upstream of 
Pv
promoter)
EBNA-1
2 (start h 
Pv
promoter)
EBNA-1 
3 (start h
Py
promoter)
EBNA-1
Total
negative 3789 47
26 21 856 1588 959.6 738.6 3286.2
59.44 14 833 587.7 349 1053 1989.7
59.58 1967 112.9 92.2 98.89 303.99
60 2937 69.64
GAPDH
EBNA-1
1 (start 
upstream of 
Pv
promoter)
EBNA-1
2 (start n 
Pv
promoter)
EBNA-1 
3 (start h
Pv
promoter)
EBNA-1
Total
negative 1967 24.4
26 1967 142 86.36 66.47 294.83
59.44 1967 77.9 46.28 139.63 268.81
59.58 1967 112.9 92.2 98.89 303.99
60 1967 46.64
Table 3.1
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Figure 3.3
RNase protection ex p e rim en t. Lane 1 - RN A m arker ladder, sizes indicated in 
nuleotides. Lane 2 - GA PD H riboprobe. Lane 3 - 5'EB1 riboprobe. Lane 4 - 
Py/IgH l riboprobe. Lane 5 - Py/IgH2 riboprobe. a. 50pg o f  various splenic RNAs 
hybridised to 5'EB1 riboprobe; lane 6 - negative RNA, lane 7 - line 26 RNA 
(tum our), lane 8 - line 59.44 RNA (tum our) lane 9 - line 59.58 RNA, lane 10 - line 
60 RNA. b. Lane 11-13; 50pg each o f  negative, line 26, and line 59.44 RNAs 
respectively hybridised to Py/IgH l riboprobe, lane 14-16; 50pg each o f  negative, 
line 26, and line 59.44 RNAs respectively hybridised to Py/IgH2 riboprobe. The 
m ajor products w ith approxim ates sizes in nucleotides in experim ent (a) are 
indicated on the left, and in experim ent (b) are indicated on the right.
to the transgenic lines can be detected. In both lines a major band of 
approximately 200 nucleotides is protected as well as, at a lower level, a band 
of approximately 215 nucleotides with both probes. These products correlate 
with protection of RNAs containing all of the polyoma promoter sequence 
and probably initiating in the proximity of the junction with the IgH enhancer 
in the transgene. In addition, in both lines there is protection of a fragment 
about 340 nucleotides in size. This would correlate with a transcript which 
initiates within the IgH enhancer (still within the IgHl probe). On close 
scrutinization of a long autoradiographic exposure it is also possible to detect 
other larger products in the line 26 samples (360 nucleotides, lane 15, 480 
nucleotides, lane 15 and 16, and 500 nucleotides, lane 12 on figure 3.3b). The 
sensitivity of this experiment is insufficient to determine whether they are also 
present in line 59. A band of 230 nucleotides not specific to the transgene, as 
it is detected in the negative control, is also present with probe IgHl. This 
could be due to protection of endogenous sequences or to incomplete probe 
digestion.
It is clear from these results that the majority of the RNAs which protect the 
entire length of the first probe (5’ EBNA-1, figure 3.3a) initiate within the 
transgene. At least two additional start sites can be postulated, which are used 
in both lines. The first and major of these upstream sites lies at the junction of 
the polyoma promoter and the IgH enhancer in the transgene. The second 
maps to within the enhancer itself. It is not possible from this experiment to 
exclude the possibility that some of the EBNA-1 containing transcripts initiate
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even further upstream within the IgH enhancer or even in cellular sequences. 
Figure 3.4 presents a summary of the predicted start sites for transcripts from 
RNase protection data.
3.4 5’ RACE PCR
From the results of Northern analysis and RNase protection assays, it is 
evident that the transcription pattern of the transgene in both lines is complex. 
Given that there are obvious differences between the two lines it is possible 
that the phenotypic differences seen correlate with transgene expression. To 
extend this analysis of expression, 5’ RACE PCR was employed to 
characterise the nature of transcripts with different 5’ ends in each of the 
transgenic lines.
A selection of line 26, line 59 and negative RNAs from spleen or lymph node 
samples were analysed by 5’RACE PCR. The primary 5’RACE PCR was 
carried out as described in Materials and Methods (chapter2, section 2.29). A 
gene specific primer (EB1 1, table 2.2) was used in the initial cDNA synthesis, 
and a nested gene specific primer (EB1 J, table 2.2) in the first round PCR 
reactions.
Figure 3.5 shows a Southern blot of primary PCR products, which were not 
visible by ethidium bromide staining, probed with 5’ EBNA-1 (probe EB1 5'). 
Lane 1 contains products from a line 26 RNA made from a lymph node which
96
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was massively invaded by a lymphoma. A number of products are visible. 
These range in size from about 300bps to about 800bps. This correlates well 
with predicted sizes of products from RNase protection assays. A transcript 
initiating within the polyoma promoter (240 nucleotides band, figure 3.3a) 
would produce a RACE product of approximately 340bps in size. A 
transcript initiating at the junction between the polyoma promoter and the IgH 
enhancer ( 200 and 215 nucleotides bands, figure 3.3b) would produce a RACE 
product of approximately 480bps. Transcripts initiating from within the IgH 
enhancer could produce RACE products up to 1.2.kb in length. There are no 
products evident in the lane containing the line 59 sample, nor is it possible to 
detect anything in any of the negative controls.
In order to enhance the amount of products from the RACE to a more easily 
detectable level, a secondary amplification by PCR was performed. Products 
of the first round were diluted and subjected to a second round of 
amplification using universal amplification primer (GIBCO) and one of a 
selection of different EBNA-1 specific primers (oligonucleotides EB1 J, EB1 
F, EB1 H, or EB1 K as described in Materials and Methods). Amplifications 
were performed a number of times on different cDNAs and isolates which had 
been tailed at different times. It is clear that the amount of product detected 
ultimately is acutely dependent on the quality of both cDNA sythesis and 
tailing reactions.
It proved extremely problematic to detect any products in initial reactions 
using two different line 59 RNAs; 59.93 and 59.102. After a
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Figure 3.5
Southern blot o f  prim ary PCR products from 5'RA CE PCR probed with 
EB1 5'. The reactions were carried out using the G ibco/B RL 5'RACE 
kit as described in M aterials and M ethods. Lanes 1-4; products o f 
5'RACE PCR reactions; cDNA synthesis prim ed with oligo EB1 I and, 
PCR reaction carried out with oligo EB1 J and the A nchor prim er 
(Gibco). Lane 1 - 26.411 LN tailed cDN A, lane 2 -59.93 spleen tailed 
cDNA, lane 3 - 60.102 spleen tailed cD N A , lane 4 - negative spleen 
tailed cDNA. Lanes 5-8 ; PCR reaction as described above carried out 
on RNAs to control for DNA contam ination o f  RNAs. Lane 5 - 26.411 
LN RNA, lane 6 - 59.93 spleen RNA, lane 7 - 60.102 spleen RNA, lane 
8 negative spleen RNA. Lane 9 - lk b  DNA m arker ladder, sizes 
indicated in base pairs.
large scale secondary PCR reaction on products from the RACE procedure 
(Materials and Methods, section 2.29), two products from 59.102 RNA 
(approximately lkb and 450bps in size) were detected on an ethidium stained 
gel (figure 3.6). However a negative control was not included in this 
experiment. Using RNA from a line 59 tumour (59.44 spleen) a wider range of 
products was obtained.
To address the specificity of products obtained, Southern blots of RACE 
products have been probed with EB1 5’ (table 2.3) and with a probe to IgH 
enhancer sequences (IgHl, table 2.3). Primary PCR products were diluted and 
subjected to secondary amplification with a nested gene specific primer (EB1 
F, table 2.2) and the universal amplification primer (GIBCO).The products 
were electrophoresed and then Southern blotted. A range of products is 
detected in both line 26 and line 59 samples with both the EB1 5’ probe and 
the IgHl probe (figure 3.7a and b). There is clearly overlap in the products 
hybridised to each probe, and as would be predicted, the IgH probe 
preferentially hybridises to the larger products. No products are detected in 
the negative controls included in this experiment (lanes 4 and 11, figure 3.7a 
and b), but this experiment also illustrates the variability in the amount of 
product obtained from EBNA-1 positive samples. Several line 59 and line 26 
samples did not yield any detectable product in this experiment (lanes 
3,6,12,13 andl4, figure 3.7a). The same RNA can give different products 
depending on the cDNA sythesis and tailing reactions (compare lanes 1 and 2, 
and lanes 7, 8 and 14, figure 3.7a).
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Figure 3.6
Ethidium bromide stained gel o f  PCR products from 
secondary amplification o f  5 'RA CE products. Primary PCR 
products were diluted 1:50 and then 5pl was used per 50pl 
reaction as described in M aterials and M ethods. Re­
amp lification was carried out using the Universal am plification 
prim er (Gibco) and oligo EB1 J. Lane 1 - Line 26. 411 LN, 
lane 2 - line 59.102 spleen, lane 3 - lk b  D N A  marker ladder.
26. 26. 59. 59. 59. 59. 59. 26. 26. 26. 59.
411 411 93 ° 60 102 44 44 61 - 418 190 478 44 M
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
506/517
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
506/517
Figure 3.7
Southern blot o f  PCR products from secondary am plification o f  5'RACE PCR 
products. The prim ary products were diluted , and re-am plified using oligo EB1 J and 
the universal am plification prim er (G ibco) as prim ers. The origin o f  the RNA used for 
cDNA sythesis is indicated. In lanes 1 and 2, the RACE procedure was carried out on 
two different cDN A preparations o f  the sam e LN RNA from m ouse 26.411. In lanes 
7,8 and 14, the RACE procedure was carried out on different cDN A preparations o f 
the same splenic RNA from m ouse 59.44. a. Probed with EB1 5'. b. Probed with 
Ig H l.
In order to maximise the levels of products from line 59 samples which had 
given variable results, a different approach was taken for secondary PCR 
reactions. In the experiment shown in figure 3.8a the primary RACE reactions 
were purified to remove any residual primers, rather than diluted. Vi0 of each 
purified reaction was subjected to a second round of PCR using a nested gene 
specific primer (EB1 K) and the universal amplification primer (GIBCO). The 
reactions were electrophoresed on an ethidium stained agarose gel and 
Southern blotted and probed with EB1 5’. A variety of products were 
obtained in both line 26 samples and line 59 samples, visible on the ethidium 
stained gel (figure 3.8a). A range of products in line 26 and line 59 samples 
also hybridise strongly to EBNA-1 sequence (figure 3.8b). The most intense 
bands on the ethidium stained gel (figure 3.8a) do not necessarily represent the 
products which hybridise most strongly to EBNA-1. For example this is 
clearly evident with sample 26.478; on the ethidium stained gel there are 
strong bands of approximately 850 and 750 bps and a very vague shadow at 
about 450bps (lane 11, figure 3.8a). The band which hybridises most strongly 
to the EB1 5’ probe is the band of 450bps. The 850bp product does not 
hybridise at all, and the 750bp product hybridises only very weakly. A strong 
band of approximately 190bps in size is detected in the line 60 sample on the 
ethidium stained gpl(lane 12, figure 3.8a). This product does not hybridise 
strongly to EB1 5’, two larger products (approximately 500bps and 380bps) 
hybridise to EB 1 5’ (lane 12, figure 3.8b) but are barely visible on the ethidium 
stained gel (lane 12, figure 3.8a).
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Figure 3.8a
Ethidium  brom ide stained agarose gel o f  PCR products from secondary am plification o f  5' 
RACE PCR products. The 5f RACE products were purified to remove prim ers (see 
M aterials and m ethods) and ream plified using EB1 K and the universal am plification 
prim er (G ibco). Lane 13 - lkb  DNA m arker ladder, sizes in base pairs are indicated. The 
anim al from w hich the RNA w as prepared is indicated. W ith the exception o f  26.411, 
which was prepared from a lym ph node, all the RNAs were prepared from spleens. T- 
indicates that the tissue w as invaded by lymphoma.
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Figure 3.8b
Southern blot o f  5' RACE PCR products generated as described in figure 3.8a legend and 
electrophoresed in an agarose gel. The gel was b lotted  as described in M aterials and 
m ethods and probed with EB1 5'. (a) and (b) are tw o  different exposures o f  the  same 
blot.
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That there is a low level of expression from the rearranged transgene in line 60 
is in agreement with previous work (Wilson and Levine 1992, Wilson, et al., 
1996). Two different transgenically negative splenic RNAs were included in 
this experiment, 26.480 and 26.91 (lanes 3 and 10, figure 3.8a and b). Neither 
of these RNAs yielded products which hybridised to EB1 5’. However, RNA 
from 26.91 gave rise to a product of approximately 850bps in size (lane 10, 
figure 3.8a). A product of similar size was detected with 26.478 RNA (lane 
11, figure 3.8a) which also did not hybridise to EB1 5’.The 850bp band is 
therefore not transgene specific and could be an artefact caused by the 
presence of some primer homology within mouse RNA sequences as it is 
clearly present in the negative control.
In order to locate start sites to the precise nucleotide, it was attempted to 
clone and sequence products detected in both lines. After the secondary PCR 
on RACE products, several reactions for line 26 and for line 59 were pooled, 
precipitated and run out on an ethidium stained gel. The major bands were cut 
out (approximately 850bps, 800bps, 650bps, 500bps 340bps and 300bps 
from the line 26 sample, and 450bps and lkb from the line 59 sample) and the 
DNA purified and cloned. Clones containing inserts were then selected for 
subsequent sequencing on the basis of the size of the insert.
The presence of the poly G tail caused a block in many sequencing reactions, 
which proved to be problematic. Many of the sequences obtained did not 
contain any homology to EBNA-1. This might have been predicted from the 
experiment above since several of the most intense bands on the ethidium gel
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Figure 3.8c
DNA sequence o f line 26 850bp 5 ’R A CE PCR product (black). 5 ’RA CE PCR 
products were cloned and sequenced as described in M aterials and M ethods. In 
this reaction the prim er oligonucleotide was EB1F. The sequence has been 
aligned with m urine im m unoglobulin heavy chain enhancer sequence (red) 
(Banerji et  al.,  1983) and polyom a origin sequence (green)(Tooze et  
a/.,1981).The ATG sequence contained within the enhancer is underlined.
do not hybridise well to EB1 5’. None of the 450bp fragments cloned from the 
line 59 sample contained any sequence resembling EBNA-1. Similarly, 
sequence obtained from the 300, 500, 650 and 800bp products (these sizes are 
an approximation taken from the position of the bands which were cut out for 
cloning) did not correlate with the expected sequence, although products of 
this size did hybridise to EBNA-1 on Southern blots of RACE reactions. 
These sequences did bear homologies to mouse and human sequences. The 
650bp product had homologies to a large number of 5’ ends of human cDNAs 
in the data base. The sequences do come from the mouse genome; when the 
650bp product is used as a probe on a Southern blot of mouse tail DNA under 
stringent conditions a single band is detected in both transgenically positive 
and negative mice. The 300bp product had strong homology to mus musculus 
osteocalcin related gene.
One product sequence did give results as expected. The 850bp product from 
line 26 contains sequence from the Ep enhancer, extending through the entirety
of the polyoma promoter and into EBNA-1. This transcript starts in the 
middle of the enhancer at position 3361 (according to published sequence, 
Banerji et al, 1983). The start of this transcript is marked on the summary 
diagram (figure 3.4)
Southern blotting of RACE PCR products has demonstrated that a number of 
different transgene specific products were obtained. However, both line 59 and 
line 26 samples also gave rise to a number of products which did not hybridise 
to the EBNA-1 sequence and sequencing confirmed that a number of these
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products contain murine sequences not transgene related. The origin of these 
products is not clear. That this technique can generate artefactual products is 
demonstrated by the detection of a product in one of the negative controls. 
Use of this technique did however allow confirmation of results obtained by 
RNase protection and precise mapping of one start site in line 26. In both line 
26 and line 59 there is heterogeneity in start site usage. Also, products of 
greater than 1.2kb were detected by this method that did hybridise to EBNA-1 
sequences. These products may therefore be bona fide, and would be predicted 
to start upstream of the transgene sequences, and possibly to contain murine 
cellular sequences.
3 .5  Transgene Integration Site and Transgene Configuration
The regulation of transgene expression in both line 26 and line 59 is complex. 
In both lines transcriptional start sites other than within the polyoma 
promoter appear to be in use. It is possible that this is directed by the 
juxtaposition of the IgH enhancer and the polyoma promoter or that this is 
due to the influence of surrounding cellular sequences in both lines. In line 59, 
there appears to be a single complete copy of the transgene plus some 
additional incomplete transgene sequences inserted at an unkown site (Joanna 
Wilson, pers. comm.). In line 26, there appear to be two copies of the 
transgene, at least one of which is intact (figure 3.9). An EcoRI digest o f line 
26 genomic DNA probed with IgH sequences reveals a fragment of
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approximately 700bps (data not shown). This fragment would be predicted if 
there are two head to tail tandem copies of the transgene in line 26. To test 
this hypothesis, it was attempted to use PCR to amplify between transgene 
sequences in line 26 and line 59. The PCR reaction used a sense primer to the 
3’ end of EBNA-1 (oligonucleotide EB1 E, table 2.1 and figure 3.9) and an 
antisense primer to the 5’ end of the polyoma promoter (oligonucleotide Py 
ORI F, table 2.1 and figure 3.9). It was not possible to obtain any product 
from line 59 DNA or from a negative control DNA. However, in line 26 three 
major products were obtained of approximate size 700bps, 900bps and 1.2kb. 
The detection of a 700bp fragment is in agreement with the hypothesis that 
there are two directly abutting copies of the transgene in line 26 (figure 3.9). 
The detection of the two larger fragments is more difficult to explain. The PCR 
reaction was carried out at a relatively low stringency (annealing temperature 
of 45°C) and so it is possible that these products are the result of mispriming 
from cellular DNA. However they are specific to line 26 and may indicate that 
the transgene integration is more complex than presented in figure 3.9.
On probing of a Southern blot of EcoRI digested standard line 26 tail DNA 
with EB1 3’ (table 2.3), two major bands are detected, one of 2.2kb, as 
predicted, and a large band of about 6.2kb (figure 3.10). During the course of 
breeding of line 26, in one unusual case a germ line rearrangement involving the 
transgene has occurred. This rearrangement has created a copy of transgene 
sequences which now reside in an 8kb EcoRI DNA fragment (figure 3.10). 
This copy of the transgene is located at some distance to or is on a separate
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chromosome from the original transgene integration site and it has been 
possible to breed a line of transgenic mice harbouring only this copy, now 
designated line 26A. Both the 6.2kb EcoRI fragment and the 8kb fragment 
contain EBNA-1 sequences, but the extent and configuration is not clear. The 
6.2kb fragment could be generated if the extreme 3’ end of the transgene 
tandem was deleted and the EcoRI site lost (illustrated in figure 3.9). If the 
truncated transgene were copied to a new site within the mouse genome this 
could explain the 8kb fragment. Probing of a Southern blot of EcoRI digested 
DNA containing the line 26A rearrangement with IgH sequences highlights a 
band of 4kb (data not shown) which is attributable to the transgene. Line 26A 
is undergoing observation for phenotype. As yet no incidence of lymphoma 
has been observed, and the animals have been monitored over a two year 
period.
3 .6  Summary and D iscussion
From Northern analysis, it is clear that the total detectable level of EBNA-1 
containing transcripts is higher in line 26 than in line 59. Although a large 
transcript is routinely detected in line 26 samples, consistently no EBNA-1 
containing transcripts are detectable in line 59 samples. This correlates well 
with the observed phenotype. Mice of line 26 have a higher tumour incidence 
at an earlier age.
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However, quantitation of the levels of transcripts containing 5’ EBNA-1 by 
RNase protection suggests that the levels of initiated transcripts are fairly 
equivalent between the two lines. There are several potential explanations for 
the apparent difference in levels revealed by these two assays. The 
riboprobes in RNase protection assays cover only the 5’ transgene sequences 
and therefore will not detect transcripts truncated at the 5’ end. By contrast, 
the probes used on Northern analysis extend over a larger region of the 
transgene and therefore may detect a wider range of transcripts than detected 
by RNase protection. The large product detected by Northern analysis in line 
26 may initiate downstream of the riboprobes used and may therefore not be 
represented in the results of the RNase protection assays. Northern analysis is 
a less sensitive technique than RNase protection and only fragments of 
consistent size (forming a band) can be detected. If the EBNA-1 containing 
transcripts vary considerably in size, then they would form a smear rather 
than a discrete band on a Northern blot which may not be detectable, 
particularly if the total level of transcripts is low as is the case in these 
transgenic lines. It is possible that the transcripts detected by RNase 
protection in line 59 have heterogeneous 3’ ends (perhaps through inefficient 
poly A site recognition, discussed below) and therefore do not form a discrete 
band in Northern analysis.
It is clear that although the total level of 5’ containing transcripts may be 
similar, the exact nature of the transcripts differs between the two lines. In line 
26, the majority of transcripts detected start upstream of the polyoma
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promoter (compare EBNA-1 peak 1 (upstream start) to EBNA-1 peaks 2 and 
3 (polyoma start), table 3.1). The major start site of transcripts in line 59 
maps to the major RNA start site of polyoma early viral transcripts within the 
polyoma promoter (compare EBNA-1 peak 3 to EBNA-1 peak 1 and 2, table
3.1).
RNase protection experiments indicate that the majority of transcripts initiate 
within the 5’ enhancer/promoter region of the transgene, and there is little or 
no run on transcription from one transgene to the next in line 26. Therefore the 
large transcript in line 26 seen by Northern analysis is likely to extend 3’ into 
cellular sequence.
The observation of a cellular-transgene hybrid transcript in line 26 is 
suggestive of a role for cellular sequences in the regulation of expression of the 
transgene in this line. The transgene integration site as well as the configuration 
of the integrated transgene in both lines may well play a role in the observed 
differences between the lines. If there is a copy of the transgene in line 26 
which is truncated at the 3’ end, then this may lack the polyadenylation site. 
The large transcript detected in line 26 could be due to the lack of this site. An 
alternative explanation is that the EBNA-1 polyadenylation site in the 
transgene may be weak, allowing a number of transcripts to run through it. 
This could give rise to transcripts with heterogeneous 3’ ends.
Whilst the relative levels of the transcripts differ, in both lines it has been 
possible to map transcript start sites to regions upstream of the polyoma
i
promoter. A number of different starts of transcripts within IgH enhancer
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sequences have been identified. The RNase protection results reveal that 
multiple 5’ start sites are used in both lines 26 and 59 splenic tissues, however 
the relative usage of these sites differs between the lines. If there are a number 
of different transcriptional initiation sites in use, then it is possible that 
different cell types or stages within the tissue use different initiation sites. The 
IgH enhancer contains binding sites for multiple different proteins which may 
differ in their importance for transcription in different cell types and cell 
stages. In a human pre-B cell line a number of messenger transcripts have been 
identified which initiate within the immunoglobulin intronic heavy chain 
enhancer and are extremely heterogeneous at the 5’ end (Neale and 
Kitchingman, 1991). More than 50 different transcriptional initiation sites 
were identified mapping near to the Ig-specific octamer ATTTGCGT. An 
octanucleotide potential promoter element (ATTTGCAT) exists within the 
core mouse enhancer sequences contained within the transgene. It may be that 
the observed heterogeneity of 5’ ends of transcripts from the transgene is due 
to multiple transcriptional start sites originating within the IgH enhancer.
Not all of the transcripts detected necessarily give rise to active EBNA-1 
protein. The 850bp 5’ RACE product sequenced contains an ATG upstream 
of the EBNA-1 translational start site, within the IgH enhancer. If translation 
occurs from this upstream ATG, this could reduce the efficiency of translation 
from the EBNA-1 ATG through competition for the translational machinery 
(Kozak, 1995). Since a greater proportion of line 26 transcripts initiate
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upstream than for line 59, this may mean that translation of line 59 transcripts 
is more efficient.
From Southern blots of 5’ RACE products, it appears that there may be 
products in excess of 1.2kb in size in both line 26 and line 59. However from 
RNase protection experiments, any starts upstream of the transgene are likely 
to be a very minor component of transgene expression. Such transcripts are 
likely to contain cellular sequence, although in line 26 they could be products 
resulting from read-through from one copy of the transgene to the next. The 
presence of differing cellular sequences in line 59 and line 26 EBNA-1 
containing transcripts may be involved in the observed differences in 
phenotype between the two lines.
Work is ongoing in the laboratory to clone out and sequence the transgene 
insertion sites in each of the transgenic lines. This may provide valuable 
information as to the sequences directing transgene regulation and their 
potential role in the observed phenotypes of the lines. Although the 
differences in the expression pattern of the transgene sequences may in 
themselves explain the different phenotypes of line 26 and line 59 mice, it is 
still possible that in line 26 activation of a cellular proto-oncogene by the 
insertion of the transgene enhances the tumourigenecity of EBNA-1.
It is not known which domain(s) of EBNA-1 protein are required for the 
oncogenicity of the protein. An analysis has suggested however that certain 
EBNA-1 variant EBV strains are more common in tumours, and therefore may 
be more oncogenic (Introduction section 1.7 andBhatia et a l, 1996). Sequence
116
analysis of the EBNA-1 transgene in different tumours could identify similar 
mutations in the transgenics which render EBNA-1 more oncogenic. In one line 
26 tumour (26.85) a rearrangement has occurred in the metastasis which leads 
to a very high level of expression of a truncated EBNA-1 containing transcript. 
It is not clear whether this had a causal role in the metastasis of the tumour to 
the lymph node or if  it is a subsequent rearrangement in a genomically unstable 
cell. Few line 26 tumours have been compared for EBNA-1 RNA expression 
between primary and metastatic lesions. Such an analysis might provide an 
insight into the significance of this rearrangement in the lymph node of 26.85. 
Given the differences in the RNA expression pattern between the transgenic 
lines and the potential role of cellular sequences, a measure of the activity of 
EBNA-1 protein in each of the transgenic lines may provide a clearer 
understanding of the differences in phenotype between line 26 and line 59 
(chapter 5).
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Chapter 4
Cell Culture from Ep EBNA-1 induced Lymphomas
4.1 Introduction
It is not known whether continued EBNA1 expression is required within the 
transgenic tumour cells or if EBNA1 only sets up a predisposition to 
lymphoma and is subsequently no longer oncogenically required. In order to 
address this question, it was attempted to derive cell lines from line 26 
tumours. Such cell lines could be used to investigate if EBNA1 continues to 
contribute to cell proliferation in culture and therefore, indirectly, whether it 
has a role in tumour maintenence in both the transgenic tumours and in the 
human disease. The effect of down regulation of EBNA1 expression in cell 
lines derived from tumours has been attempted here.
4.2 Derivation and Analysis of Primary Cell lines from line 26  
Tumours
It was attempted to derive primary cell lines from line 26 tumours from both 
spleen and lymph node tissues from a number of different animals. The tissues 
were mashed in lymphocyte medium (chapter 2, section 2.32) and the 
resultant cell suspension seeded at a minimal cell density of 2 xlO5 live cells 
per ml. For the majority of tissues used the cells did not survive any longer 
than 1-2 weeks in culture, which is up to twice as long when compared to cells 
derived from negative controls (Joanna Wilson pers. comm.). Cells derived
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from lymph node suspensions died sooner (within the first week) than cells 
derived from spleen suspensions. The majority of cultures monitored did not 
show an increase in cell number during culture. However one line 26 tumour, 
26.305, did give rise to a cell line which was propagated in culture for more 
than 12 weeks. This line 26 mouse was unusual in that it did not succumb to 
lymphoma until it was over 1 year old (421 days old at death). Both spleen 
and lymph node tissues were massively invaded by the tumour and were used 
to derive cell suspensions, as described in materials and methods (chapter2, 
section 2.32). The spleen was mashed in 1 xPBS, the capsule removed and the 
cell suspension spun down briefly. Most of the supernatant was removed, and 
the cells resuspended in the remaining 2mls of PBS. O.lmls aliquots of this 
concentrated suspension was diluted with 1ml of the media as described below 
(table 4.1). In addition to the components listed, all media contained glutamine 
andpenstrep as described in materials and methods (chapter 2, section 2.32). 
The resultant confluent suspension culture was incubated overnight at 37°C. 
The lymph node suspension was made using the same protocol, but the cells 
were ultimately at a lower concentration (approximately 3 x 106 live cells per 
ml) in 5 mis of the media as described below (table 4.2).
The cells were observed daily for any change in appearance or obvious 
outgrowth. None of the cells in DMEM medium (S4 - S6, LD, LE, LF) or the 
RPMI 1640/ DMEM mix(S7, S8) survived. Tables 4.3, 4.4, 4.5 and 4.6 list 
the observations made on the cell line over the 12 weeks it remained in
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continuous culture. The cells in SI and S2 were all dead after 12 days in
culture.
Vial Name Medium Components
SI RPMI 1640, 10% FCS, 50pM pME
S2 RPMI 1640, 10% FCS, 50pM {3ME, 7p,g/ml dextran sulphate
S3 RPMI 1640, 20% FCS, 50pM pME, 7pig/ml dextran sulphate
S4 DMEM, 10% FCS, 50pM pME
S5 DMEM, 10% FCS,
S6 DMEM, 10% FCS, 50pM |3ME, 7pg/ml dextran sulphate
S7 1:1 RPMI 1640.DMEM, 10% FCS, 50pM |3ME, 7pg/ml dextran sulphate
S8 1:1 RPMI 1640:DMEM, 15% FCS, 50pM |3ME, 7pg/ml dextran sulphate
Table 4.1 Spleen cell culture
Vial Name Medium Components
LA RPMI 1640, 10% FCS, 50pM 0ME
LB RPMI 1640, 10% FCS, 50jiM pME, 7p,g/ml dextran sulphate
LC RPMI 1640, 20% FCS, 50pM pME, 7pg/ml dextran sulphate
LD DMEM, 10% FCS, 50pM pME
LE DMEM, 10% FCS,
LF DMEM, 10% FCS, 50pM pME, 7pg/ml dextran sulphate
Table 4.2 Lymph node cell culture
The survival of cells in SI, S2 and S3 is plotted on a graph (figure 4.1). After 9 
days in culture an aliquot of S3 was removed and lipopolysaccharide added to 
it in an attempt to stimulate the growth of the cells. These cells were then 
labelled S3B and their growth monitored separately. The growth of the cells in 
S3 and S3B is plotted on a graph (figure 4.2). No obvious difference in the rate 
of cell growth in the presence and absence of lipopolysaccharide was noted.
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Figure 4.1
Graph showing cell survival o f  26.305 splenocytes under different conditions. SI 
(RPM I 1640 + 10%  FCS + 50pM  pM E), S2 (RPM I 1640 + 10%  FCS + 50pM  pM E + 
7pg/ml dextran sulphate), S3 ( RPMI 1640 + 20%  FCS + 50pM  pM E + 7pg/ml 
dextran sulphate)
0
48 148 248 348 448 548 648
, Time (hours)r igure 4.1 '
 S3 + S3B
— ----
 S3 + S3B
 S3B
Primary splenocyte culture; 26.305
■3 60ua
2  40
20
48 148 248 348 448 548 648
Time (hours)
Figure 4.2
Figure 4.2
Graph showing cell survival o f  S3 splenocytes and the effect o f  LPS addition. LPS 
w as added to an aliquot o f  S3 cells after 9 days in culture (S3B).
After 11 weeks in culture, the cell line derived from 26.305 splenocytes grew as a 
single cell suspension. An aliquot of the cells was sent to George Klein’s 
laboratory for culture and karyotypic analysis. It was found by Western analysis 
to express readily detectable full length EBNA1 protein (Santiago Silva and 
George Klein, pers. comm.).
The cell line was maintained in continuous culture for more than three months, but 
ultimately could not be maintained indefinitely. It was attempted to re-establish 
the cell line from stocks of S3B frozen at 11 weeks, however this was 
unsuccessful.
4.3 Antisense Oligonucleotide inhibition of EBNA1 Expression
Analysis of the 26.305 cell line (by our collaborator Klein and colleagues) 
established that EBNA1 expression was maintained in the cells even after 11 
weeks in culture. What function EBNA1 plays in tumourigenesis is not clear. To 
assess whether EBNA1 expression is required for the maintenance of tumour 
phenotype in culture (and therefore possibly also in vivo) it was attempted to use 
antisense oligonucleotides spanning EBNA1 coding sequences +1-+15 (EB1C) to 
reduce the expression of EBNA1 in cells taken from line 26 tumours. Two 
different line 26 spleens (26B63 and 26.463), both heavily infiltrated by tumour, 
were made into a cell suspension as described in materials and methods (chapter2, 
section2.32). After an overnight incubation, the cells were aliquoted and
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oligonucleotides added directly to the growth medium as described in materials and 
methods (chapter2, section2.32). To control for possible non specific effects of 
the oligonucleotides, an EBV negative mouse plasmacytoma cell line MOPC31C 
was also included in the assay. In addition, the sense oligonucleotide (EB1D) 
should not effect EBNA1 expression within the cells and so the addition of this 
oligonucleotide also acts as a control for any non specific effect on cell growth or 
survival. The experiment was set up as illustrated in table 4.7. The survival of the 
cells was monitored daily. Both line 26 cell suspensions were replete with very 
large numbers of dead cells and cellular debris, as seen in earlier attempts to 
establish the tumour cells in culture. Trypan blue staining was used to ensure that 
only viable cells were counted. For each vial, the viable cell count was repeated at 
least 8 times at 24 hourly intervals and the results from the two duplicate vials 
were pooled and an average cell count calculated. Using the values thus obtained 
growth curves for each cell line have been plotted (figure 4.3). Although there is 
fluctuation in cell counts, there is no evidence that this is in response to the 
oligonucleotides in either sense or antisense orientation. The control cell line did 
not grow on a logarithmic scale as would have been predicted. All of the cell lines 
demonstrated slow growth initially. The addition of the antisense oligonucleotide 
may have retarded the growth of the 26B63 cells on day 3 and day 4. However 
this difference in growth is not at all evident by day 5 (figure 4.3b).The growth of 
the 26.463 cells may be marginally retarded by the presence of the antisense
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oligonucleotide on day 1 and day 4, (following large additions of the 
oligonucleotide) but not obviously at other time points (figure 4.3c).
4.4 Summary and D iscussion
Cell lines from line 26 tumours cannot easily be established in culture using 
standard media and foetal bovine serum supplement. Cultures derived from the 
spleen survive more readily than cultures derived from lymph nodes. This 
may be due to the presence of additional supporting cells and growth factors 
in the splenic suspension. The fact that the 26.305 cells were only able to 
survive in 20% FCS is supportive of them requiring a high concentration of 
some factor present in the serum. Addition of supplementary cytokines may 
aid the establishment of cell lines from line 26 tumours. This approach will be 
used in future attempts to derive cell lines from line 26 (and line 59) tumours. 
Normal human B cells can be grown in culture through the addition of anti- 
CD40 and IL4 (Banchereau et al., 1991). These could be used in future 
attempts to stimulate the growth of line 26 tumour cells, although anti-CD40 
is not currently readily available to mouse.
Latency I Burkitt lymphoma cells, which express only EBNA1, are sensitive 
to apoptosis in culture. In contrast latency III Burkitt lymphoma cell lines, 
expressing all the EBV latent genes, are resistant to apoptosis (reviewed in 
introduction section 1.1) The additional expression of one or more of the other 
EBV latent antigens in line 26 tumour cells might increase their ability to
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survive in culture. LMP-1 is an obvious target, particularly as current evidence 
suggests that LMP-1 may activate CD40 (reviewed in introduction section
1.1). Indeed, in the laboratory a cell line has recently been established from a 
tumour in a mouse carrying an Ep-LMP-1 transgene in addition to the Ep- 
EBNA1 transgene (Joanna Wilson pers comm.).
The pattern of growth of the 26.305 cell line is suggestive of additional 
changes having occurred in a subpopulation of cells to allow extended (if 
limited) survival in culture. The cells went through a number of crisis points 
where the number of live cells was decreasing before ultimately giving rise to a 
cell line growing steadily in culture. It is of interest that the expression of 
EBNA1 was maintained at a high level in these cells, as it is in in vivo passage 
(Wilson, Bell and Levine, 1996), however, any continued function of EBNA-1 
in these cells remains unclear. The tumour in mouse 26.305 was not detected 
until the mouse was well over a year old, older than most other line 26 mice. 
The tumour was well established; the spleen and lymph nodes were 
massively invaded. It may be that cells of this tumour carried additional 
genetic changes which allowed survival in culture where other line 26 tumour 
cells have died.
From the antisense oligonucleotide experiment attempted it is not possible to 
make any conclusion about the requirement for EBNA1 for cell survival in 
vitro. It is not clear whether the oligonucleotide used had a specific effect in 
the reduction of EBNA1 protein levels. The antisense oligonucleotide used 
here has been subsequently shown to have an inhibitory effect on the growth
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of EBV positive cell lines (Roth, Curiel and Lacy, 1994), however this effect 
was only noted after seven days continuous culture in the presence of the 
oligonucleotide. Another oligonucleotide spanning nucleotides +16-+30 of the 
EBNA1 open reading frame was shown to have a much more dramatic effect 
on cell growth, although again only after seven days in culture. In any future 
experiments it might be possible to improve the downregulation of EBNA1 by 
using two oligonucleotides in combination. The primary difficulty in these 
experiments resided in the lack of established cell lines. The line 26 cell 
suspensions do not survive well for more than a week in culture. Even in the 
absence of oligonucleotide, a large proportion of the line 26 cells died over the 
course of the experiment. Furthermore, EBNA1 is a stable protein and 
prolonged exposure to the antisense oligonucleotide may be necessary to 
significantly decrease the absolute level of protein. To derive meaningful 
results from an experiment of this nature it would be necessary to use an 
established cell line such as that derived from 26.305 or from the crossbreeds 
(as mentioned above) and continue the experiment for a longer time period. 
Other methods of EBNA-1 inhibition could also be employed, for example the 
expression of potential dominant negative forms of the protein (Kirchmaier 
and Sugden, 1997).
Due to the difficulties in establishing a cell line from the tumours at this time 
and the ambiguities in the antisense experiments in primary cells, this line of 
investigation was not continued further.
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Chapter 5
Protein DNA Binding Activity of EBNA1 and LR1 in Ejx 
EBNAlTransgenic Lines
5.1 Introduction
Both protein and RNA expression analysis of EBNA1 in line 26 and line 59 
have suggested that there are clear differences between the lines (chapter 3, 
Wilson and Levine, 1992, Wilson, Bell and Levine, 1996).
Although line 26 has the stronger phenotype, more protein is detected in line 
59 by Western analysis. However, RNA expression in line 59 is not detected 
by Northern analysis whilst a large product is evident in line 26 samples. It is 
clear that the expression pattern of the transgene is complex in both lines, but 
not how this relates to tumourigenesis.
EBNAl is a pleiotropic protein (see introduction section 1.3) and the 
mechanism by which it acts as an oncogene is not clear. It is likely that the 
tumourigenic action of EBNA1 requires the DNA binding activity of the 
protein, potentially to act as a transcriptional enhancer of cellular genes. 
Measuring the level of expression of EBNA1 either by protein or RNA 
analysis does not address the activity of the protein in the transgenic lines. 
Particularly given the ambiguity of expression data, it was attempted to 
address the activity of EBNA1 as a DNA binding protein in each of the
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transgenic lines. The following section describes experiments designed to 
address the relative amounts of EBNAl DNA binding activity between the 
different transgenic lines.
LR1 is a B cell specific, sequence specific DNA binding activity which 
regulates transcription in activated B cells. It consists of two polypeptides one 
of which has been identified as the ubiquitous protein nucleolin (Hanakahi et 
al., 1997). Given the relationship between LR1 and c-myc in humans, and the 
role of LR1 in immunoglobulin isotype class switching (see introduction 
section 1.7b), this protein could well have a role in development of Burkitt’s 
lymphoma. To investigate whether this protein has a role in EBNAl induced 
tumours, its DNA binding activity in nuclear extracts from transgenic tissues 
has been investigated.
The levels of both EBNAl and LR1 DNA binding activities were investigated 
using gel retardation assays. In these assays the protein of interest is allowed 
to form a complex with a labelled duplex oligonucleotide containing the DNA 
sequence of the protein binding site of interest. Complexes are separated by 
electrophoresis and analysed by autoradiography.
5.2  EBNAl DNA Binding activity in Transgenic Mouse Lines
A series of preliminary experiments was carried out to address the nature and 
specificity of complexes detected using mouse splenic extracts on the EBNAl 
DNA binding site oligonucleotide. This was particularly important given that
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data published on EBNA1 binding activity has all been collected from human 
cell protein extracts, cell lines, or bacterially expressed EBNAl and the 
binding activity of mouse tissue protein extracts on an EBNAl binding site has 
not been addressed.
Protein extracts were prepared from whole spleens as described in Materials 
and Methods (chapter 2, section 2.30). The EBNAl DNA binding site 
oligonucleotide used in binding assays contains a single copy of the EBNAl 
binding site. All binding reactions contained poly dldC as a competitor for non 
sequence specific DNA binding proteins.
Two different approaches were used to address the specificity of complexes 
detected. Firstly, specific and non specific unlabelled double stranded DNA 
oligonucleotides were included in the binding reactions as competitors for 
binding to the labelled probe (figure 5.1). In this experiment an extract from an 
EBNA-1 positive line 26 mouse spleen (26.505) which was invaded with 
lymphoma was used. A number of complexes are seen in the absence of a 
competitor oligonucleotide (lane 1, numbered 1-5). In lanes 2, 3 and 4, 
increasing amounts of the unlabelled EBNAl binding site oligonucleotide was 
added as a specific competitor for binding. Even at the lowest concentration, 
this oligonucleotide clearly competes out complex 1. In addition, complex 2 is 
depleted by the presence of this competitor. In lanes 5,6 and 7, increasing 
amounts of the unlabelled oligonucleotide containing the LR1 binding site was 
used as competitor. This oligonucleotide does not compete well for complex 1 
binding, although it does deplete complex 2 to a similar extent as the first
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Figure 5.1
Gel retardation assay o f  D N A /protein  complexes. Nuclear extracts from line 
26 spleens were incubated w ith a labelled EBNA-1 binding site 
oligonucleotide and electrophoresed on a 4%  polyacrylam ide gel @ 200V, as 
described in M aterials and M ethods. Lanes 1-10 contain splenic protein 
extract from m ouse 26.505, lanes 11-12 contain splenic protein  extract from 
m ouse 26.520, lanes 13-14 contain splenic protein  extract from m ouse 
26.363. In lane 15 no protein extract w as added. In lanes 2-4 the unlabelled 
EBNA-1 binding site oligonucleotide w as added as a specific com petitor for 
EBNA-1 binding at 1 , 10  and 100 fold molar excess over probe respectively. 
In lanes 5-7 unlabelled LR1 binding site oligonucleotide w as added at 1, 10 
and 100 fold molar excess over probe respectively. In lanes 8-10 unlabelled 
SP1 binding site oligonucleotide was added at 1, 10 and 100 fold molar 
excess over probe. A rrow s indicate protein  D N A  complexes detected.
oligonucleotide. In lanes 8,9 and 10, an oligonucleotide containing an Spl 
binding site was used as a non-specific competitor. This oligonucleotide only 
has an effect on the complexes at the highest concentration. At 100 fold excess 
(lane 10), the levels of all of the complexes appear reduced.. There is no 
apparent sequence homology between the EBNAl, LR1 and SP1 binding site 
oligonucleotides. Complexes 3,4 and 5 appear to be relatively non specific in 
their binding; they are only minimally affected by any of the competitors used. 
These results indicate that the most specific complex is complex 1. This 
complex is effectively competed for by the unlabelled probe fragment although 
it is not affected by either of the other two competitors used. The LR1 
oligonucleotide competes as well as the EBNA1 oligonucleotide for complex 2, 
although this complex is not affected by the SP1 oligo.
In order to determine whether any of the complexes detected contain EBNAl, 
a second approach was taken. Antibodies to EBNAl were included in the 
reaction mixture. EBNAl containing complexes should be further retarded on 
electrophoresis.
As above, in the following assays an extract from a line 26 mouse spleen 
(26.505) was used, as well as two further line 26 EBNA-1 positive extracts 
(26.520 and 26.363). In initial experimients (figure 5.2), the antibody was 
added to the binding reaction after the protein had been exposed to the 
oligonucleotide. A further incubation period was allowed for antibody binding 
prior to electrophoresis of the reactions. Increasing amounts of the monoclonal 
antibody Aza2E8 does not appear to affect the position or intensity of any of
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Figure 5.2
Supershift assay. Nuclear extracts from line 26 spleens were incubated w ith  a labelled EBNA-1 
binding site  probe, after 20 mins anti EBNA-1 antibodies were added, after a further 20 mins 
the reactions were electrophoresed on a 4%  polyacrylam ide gel @ 200V, as described in 
M aterials and M ethods. Lanes 1-7 contain splenic protein  extract from m ouse 26.505, lanes 8-9 
contain splenic protein extract from m ouse 26.520, lanes 10-11 contain splenic protein  extract 
from m ouse 26.363. In lane 12 no protein  extract was added. +  -antibody added, ~ -no 
antibody. A za2E8 -mouse monoclonal antibody, AM  -human serum  1, WS -human serum  2. 
T he various dilutions o f  antibodies used are indicated. The EBNA-1 specific com plex is 
indicated by the arrow.
the detected complexes (lanes 2,3 and 4). However, increasing concentrations 
of the EBV positive human serum AM depletes complex 1 (lanes 5 and 6). A 
different EBV positive human serum, WS, was added to the reaction which 
also depletes the level of complex 1 (lane 7).
The fact that both human sera deplete complex 1 suggests that this complex 
contains EBNAl. It is possible that the sera react with a mouse protein 
specifically upregulated in line 26, but the apparent mobility of the complex 
correlates well with published data on EBNAl binding (Polvino-Bodnar and 
Schaffer, 1992).
Aza2E8 does not appear to react with EBNAl from this line 26 splenic 
extract. This could suggest that the protein is in a form that the monoclonal 
does not recognise, or that the antibody is unable to recognise EBNAl which is 
bound to DNA. In order to address this the protein extract was incubated with 
the oligonucleotide probe and the antibody simultaneously (figure 5.3). In this 
case the presence of the antibody does deplete complex 1. This suggests that 
the monoclonal does not recognise EBNAl which is already bound to DNA. It 
is believed that Aza2E8 may bind to EBNAl at or near the DNA binding 
domain (Orlowski e ta l , 1990).
Taken together the results of the above experiments suggest that complex 1 
contains EBNAl.
Having determined that EBNAl DNA binding activity is detectable in line 26 
extracts, the relative levels of EBNAl DNA binding activity between the 
different transgenic lines was compared (figure 5.4a and 5.4b). The extracts
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Figure 5.3
Supershift assay. Nuclear extracts and antibodies were incubated w ith  a labelled 
EBNA-1 binding site probe for 40 mins and then electrophoresed @ 200V on a 
4%  polyacrylam ide gel as described in M aterials and M ethods. Lanes 1-4 - 
splenic protein extract from m ouse 26.505, lanes 5-6 -splenic pro tein  extract 
from mouse 59.194, lane 7 -no protein  extract. In lanes 1 and 5 no antibody w as 
included. Antibody was included in lanes 2-4 and lane 7. A za2E8 -m ouse 
monoclonal antibody, undiluted; AM  -human serum  1, 1:100 dilution; WS - 
human serum 2, 1:100 dilution. A rrow  indicates EBNA-1 specific complex.
compared were each prepared from frozen spleen samples as above. An 
equivalent amount of protein was used in each reaction. In order to compare 
the integrity of the extracts, in addition to addressing the protein binding to the 
target EBNAl binding site, extracts were analysed for their ability to bind to 
an Spl binding site. Spl was chosen because it is a ubiquitously expressed 
transcription factor and it was anticipated that the level of this protein is 
equivalent between the transgenic and normal spleens.
Figure 5.4a shows a direct comparison of a line 26 (26.460), a line 59 (59.196) 
and a negative (59.223) extract (lanes 1,2 and 3), respectively. Complex 1, the 
EBNAl containing complex, is detectable in the line 26 sample albeit at a low 
level (marked with an arrow on figure 5.4a). No EBNAl containing complex is 
detected in either the line 59 or the negative sample. This lack of detection of 
EBNAl in the line 59 sample is unlikely to be due to poor integrity of the 
protein extract as the Spl binding activity in the line 59 extract is at least 
equivalent to that seen in the line 26 extract (figure 5.4b lanes 1 and 2). 
Increasing the amount of protein added and the total reaction volume does not 
greatly enhance the binding detected (figure 5.4a lanes 4,5 and 6).
A selection of different line 26 extracts were also compared (figures 5.4a, lanes 
7-10). In this experiment complex 1 is only detected in the sample 26.363 
(lane 9). However, the samples 26.534 (lanes 7 and 8) and 26.520 (lane 10) 
have reduced Spl binding activity (figure 5.4b). In lanes 7 and 8 the amount of 
complex 1 appears reduced and the levels of complexes 3 and 4 increased, 
suggestive of protein degradation. Two different line 59 extracts, 59.140 and
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Figure 5.4a
G el retardation assay. 2p,g to ta l p ro tein  o f  each o f  various splenic nuclear 
extracts were incubated w ith a labelled EBNA-1 binding site 
oligonucleotide and electrophoresed on a 4%  polyacrylam ide gel at 200V, 
as described in M aterials and M ethods. In lanes 4-6 the reaction volume 
w as doubled, and 4p,g to tal p ro tein  o f  each splenic extract as added. 26 - 
p ro te in  extract from line 26 m ouse, 59 - p ro tein  extract from line 59 
m ouse, 60- protein extract from  line 60 m ouse, 61- protein extract from 
line 61 m ouse, ° - p rotein  extract from a transgenically negative mouse. 
A rrow s indicate protein  D N A  complexes detected.
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Figure 5.4b
Gel retardation assay. 2pg  to ta l p ro tein  o f  each o f  various splenic 
nuclear extracts (as in fig 5.4a) w ere incubated w ith a labelled SP1 
binding site oligonucleotide and electrophoresed on a 4%  
polyacrylam ide gpl at 200V, as described in M aterials and M ethods. 
In lanes 4-6, 4fxg o f  total protein  o f  each extract was added. 26 - 
protein extract from line 26 m ouse, 59 - p ro tein  extract from line 59 
mouse, 60- protein  extract from line 60 m ouse, 61- protein  extract 
from line 61 mouse, => - protein  extract from a transgenically negative 
mouse. A rrow s indicate protein  D N A  complexes detected.
59.236 (lanes 11 and 12), a line 61 extract, 61.53(lane 13) and a line 60 extract, 
60.112 ( lane 14) were also assayed. None of these samples has any detectable 
EBNAl DNA binding activity.Using several different extracts from different 
line 59 animals, no EBNAl DNA binding activity has been detected. The level 
of EBNAl binding activity detected in line 26 samples is low and is acutely 
dependent on the quality of the protein extract.
The tumour status of the tissues may also be relavent to the detection of 
EBNA-1 DNA binding activity. All of the line 26 tisssues used were invaded 
by lymphoma. The line 59 samples were pre-neoplastic.
5.3 . LR1 DNA Binding Activity in EBNAl Transgenic Mice
The ability of the LR1 binding site oligonucleotide to compete for complex 2 
bound to an EBNAl binding site oligonucleotide (figure 5.1 lanes 5,6 and 7) 
prompted further investigation of LR1 DNA binding activity in transgenic 
protein extracts.
As yet no antibody to LR1 is available, therefore it has only been possible to 
address the specificity of complexes detected with an oligonucleotide 
containing an LR1 binding site by competition experiments. A line 26 protein 
extract from a mouse spleen, 26.460, which was invaded with lymphoma 
(figure 5.5) was used to address the specificity of complexes detected. A 
number of complexes are detected, labelled A to D (marked with arrows on 
figure 5.5). Complex C is a very diffuse band(s) in this experiment and has
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Figure 5.5
Gel retardation assay. Nuclear extract from line 26.460 spleen w as incubated 
w ith a labelled LR1 binding site oligonucleotide and electrophoresed on a 6% 
polyacrylam ide gel @ 200V, as described in M aterials and M ethods. In lane 11 
no protein extract was added. In lanes 2-4 the  unlabelled LR1 binding site 
oligonucleotide was added as a specific com petitor for LR1 binding at 1 , 10  and 
100 fold molar excess over probe respectively. In lanes 5-7 unlabelled EBNA-1 
binding site oligonucleotide was added at 1, 10 and 100 fold molar excess over 
probe respectively. In lanes 8-10 unlabelled SP1 binding site oligonucleotide 
was added at 1, 10 and 100 fold molar excess over probe. A rrow s indicate 
protein D N A  complexes detected.
been variably detected in other experiments. In lanes 2, 3, and 4 an increasing 
amount of the unlabelled LR1 binding site oligonucleotide has been added to 
the reactions. This appears to compete most effectively for complexes A and 
B, and for complexes C and D only at the highest concentrations of 
competitor. Increasing concentrations of the unlabelled EBNAl binding site 
oligonucleotide was also included as a competitor in this assay (lanes 5, 6 and 
7). Complex A and notably complex D appear to be depleted by high 
concentrations of this competitor. Complexes B and C do not appear to be 
effected. The addition of increasing amounts of the unlabelled Spl binding site 
oligonucleotide as a competitor appears to have a minimal, if any, effect on all 
of the complexes even at its highest concentration lanes 8,9 and 10).
From this experiment it appears that the complex with the highest specificity 
for the LR1 binding site is complex B. It is probable that this complex contains 
LR1. The nature of the protein content of the other complexes is not known. 
From this result, in combination with the EBNAl competition experiment 
(figure 5.1, lanes 5,6 and 7), it appears that there is a mouse protein or proteins 
(detectable in both transgenic and negative protein extracts), which bind semi- 
specifically to both EBNAl andLRl binding site oligonucleotides. The nature 
of this protein or proteins is not known, nor is the relevance to the observed 
transgenic phenotype.
IfL R l has a role to play in EBNAl inducedtumourigenesis, it may be that the 
overall level, or the activity of the protein, is increased in transgenically
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Figure 5.6
Comparison of the DNA binding activity of various splenic protein extracts to 
a labelled LR1 binding site probe (lanes 1-7) and a labelled SP1 binding site 
probe (lanes 8-14). 2pg total protein of each protein extract was incubated with 
the appropriate probe for 20mins and then electrophoresed in a 6% 
polyacrylamide gel at 200V, as described in Materials and methods. The mouse 
from which protein was prepared is indicated. Arrows indicate the complexes 
detected with the LR1 binding site probe.
positive animals. In order to address this a number of different splenic protein 
extracts from line 26, line 59 and negative animals have been compared for 
levels of LR1 DNA binding activity (figure 5.6a). As a control for the integrity 
of the protein extracts, Spl DNA binding activities have simultaneously been 
compared (figure 5.6b). As described above, Spl binding is used as a control 
because it is ubiquitously expressed. Although complexes are detected with the 
LR1 binding site using each extract, only the line 26 sample, 26.460 (figure 
5.6a, lane 1) gives a clear complex B. The Spl activities of the two line 59 
samples, 59.140 and 59.196, are similar to line 26.460 Spl activity, however 
there is no evidence of complex B with either extract (compare lanes 1, 3 and 4 
with lanes 8,10 and 11 in figure 5.6).
Mouse 26.460 had a lymphoma, none of the other tissues used in this 
experiment were neoplastic.
That LR1 DNA binding activity (complex B) is not detectable in any of the 
extracts other than 26.460 is suggestive that the protein is more active or 
present at a higher level in this spleen than in the others looked at.
5.4 Summary and Discussion
The protein/DNA binding studies using an EBNA-1 binding site allowed 
detection of a line 26 specific complex. The apparent mobility, specificty of 
binding and recognition of this complex by EBV positive human antisera 
suggest that it contains EBNA-1. Given this, it appears that the level of
148
EBNAl protein DNA binding activity detected correlates directly with the 
degree of phenotype in the two lines. EBNAl DNA binding activity is only 
detectable in line 26, in which 100% of positive mice succumb to monoclonal 
B- cell lymphoma, while any EBNAl DNA binding activity inline 59 samples 
is below the resolution of the assay used. This result correlates with the level 
of EBNAl RNA detected by Northern analysis in line 26 and line 59 (chapter 
4, Wilson, Bell and Levine, 1996). However it should be noted that there was 
no evidence of tumour in any of the line 59 samples used in these experiments, 
whereas the line 26 spleens were all invaded by lymphoma. Therefore it may 
be that EBNA-1 DNA binding activity is enhanced in tumours, and this could 
also apply to line 59 tumours. Although normal peripheral blood cells carry 2- 
3 subtypes of EBV with EBNA-1 sequence differences, in Burkitt’s 
lymphoma cells only one subtype is detected in each tumour, and an EBNA-1 
variant V-leu is only detected in BL cells.(Bhatia et al., 1996) These sequence 
variants may be more active in oncogenesis. Future experimental work should 
compare the EBNAl DNA binding activities found in pre-tumour and tumour 
tissues of both lines. It would also be valuable to look at the sequence of 
EBNA-1 in pre-tumour and tumour tissues.
If the binding of EBNAl to DNA is a required function for the protein in its 
tumourigenic role, then this difference in the detected activity may explain the 
phenotypic differences between the two lines.
The family of repeats unit of oriP has been shown to act as an enhancer in the 
presence of EBNAl. This activity requires the DNA binding activity of
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EBNAl (reviewed in introduction section 1.3). The oncogenic activity of 
EBNAl could be due to transcriptional transactivation or repression of 
murine genes.
There is a clear discrepancy between the amount of protein detected in both 
lines by Western analysis (Wilson, et al., 1996) and the amount of detectable 
DNA binding activity. There are a number of potential explanations for the 
discrepancy between detectable protein and detectable DNA binding activity. 
It may be that, when expressed to a high level, EBNAl protein dimerises or 
multimerises even in the absence of DNA binding. EBNAl binds to DNA co­
operatively and linkage can occur between bound EBNAl protein dimers 
(Frappier and O’Donnell, 1991, Middleton and Sugden, 1992, Su et al., 1991, 
Mackey etal., 1995). If this can also occur when the protein is in an unbound 
state, then it may be that EBNAl protein in line 59 is formed into assemblies 
which are less readily available to bind to DNA.
In the experiments described here, nuclear protein extracts were prepared and 
used. It has been assumed that EBNAl protein would be nuclear. There is no 
direct evidence for this. It may be that the protein expressed in line 59 is not 
imported into the nucleus, perhaps due to a mutation within the transgene 
sequences or to the effect of cellular sequences in the expressed transcripts 
(chapter 3). If this is the case, it may be possible to detect EBNAl by Western 
analysis of the cytoplasmic fraction. It was attempted to address this using 
immunostaining of spleen and liver tissue sections from line 26, line 59 and 
negative mice. (See Materials and Methods). However, in a preliminary
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analysis using a number of different techniques no EBNAl staining of either 
line 26 or line 59 tissues was detected. These experiments did not include any 
slides of EBV positive cell lines as a positive control for the assay. Given the 
limitations of time for completion of the PhD thesis, this work was not 
completed. Further pursuit of this line of experimentation would be valuable.
It is possible that the difference in the amount of protein detected in tissues in 
each of the lines does not reflect the true level of protein expressed, but is a 
reflection on the ability of the anti EBNAl antisera to recognize differing 
states of EBNAl. In order to detect EBNAl protein on Westerns, it was first 
necessary to carry out an immunoprecipitation on cellular extracts. It may be 
that there is EBNAl protein which is not recognized by the antisera used and 
therefore the apparent levels of EBNAl may not be the true total levels. 
Perhaps the results of the Westerns do give a true indication of the levels of 
EBNAl protein, but the protein in line 59 is less active or alternatively, the 
protein in EBNAl induced tumours is more active (since protein activity in 
pre-tumour line 26 samples has not been addressed). There may be differences 
in the phosphorylaion status of the protein in either line. The integrated 
transgene has not been sequenced in either transgenic line, therefore it is not 
possible to rule out the presence of mutations within the transgene in either 
line. However, a preliminary SSCP analysis of genomic DNA of the lines has 
been carried out to screen for mutations and none were detected (Gordon and 
Wilson, unpublished results).
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In addition to EBNAl, the gel retardation assays performed revealed a number 
of mouse cellular factors which bind to the EBNAl DNA binding site with 
varying degrees of specifity. In human cell extracts, cellular factors have been 
identified which bind to oriP and can compete with EBNAl for binding (Wen 
etaL, 1990, Oh et al., 1991, Zhang and Nonoyama, 1994). These proteins may 
play a role in the replication or maintenance of episomes of DNA from oriP, or 
in the transcriptional transactivation by EBNAl. The cellular factors detected 
in the current assays may represent the mouse equivalent of the human 
proteins.
There would appear to be a factor(s) present in mouse nuclear protein extracts 
which can bind both the LR1 DNA binding site and the EBNAl DNA binding 
site (figure 5.1 complex 2, figure 5.5 complex D). This factor may have a role 
to play in the modulation of EBNAl activity. Nucleolin, one of the 
components of LR1, has been proposed to play a role in the structural 
organisation of S region DNA during recombination (Hanakahi et a l, 1997) . 
Perhaps nucleolin or a related factor has a role to play in the organisation of 
oriP. Supershift assays using an antibody to nucleolin would identify whether 
nucleolin is a component of any of the complexes detected with either the 
EBNA-1 or the LR1 binding site probes.
LR1 has been proposed to have a role in the deregulated expression of c-myc in 
Burkitt’s lymphoma cells and has multiple binding sites within the 
immunoglobulin heavy chain locus (Brys and Maizels, 1994). If the 
expression or activity of this protein is altered by the presence of EBNAl
152
within cells, then this could lead to changes in c-myc expression which might 
be oncogenic. In at least one line 26 tumour there is an elevated protein binding 
activity to an LR1 binding site. LR1 is known to be induced by LPS 
stimulation of resting B-cells (Williams and Maizels, 1991). The induction is 
relatively slow and parallels the induction of switch recombination. It is not 
clear whether the presence of an LR1 binding activity in a line 26 tumour 
protein extract represents an activity required for tumour status or is a 
refection of the actively cycling or differential status of tumour cells. In the line 
59 and negative extracts which are non tumour the number of actively cycling 
cells is likely to be lower. An analysis of LR1 binding activities in line 26 
extracts from pre-neoplastic and early neoplastic tissues would indicate 
whether the detection of this activity is common in line 26 tissues and whether 
its presence precedes other neoplastic events.
LR1 activity has been shown to increase c-myc expression in both EBV 
positive and EBV negative lymphoma cell lines (Brys and Maizels, 1994). 
However, the degree of upregulation of expression is greater in the EBV 
positive cell line (5.5 fold in EBV positive cell line, 3.8 fold in EBV negative 
cell line). Perhaps the presence of EBNAl is a factor in this difference.
The pattern of expression of LR1 protein has led to the proposal that it may 
be directly involved in the recombination of the immunoglobulin loci in B-cells 
(Williams and Maziels, 1991, Brys and Maizels, 1994). If this is in fact the 
case, it is possible to speculate, given the large concentration of LR1 binding 
sites at the c-myc gene locus as well as at the immunoglobulin loci, that this
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protein may facilitate improper recombination events between these two loci 
giving rise to the translocations associated with Burkitt’s lymphoma.
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Chapter 6
Co-operating Cellular Factors in Ep EBNA-1 induced 
Lymphomas
6.1 Introduction
Although two different lines of EBNA-1 transgenic mice succumb to B-cell 
lymphoma, all the tumours are monoclonal (Wilson and Levine, 1992, Wilson, 
etal., 1996). The expression of EBNA-1 alone is not sufficient therefore for 
malignant conversion of a B cell. The following sections describe a number of 
experiments designed to investigate what cellular factors play a role in 
tumourigenesis and maintenance in concert with EBNA-1 in these transgenic 
mice. Identification of factors which co-operate with EBNA-1 may also shed 
light on the mechanism by which EBNA-1 acts in tumourigenesis. 
Rearrangements of one or several known proto-oncogenes may be involved in 
the EBNA-1 induced lymphomas. Given the association between c-myc and 
EBNA-1 in Burkitt’s lymphoma, the c-myc locus is a strong candidate for 
rearrangement in EBNA-1 induced lymphomas. The rearrangement could take 
a number of forms including translocation, chromosomal amplification or 
deletion and point mutations. Local DNA rearrangements can be detected by 
Southern analysis. Point mutations are often not detected by this technique. 
Single stranded conformational analysis (SSCP) is a powerful technique for the 
detection of point mutations. Karyotyping of tumour cells allows detection of
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gross chromosomal rearrangements such as translocations and changes in 
ploidy.
Ep EBNA-1 transgenic mice are remarkably similar in phenotype to those
described in E\i-c-myc transgenic mice (Adams et al., 1985). This raises the
possibility that the EBNA-1 phenotype is caused by a direct action of 
EBNA-1 on c-myc expression. In order to address this, the levels of c-myc 
RNA expression have been analysed in both pre-neoplastic and neoplastic 
tissues from line 26 and line 59 mice compared to transgenically negative 
controls.
To look directly for a co-operative effect in lymphomagenesis between 
deregulated c-myc expression and the presence of EBNA-1, an attempt was 
made to cross E\i-myc transgenic mice with the EBNA-1 transgenic lines. In
another approach, injection of mineral oil into certain substrains of Balb/c mice 
causes the development of plasmacytomas bearing a c-myc translocation 
similar in nature to that found in sporadic BL (introduction section 1.2, 1.6d). 
This protocol has been utilised to attempt to induce c-myc translocations in 
vivo in Ep EBNA 1 mice. Both the rate of onset of tumourigenesis and the
localisation of any c-myc translocations could be effected in transgenic versus 
negative animals.
A number of proto-oncogenes have been identified which cause 
lymphomagenesis in transgenic mice when the expression of the gene is 
directed by the immunoglobulin heavy chain enhancer (reviewed in Adams and 
Cory, 1991 and introduction section 1.4,1.8). Both bcl-2 andpim-1 are proto­
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oncogenes which have been shown to cooperate with c-myc when the 
transgenic mice in the separate lines have been crossbred (reviewed in 
introduction section 1.8). We have crossed both line 26 and line 59 mice with 
Ep bcl-2 mice and Ep pim-1 mice in order to investigate to which oncogene 
complementation group EBNA-1 might belong.
6.2 The Role of c-m yc  RNA expression in EBNA-1 Induced 
Lymphomas
In cell lines and tumours in which c-myc expression is deregulated, the level of 
c-myc RNA is upregulated compared to that in normal cells. A panel of 
transgenically positive total RNAs have been compared to negative total 
RNAs for the level of c-myc expression by slot blot analysis (figure 6.1). RNA 
loading was normalized by reprobing the blots with GAPDH (as described in 
section 2.x). The RNAs used were prepared from the spleens (or in some 
cases lymph node) of animals which varied in age and in tumour status. The 
transgenically negative RNAs examined exhibit an approximately three fold 
variation in the level of c-myc RNA detected. This probably reflects the 
variation in the age of the mice and normal proliferative state of the spleens. It 
does not appear that the level of c-myc RNA in line 26 or line 59 tumours is 
consistently higher than that detected in normal (non-neoplastic) spleens. 
Equally there is no obvious difference between transgenically positive and 
negative non tumour samples. Only one sample shows a greatly elevated level 
of c-myc, 26. 478 (number 17). This RNA was prepared
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loading 
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from the spleen of a 3 week old line 26 mouse. The higher level of c-myc 
expression detected in this sample may be due to the young age of the mouse, 
rather than an effect of EBNA-1. However, it is not possible to determine this 
as no negative control of the same age was included in this experiment. The 
spleen was histologically normal.
Recent evidence has suggested that EBNA-1 expression in cell lines in vitro 
leads to the induction of the recombinase activating genes 1 and 2 (Srinivas and 
Sixbey,1995). A probe for RAG2 was used on the RNA slot blot described 
above and the results plotted on a graph (figure 6. lb). The level of RAG2 
expression was extremely low in all samples. Despite this, there is no evidence 
of an upregulation of RAG2 in EBNA-1 transgenic tissues, whether or not 
they are neoplastic.
6.3 DNA Rearrangements in EBNA-1 induced Lymphomas
Detection o f  DNA Rearrangements by Southern Analysis 
Tumours in line 26 and line 59 have been routinely screened for the presence 
of DNA rearrangements of the c-myc gene by Southern blot analysis. In figure 
6.2a, DNAs from 12 different tumours digested with EcoRl and EcoKV reveal 
no rearrangements of c-myc. The same result was obtained from 13 other line 
26 tumour DNA samples (Wilson, et al., 1996). This would suggest that there 
are no local rearrangements of the c-myc locus in these tumours. However, it is 
possible that digestion with further enzymes could reveal rearrangements not
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Figure 6.2
5[xg o f  tissue DNAs digested with EcoRI or EcoR V  as shown, and Southern blotted 
and probed, stripped and reprobed as described in M aterials and M ethods.
Lane 1 and 14 -tum our, 26.3 spleen; lane 2 and 15 -tum our, 26.4 spleen; lane 3 and 
16 -tum our, 26.7 lmph node; lane 4 and 17- tum our, 26.16 spleen; lane 5 and 18 - 
tumour, 26.17 liver; lane 6 and 19 -tum our, 26 .20 liver; lane 7 and 20 -tum our,
26.21 spleen; lane 8 and 21 -tum our, 26.24 lym ph node; lane 9 and 22 -tum our, 
26.30 liver; lane 10 and 23 -tum our, 26.41 lym ph node; lane 11 and 24 -tum our,
59.21 lymph node; lane 12 and 25 -M oM LV induced tum our, 26.175 thym us; lane 
13 and 26 -norm al transgenically negative spleen.
a. c-m yc probe (m m ycl 1, table 2.3); b. Bcl-2 p robe (m b c ll, table 2.3); c. p53 probe 
(mp531, table 2.3); d. cyclin D1 probe (m c y c D l, table 2.3)
discernible here due to the large size of the fragments and consequent poor 
resolution of similar sized bands. The Southern blot described above has been 
reprobed with probes to a number of other genes thought possibly to have a 
role in lymphomagenesis; bcl-2 (figure 6.2b), p53 (figure 6.2c), cyclinD 1 (figure 
6.2d), pim -l (data not shown). No rearrangements in these genes have been 
detected using this approach.
Detection o f  DNA Rearrangements by SSCP Analysis
It has been shown that in many Burkitt’s lymphomas and mouse 
plasmacytomas there are mutations within the coding sequence of the 
expressed c-myc allele (Bhatia et al., 1993) using single stranded 
conformational polymorphisms analysis (SSCP)in clonal cell lines. It has been 
proposed that these mutations may lead to a more active c-myc protein. SSCP 
has been utilised to screen line 26 and 59 tumour DNAs for the presence of 
mutations within the c-myc coding sequence. Bhatia et a l found that the 
majority of mutations detected were located within residues 1-80 (c-myc exon 
2, 5’). Tumour DNAs from line 26 and line 59 were screened by SSCP for the 
presence of mutations within residues 1-85 (figure 6.3a). Each PCR reaction 
was repeated at least twice and the products analysed under a number of 
different gel electrophoresis conditions. The DNAs were prepared from tissue 
samples which contained a range of cell types, even tumour bearing samples 
would contain a significant proportion of ‘normal’ cells. Moreover any DNA 
mutations might only effect one of the copies of c-myc within the cell.
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Therefore ‘normal’ DNA forms are likely to be the most prevalent even in 
tumour samples and tumour specific mutations would be expected as 
additional, perhaps faint, bands. In some samples additional faint bands were 
detected, however, variably some transgenically negative non tumour samples 
also contained these bands and they therefore may reflect alternative 
conformations. No additional bands could be unambiguously assigned 
specifically to tumour bearing DNA. Tumour DNAs have also been screened 
for mutations within exon2, 3’ (residues 46-124) , again no unambiguous 
additional bands were apparent (figure 6.3b).
Therefore, under the conditions described here using SSCP with tissue 
samples, it was not possible to determine if point mutations were present 
within any of the c-myc sequences or not. A method to overcome this 
(without generating cell lines) would be to sort the cells in the tissues first 
(FACS) in order to enrich for B cells.
Detection o f  DNA Rearrangements by Karyotyping
Many of the c-myc/IgH translocations found in endemic Burkitt’s lymphoma 
occur distal to the c-myc locus and therefore are not easily detected by 
Southern analysis. Karotypic analysis of tumour cells is a method to detect 
gross chromosomal abnormalities in EBNA-1 induced lymphomas. 
Karyotypic analysis of EBNA-1 tumours is being carried out by our 
collaborators in Stockholm (Santiago Silva and George Klein). Cell suspensions 
were prepared from line 26 tumours and frozen as described in materials and
166
methods (chapter 2, section 2.32). Aliquots were subsequently transported to 
Stockholm. An attempt was made to passage some of the cell samples in SCID 
mice prior to karyotypic analysis. For the majority of cell suspensions this 
technique was unsuccessful. However, using this approach 2 line 26 tumours 
(C57B1/6 background) and 3 tumours from mice double positive for the 
EBNA-1 transgene and an N-myc transgene (section 6.2) have been 
successfully karyotyped (figure 6.4 a-e). A further 13 EBNA-1 positive 
tumours have been karyotyped directly from cell suspensions without 
freezing or passage in SCID mice. The most common changes are illustrated in 
table 6. 1. Trisomy 10 was present at a variable incidence (percentage of plates 
counted) in 10 of the 18 tumours analysed. Trisomy 15 was present in 63% of 
the tumours positive for the EBNA-1 transgene only and in 100% of tumours 
carrying both the EBNA-1 and N-myc transgenes. However trisomy 15 has 
not been detected in any of 5 tumours positive for both EBNA-1 and c-myc 
transgenes. Trisomy 10 and trisomy 15 were concurrent in 6 of the tumours. 
Other abnormalities were also detected, but they vary from tumour to tumour. 
Only 2 translocations were detected, one thought to be t(2;5;12) in a line 26 
tumour, and one t(12;15) in a line 26/N -myc double positive tumour.
6.4 Crossbreeding of EBNA-1 and m yc  Transgenic Mice
Assessment of the rate of tumour development and tumour types in mice 
positive for both the EBNA-1 transgene and the E\x-myc transgene (Adams et 
a l, 1985) could give valuable information about any
167
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co-operative effect of the two oncogenes. It was therefore attempted to 
crossbreed E\i-myc transgenic mice with Ep EBNA-1 mice of both line 26 and
line 59. Ep-c-myc transgenic mice in the FVB strain background were imported
from Anton Bems’ laboratory in Amsterdam. These mice were generated in 
the laboratory of Professor Bems using the same transgene as originally 
described by Adams etal. (1985). The construct contains the immunoglobulin 
heavy chain enhancer inserted 5’ to the murine c-myc gene. A tag of 600bps of 
<j)xl74DNA was included in the 3’ untranslated region of c-myc exon 3. At the
time of import it was noted in Professor Bern’s laboratory that there were 
difficulties in maintaining the line. These mice were bred in quarantine and 
their progeny used to form a colony of mice designated line 86. Initially, tail 
DNA from line 86 mice was screened by slot blot analysis using a probe 
fragment supplied by the Bems laboratory (chapter2, section 2.33). Mice 
identified as apparently positive by this screen were used in subsequent 
breedings to line 26 and line 59. This gave rise to 76 offspring in the line 26 
background, designated line 26/86, and 61 offspring in the line 59 background, 
designated line 59/86. It was attempted to determine the Ep-c-myc transgene
status of these mice using Southern blot analysis. Using the probe fragment 
and conditions supplied by the Bems laboratory it was not possible to detect 
any mice positive for the Ep-c-myc transgene. The line 86 mice used in the
initial round of breeding were retested for transgene status by Southern blot 
analysis and no positives were detected. In addition, Southern blots of line 86 
and line 26/86 DNAs were hybridised with a probe to the IgH enhancer and to
172
mouse c-myc exon 2 and 3, but no evidence was found that any of the mice 
harboured E\i-c-myc transgene sequences. Finally a PCR approach was 
attempted to assess the transgene status. Primers were designed to amplify 
transgene sequences between the IgH enhancer and c-myc exon 1 (Myc 1 and 
IgH 1, chapter 2, table 2.2). A product of lkb in size should only have been 
obtained from transgenically positive DNA. As a control for the PCR reaction, 
primers to c-myc exon3 were included (MycE 3 5’ and MycF 3 5’) which 
should yield a product of 200bps in size. A range of line 86 and line 26/86 
DNAs was used. In all the reactions the control 200bp product was detected, 
but no additional products were detected (data not shown). The DNAs used 
were intact and the Southern blots were in order as these have been reprobed 
using an EBNA-1 probe and the EBNA-1 transgene status has been 
unambiguously determined. It has therefore been concluded that none of the 
mice used to establish line 86 was in fact positive for the E\i-c-myc transgene. 
All of the 26/86 and 59/86 progeny have been closely monitored for tumour 
appearance. The data collected on these mice (transgene status and tumour 
phenotype) is presented in tabular form (Appendix 1.1 and figure 6.5). The 
Ep-EBNA-1 positive mice of cross 26/86 succumbed to monoclonal B cell
lymphoma indistinguishable in appearance to the usual line 26 lymphoma 
pathology, but with an increased latency when compared to standard line 26 
mice in C57B1/6 background (figure 6.5a and b). The strain background of the 
26/86 and 59/86 mice was FI FVB / C57B1/6. Of the EBNA-1 negative mice in 
the 26/86 cross (n=36), only 3 suffered from suspected lymphoma (16,18, and
36), and in the 59/86 cross (n=42) only 2 (23 and 26). The lack of lymphoma 
phenotype in the EBNA-1 negative mice is also supportive of the above 
conclusion that the mice did not harbour a c-myc transgene. It is not clear 
whether the lymphoma phenotype in the five EBNA-1 negative mice was due 
to any potential cryptic myc transgene sequences. The mice were old at 
presentation with the phenotype (2 years) and the spontaneous tumour rate in 
this hybrid strain background is not known. This incidence is within the 
spontaneous frequency that might be detected in old mice in normal colonies 
(although satistics on this particular FI strain are not available).
As it was not possible to establish a clearly c-myc transgene positive stock 
from line 86, a further attempt to import E\i-c-myc mice was made, this time
from Professor Klein’s stock established from the original line generated by 
Adams et a l . Due to Home Office and Ministry of Agriculture regulations 
(with UK quarantine restrictions) it is a good deal faster to export than import 
mice. During the process of importing Ep c-myc mice (from the original Adams
et a l stock) and Ep N-myc (Dildrop et a l, 1989), lines 26 and 59 were 
exported to the Klein laboratory. Dr. S Silva has initiated the crossbreeding of 
both line 26 and line 59 with Ep N -myc mice and Ep c-myc mice. The Ep c- 
myc mice succumb to rapid onset lymphomas, the tumour incidence in this line 
of Ep N-myc mice is low as is the level of transgene expression. The first 
progeny in these crossbreeds are described. The first litter of mice from the
174
Figure 
6.5
Survival of 
26/86 
progeny, a. G
raph 
show
ing 
percentagesurvival of 
E
B
N
A
1 
positive 
26/86 
progeny 
com
pared 
to 
line 
26 
in 
the 
C
57B
1/6 
strain 
background, h. Diagram
 
illustrating 
incidence 
of 
neoplasia 
in 
26/86 
progeny. W
hite 
boxes 
indicate 
m
ice 
still survivng. Red 
boxes 
indicate 
death 
due 
to 
lym
phom
a, stripes 
indicates 
an 
early 
stage 
of 
neoplasia. Green 
boxes 
indicate 
end 
of 
experim
ent with 
no 
abnorm
alities 
detected. Blue 
boxes 
indicates 
death 
due 
to 
som
e 
abnorm
ality 
other than 
lym
phom
a.
■ ■a
O O Q
H
□□
><a<i
a
a>
SB su rv iva l
' : % .
.
- V; -/' .<> i
i— —......... .
— K 
8 2
25 3 o ^
L /i o
C/3
<<’
29
3
ft
ts>
oc
Os
oTOft3
no
3-a
29■n
O.
Q .3
ftK»Os
line 26 cross with Ep N-/wyc mice were followed until they were
approximately 170 days old (figure 6.6a). 4 out of 5 double positives all 
succumbed to lymphoma between 90 and 120 days of age. Only 1 of 4 
EBNA-1 positive/N-mjyc negative mice succumbed to lymphoma within this 
time period (at 140 days of age). For a number of mice included in this study 
,the N-myc transgene status is unclear (tested by S.Silva); on the figure these 
animals have been included as N-myc negative. One mouse which was EBNA- 
1 negative and status unclear succumbed to lymphoma at around 150 
days of age. The first litter from the line 59 cross with the Ep N-myc mice
have been monitored to approximately 330 days of age (figure 6.6b). 2 of 5 
double positive mice have succumbed to lymphoma within this time period 
(one at about 300 days of age and one at about 330 days of age). None of the 
single positive mice or the negative mice have succumbed to tumours within 
this time period. Whilst preliminary, these results (a shorter latency to tumour 
onset in double positive mice) are suggestive of a co-operation between 
EBNA-1 and N-myc in tumourigenesis. In the cross between line 26 and Ep c-
myc mice, 11 out of 11 double positive mice have succumbed to tumours, the 
majority in less than 75 days (figure 6.6c). In a 300 day observation period, 
only 2 of 6 EBNA-1 positive/c-myc negative mice have succumbed to 
tumours, one at 59 days and 1 at 83 days. 2 of 4 EBNA-1 negative/c-myc 
positive mice succumbed to tumours, both at 77 days. In the cross between 
line 59 and Ep c-myc mice, sixteen double positive mice have been obtained
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(figure 6.6d). Over a 300 day observation period 9 tumours have arisen in 
these mice, the majority of which have arisen in less than 100 days. Few 
tumours have arisen in EBNA-1 positive/o/wyc negative mice; 2 in 12 mice, and 
both after 100 days. Only one tumour has arisen in the EBNA-1 negative/c- 
myc positve mice, at 112 days. The results of the crosses of both Ep EBNA-1
transgenic lines with Ep c-myc transgenic mice are strongly suggestive of a co­
operation between EBNA-1 and c-myc in tumourigenesis.
6.5 Induction of c-m yc  Rearrangem ent in vivo 
In another approach to investigate the effect and mechanism of c-myc 
translocation in EBNA-1 induced lymphomas, the susceptibility of some 
substrains of Balb/cmiceto plasmacytomas by induction with the mineral oil, 
pristane, was utilised. This investigation was designed to address whether the 
induction of c-myc translocations co-operates with EBNA-1 in 
tumourigenesis, and also (in the longer term) whether the nature of any 
translocations detected differs from those found in plasmacytomas in negative 
mice. This experiment is similar to the cross breeding with Ep c-myc transgenic
mice in that it addresses whether EBNA-1 expression and deregulated c-myc 
can co-operate in tumourigenesis. In addition however this experiment can 
address whether the presence of EBNA-1 can effect the translocation process 
in vivo. Differences in the precise location of the DNA breakpoints in 
translocations have been found between endemic Burkitt’s lymphoma (99%
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EBV positive) and sporadic Burkitt’s lymphoma (70% EBV negative) 
(Introduction section 1.2). Both line 26 and line 59 mice were bred into a 
Balb/cAnN background, generating line 26B and line 59B respectively. Due to 
the limitations of time it was not possible to breed the lines into a pure 
Balb/cAnN background. However the mice used in the pristane induction 
experiment were from at least the second backcross into the Balb/c background 
(on average 75% or more Balb/c).
Line 26B and line 59B mice were injected with pristane and their subsequent 
lymphoma development closely monitored. The protocol requires 3 injections 
of pristane, 2 months apart, as described in Materials and Methods. Very few 
overt plasmacytomas were detected in either of the lines. However, the 
pathology of the pristane injected mice was complicated. The incidence of 
neoplasia was low in the negative mice (figure 6.7). Incidence of lymphoma 
was usually grossly obvious due to tumour invasion of the spleen, lymph 
nodes and/or liver. Diagnosis of plasmacytoma was more subjective. Samples 
of spleen, liver, lymph node, thymus and any other tissue of abnormal 
appearance were sent for pathological analysis from all animals included in this 
study. Pristane is an irritant which causes granulomas and the production of 
ascites fluid in the peritoneal cavities of injected mice. Animals in this study 
were euthanased on any outward sign of ill health, or on gross swelling of the 
abdomen (which was most often as a result of the build up of ascites fluid). 
Previous studies of plasmacytoma incidence have assigned a diagnosis of 
plasmacytoma on the basis of the appearance of cells in one drop of the
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ascites fluid. The presence of 10 ‘characteristic plasmacytoma cells’ per slide 
led to the diagnosis of plasmacytoma (Potter et al., 1985). In this study 
diagnosis was on the basis of the appearance of solid tissues and hence 
incidence of plasmacytoma may be under-represented as a result. An analysis 
of all of the 26B pristane injected mice does not indicate any clear co­
operation (in terms of tumour onset) between EBNA-1 and pristane in 
tumourigenesis (figure 6.7 and 6.8). However there were two variables in this 
study; the mice injected ranged in age at the first injection of pristane and also 
in their backcross status into the Balb/c background, both of which may 
influence tumour onset. At the start of the study mice of backcross 2 (on 
average 75% Balb/c) received the first injection of pristane at different ages : 7 
mice at 162 days old, 9 mice at 105 days old, 10 mice at 78 days old, 9 mice at 
50 days old. Subsequently mice of backcross 3 (87.5% Balb/c) and backcross 4 
(93.75% Balb/c) all received the first injection between 24 and 34 days of age 
(25 mice in total). When these two groups of mice are analysed separately, a 
clear difference in tumour onset is observed (figure 6.9a). Taking age only into 
account the curve of the graph for those mice under 2 months of age at the first 
injection (pink) is less steep than when taking age and backcross into account 
(figure 6.9b, red). This suggests that both variables probably influence tumour 
onset. Comparing the phenotypes of mice of backcross 2 injected at different 
ages (figure 6.9c, blue boxes) there is no striking difference in tumour onset. 
However, tumour onset is accelerated in the mice of backcross 3 and 4 (figure 
6.9c red box). The numbers of mice involved in these comparisons are small,
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Effect of Pristane on Line 26B Survival
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Figure 6.9
Graphs illustrating the effects that backcross stage to BalbcAnN and age at first 
pristane injection have on the survival o f  line 26B m ice injected w ith pristane. a. 
Illustrates the effect o f  backcross status and age at first injection o f  pristane. The 
survival o f  pristane injected m ice o f  backcross 2 (blue) and o f  backcross 3&4 
(red) have been plotted separately. M ice o f  backcross 2 varied in age at first 
injection o f  pristane. M ice o f  backcross 3&4 were all less than tw o m onths old 
when first injected with pristane. For com parison the survival o f  26B m ice without 
pristane injection has also been plotted (green) and with pristane injection 
(yellow), b. Illustrates the effect o f  age at first injection o f  pristane on survival.
The survival o f  26B m ice o f  all backcrosses which w ere less than two m onths old 
when first injected with pristane (pink) is com pared to the survival o f  all pristane 
injected 26B mice (yellow).
2  cp o o
=*• a
<c 3 
CP CTQ
cr. as 
cp rjQ o rt
cp as 
C L  - *
c r  5cp rx
3
o_
c
C lCDQ-
H
a5’era’(JQ s—J rjft
3 3\
mi o“ o
2  S’
£ Z.
t3 -
=» 8  
t o  cr. 
4-l o
as
a  a.
U> 33 
4- 2 .
Q- &as as
V I  3  C/s O
£> H3 3“(JQ CP CP —s CP CL
O
c r  o
— ; £) 
3 3s -3 —•3 -  cr» C® 3"
3“ o CP
-3 <5.3" CP 
CP o3CP 
C l  •“+ ^  vf
2O CP
X  c/a
—  O
3“
CP
CP
3O
v?■o
cp
3“CP
cr 3o rr o-io
c/a
C /a
to* O
H ^3“ CXn> y
3 °
5 .
o '  o  cp e
cr cr re3 &s 3o < cp 7T CD a
^  a *  ro cp o c/s CP X1/3 3 MU>
Rp "Oo
CP4L 33 
3  —t  c/a
3  » co ?p <CL CP
u>
SP-fL
CL lO3 4L v: I
C /a  0 3
4L
K>
UiOCL3v-
K)
-o00CL3V-c/a
CL CP 3 Ocr cp
s  °CP >-+j 
^  3
o SX U  
cp 3
c/a c/a
8
CP
C l
moc
z
>
33O
□ 
cP fe
□□
m ~e
to to
001 CL 3 ’<
ONtoCL3v;
to
u>
£p-fL
□ □
□
□
c f e
Age 
at 
first
Backcross 
injection
CL 3 '
<T> 3  qg 9t 
p  P
s* s -
C l  c/ 2
cr
cr
c p
cp c/3
cr
p
cr
cp
p
3
dVi
cr
p
<cp
P
Cl
<!
C P-
o
T3
3 'crq
*3
$
3
V !
<—f
O
3
p
cr
CP
oz>
3o
cC/5
CD
az>
$
&
cc
CL
CP
CL
cr
v
p
f —t -c
3oc
H
p
CPT3
3
CP
Cl
moo
2 :>
c'
CL
o '
&
CP
C/3
f—hcr
CP
c /3
3'ca
CP
3
c!-»
CP
C/3
5*
o
£ .  
c p
*  CL
1 8 
I! 05
o ’ os ICP“  3
*“ c
<8
CL
^  3 
§. ^  
E  ->s
cn *n o — 
C  TO 
*-► C 
= “ -t cp -  g  
C
<8
CL
?
I
cr
~  X3
O 0
§  s- 
>  <
£
CL
a
CP
a
CP
Cl
5 ‘
£L
O
(/)
C/3
2 :
C/3
3-vj
C/3
CP
CP
a
CP
3  P- o '
O' _3 >pa l—1
3 :  3 -  " a
v i  cp ^
3  3  a*
E  cp
3 *  CP <  ►“!
CP CC3
O o
C / 3  P— 1
3
£*o '
3
CP
CD
® \
cr
o'
r —f
O1-+3
tfloo
2
CL
<8
C / 3<“*-
CP
CL
C / 3
*3-
CP
3  
o'
3 o-
9- S
O  CP3  »
CP q
o
5T $
26B14 HH H
$26827 Hh H 
26B28 + H  
26B29 ■
26530 ■
26532 H
26B35 H
26B39 -fr H
26B43 H
26B44
26B45 •
2 6 5 4 6  HH H *
26547 «
26552 ■ H 
26555 h  
26567 + H 
26B70 + H 
26B80 « 
tail DNA
and it is not possible to separate the effects of these two variables. Given that 
susceptibiltiy to pristane induction is known to be tightly strain dependent, 
and that heterogeneity in genetic background can greatly influence the onset of 
tumour development (as is clear from the effect of crossing C57B1/6 line 26 to 
FVB mice, figure 6.5), it is more relevant to use the data set from backcross 3 
and 4 in making conclusions about the effect of pristane induction. By this 
criteria, the current evidence indicates that pristane induction in the Balb/c 
strain background does accelerate the development of tumours in line 26B, 
compared to non injected in C57B1/6 strain background. All of the line 59B 
mice were of backcross 2 and were first injected between 30 and 50 days of 
age (appendix 1.2). As yet the numbers of mice which have developed any 
phenotype are small, but there is no observable difference between the 
transgenically positive and negative mice.
Splenic DNA has been prepared from the majority of pristane injected mice. 
By Southern analysis no rearrangements involving the c-myc locus have been 
detected in any of the DNAs (figure 6.10). However, only an EcoRl digest of 
the DNA has been used. Digestion with further enzymes could reveal 
rearrangements not discernible here due to the large size of the fragments and 
consequent poor resolution of similarly sized bands. A number of cell 
suspensions were prepared from tissues (spleen, lymph node or thymus) of 
line 26B pristane injected mice as described in materials and methods (chapter 
2, section 2.32). These were sent to George Klein’s laboratory in Stockholm 
and are awaiting karyotypic analysis.
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6.6 Cross breeding to E\i-bcl-2 Transgenic Mice
The oncogene bcl-2 is commonly involved in follicular lymphoma in humans. 
Mice carrying an E\i-bcl-2 transgene develop monoclonal B-cell lymphomas
with a very long latency to tumour development (reviewed in intoduction 
section 1.7d). To address whether there is any co-operative effect between 
EBNA-1 and bcl-2 in tumourigenesis, both line 26 and line 59 mice have been 
crossed with E\i-bcl-2 transgenic mice. The bcl-2 transgenic mice have been
designated line 85. In the line 26 cross there are 68 offspring (tabulated in 
appendix 1.3), of which it would be expected that 25% would be double 
positives if there were no detremental developmental consequences. The actual 
representation of double positves was slightly lower than expected (19%), but 
this was the same as the percentage of mice EBNA-1 negativdbcl-2 positive 
(figure 6.11). In the line 59 cross there are 40 offspring (tabulated in appendix 
1.4). Again, the representation of double positive mice is lower than expected 
(11%) and lower than either transgene singly (figure 6.12). However, the total 
number of mice involved in this study is still small and therefore these 
differences may not be significant, as the mice of lines 59 and 85 are long lived 
with a long latency period to tumour onset. The study of the line 59/85 
crossbreed is ongoing. As yet there is no observable increase in the rate of 
lymphoma onset between the single positive mice and the double positive 
mice. Over a two year observation period, no tumours have arisen in 4 double 
positive mice. Of the 7 EBNA-1 positive/bcl-2 negative mice, 3 have
190
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Figure 6.11
Pie chart showing percentage distribution o f  transgene status o f  offspring in line 26/line 85 
cross
Line 59 X Line 85
EBNA1-/Bcl2-
51%
EBNA1+/Bcl2-
19%
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11%
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Figure 6.12
Pie chart showing percentage distribution o f  transgene status o f  offspring in line 59/line 85 
cross
succumbed to lymphoma, and the cause of death of two further mice is not 
known. 4 of 10 EBNA-1 negative/bcl-2 positive mice have succumbed to 
lymphoma, and the cause of death of 3 further mice is not known (fig 6.13). 
The majority of the EBNA-1 positive mice in the 26/85 cross have 
succumbed to lymphoma (figure 6.14a). Comparing littermates, there is very 
little difference between the lymphoma incidence of EBNA-1 positive mice 
and that of the double positive mice (figure 6.14a and b). The numbers of mice 
involved in these comparisons are still relatively small; 14 mice EBNA-1 
positive/6c/-2 negative and 10 mice EBNA-1 positivdbcl-2 positive. 
Unfortunately, the date of death of 3 double positive mice was not recorded. 
All three mice survived beyond 280 days of age, but died at some point in the 
following 60 days and are represented at the mid point of this peroid (310 
days) (marked in purple on figure 6.14a). As the total numbers of mice are 
small, the inclusion of these 3 mice does alter the death curve (figure 6.14c, 
red). In addition, the shape of the EBNA-1 positive/Z>c/-2 negative death curve 
is altered by the inclusion of another 3 mice. One of these mice did not 
succumb to lymphoma and survived for two years. For the other two of these 
mice, the exact date of death was not known, although they survived beyond 
365 days of age (figure 6.14c, dark blue). If the survival of the double positive 
mice is compared to the survival of standard line 26 (figure 6.14b and c, pale 
blue) ,then there is no difference detectable in the rate of tumour onset (figure 
6.14a,b and c). The strain background of the standard line 26 and the line 85 
mice is predominantly C57B1/6, thus there should be little or no strain
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Figure 6.14b
Graph illustrating the incidence o f  lym phom a in progeny from the cross betw een line 26 and Bcl2 
transgenic mice. For com parison the survival o f  line 26 m ice from  outw ith this cross (100 m ice o f 
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Figure 6.14c
Graph illustrating the incidence o f  lym phom a in progeny from the cross betw een line 26 and 
Bcl2 transgenic mice. These curves include som e m ice for which the age at death was not 
recorded. Three EBNA1+/Bcl2+ m ice survived for m ore than 280days, but died at som e point in 
the following 60 days without being recorded and have been plotted at 310days. Tw o EBNA-1 
positive mice survived for m ore than 370 days and died at some point within the following 12 
months without being recorded and have been plotted at 550 days. In addition one EBNA-1 
positive m ouse did not succum b to lym phom a but was normal when sacrificed at 2 years o f  age. 
For com parison the survival o f  line 26 mice from outw ith this cross (100 m ice o f  predom inantly 
C57B1/6 strain background) has also been plotted.
difference between the two transgenic lines. The average age to death of the 
EBNA-1 positive//>c/-2 negative mice in this study is 239 days. The average 
age to death of the standard line 26 mice is 204 days. The average age to death 
of the double positive mice is 223 days bearing in mind that the 3 mice for 
which the exact date of death is unknown are included, assuming death at 310 
days. The overall conclusion of this study is that there is very little, if any, 
difference in the onset of tumourigenesis between line 26 EBNA-1 positive 
mice and line 26 EBNA-1 positive/6c/-2 positive mice. These results indicate 
that there is no co-operation between EBNA-1 and bcl-2 in tumourigenesis.
6.7 Cross breeding to Ep-.Pi//i-l Transgenic Mice
E\i-pim-l transgenic mice were imported from Professor Bern’s laboratory in
Amsterdam. 5-10% of E\i-pim-l transgenic mice develop T-cell lymphomas of
by 7 months of age (van Lohiuzen et ol, 1989). Overexpression of pim-I co­
operates very strongly with deregulated c-myc expression in tumourigenesis 
(reviewed in introduction section 1.7e). A cross breeding experiment between 
both EBNA-1 transgenic lines and E\i-pim-l transgenic mice (designated line
87) was set up to investigate whether there is any co-operative effect between 
these two oncogenes in vivo. In the line 26 cross, there are 22 offspring 
(appendix 1.5). The representation of double positives at 18% is less than the 
25% which would be predicted. The 26/87 offspring were derived from a cross 
where one parent was hemizygous for the Ep EBNA-1 transgene (C57B1/6
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strain background) and the other parent was hemizygous for the E\i-pim-l 
transgene (F VB strain background). Given that the number of mice positive for 
the E\i-pim-l transgene only is also lower than expected (14%), this may well
be due to a low rate of transmission of the E\i-pim-l transgene, rather than to a
co-operative detremental developmental effect between the two transgenes 
(figure 6.15). In the line 59 cross there are 35 offspring, all of which are 
positive for the EBNA-1 transgene (since the line 59 mice used as parents in 
this cross were homozygous for the EBNA-1 transgene) and 13 of which are 
also positive for the E\i-pim-l transgene (appendix 1.6). The representation of
double positive mice is less than might be predicted (37%), however, given 
than the representation ofpim-1 positive mice in the line 26 cross is also low 
this may be due to a low rate of transmission of the E\x-pim-l transgene (figure
6.16). The line 87 mice were of the FVB strain background. Both line 26 and 
line 59 mice used in this study were of C57B1/6 strain background. All the 
progeny of these crosses were therefore FI hybrids of these two strains. All 
of the 26/87 EBNA-1 positive mice succumbed to lymphoma. The double 
positive mice were all euthanased with lymphoma symptoms before the age of 
12 months, whereas the EBNA-1 positive//?/m-/ negative mice survived longer 
(figure 6.17 a and b). The average age to death of the double positives is 284 
days compared to 369 days for the EBNA-1 positive//?/m-7 negative mice. 
However, the numbers of mice involved in this study are still small. The 
EBNA-1 positive mice from the line 26 cross with
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Line 26 X Line 87
EBNA1+/Pim
27%
EBNAWPim
41%
EBNA1+/Pim+
18%
EBNA1-/Pim+
14%
Figure 6.15
Pie chart showing percentage distribution o f transgene status o f offspring in line 26/ line 87 
cross
EBNA1+/Pim+
37%
EBNA1+/Pini
63%
Figure 6.16
Pie chart showing percentage distribution of transgene status of offspring in line 59/ line 87 
cross
line 86 (section 6.4) have the same strain background to the 26/87 offspring. 
Given the conclusion that the 26/86 mice do not harbour an E\i-myc transgene,
these mice can be used as a control for the line 26 phenotype in this FI strain 
background (figure 6.17 a and b). The average age to lymphoma of the 26/86 
EBNA-1 positive mice is 297days. Given the larger number of animals in this 
group it is probably more valid to use this as a control group (for strain 
background influence). Even using these mice as a control for the line 26 
phenotype, it is difficult to determine if there is any co-operation between the 
two transgenes, with only 4 mice in the double positive group. Only by 
increasing the numbers of mice in this study will it be possible to make a firm 
conclusion about any co-operation between the two transgenes. However, in 
the line 59 cross with the E\i-pim-l transgenics the latency to tumour onset 
appears to be less in the double positive mice than in mice with either 
transgene alone (figure 6.18). 54% of the double positive mice have succumbed 
to lymphoma by two years of age (average age of onset 466days), compared 
to 33% of the EBNA-1 positive/pw*-/ negative mice (average age of onset 671 
days). This could be suggestive of a co-operative effect between the two 
oncogenes.
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6.8 Summary and Discussion
A variety of approaches have been used to identify factors which co-operate 
with EBNA-1 in tumourigenesis.
An analysis of the level of RAG2 expression in RNAs from EBNA-1 
transgenics has not revealed any consistent RAG2 upregulation in EBNA-1 
expressing cells. It is tempting to speculate that, given that EBNA-1 induces 
RAG1 and RAG2 expression in tissue culture cells (Srinivas and Sixbey,1995), 
its oncogenic action might be exerted through enhanced RAG expression giving 
rise to an increase in aberrant translocations. However the evidence presented 
here does not support this. Not only is there no apparent consistent RAG2 
upregulation, but of 18 EBNA-1 positive tumours karyotyped, only two have 
been found to carry a translocation. This is a common observation in mice 
compared to men: human lymphomas often carry translocations, while in 
mouse tumours translocations are infrequent and polysomy more common (S. 
Silva, pers.comm).
The strong association between EBNA-1 expression and c-myc deregulation in 
Burkitt’s lymphoma leads to the speculation that EBNA-1 may act through, 
or in contrast in concert with, c-myc in tumourigenesis. It is possible that 
EBNA-1 can contribute to the deregulation of c-myc expression through 
directly transactivating the translocated c-myc gene (for example through an 
effect on the IgH enhancer), or indirectly through transactivation of another 
gene which subsequently contributes to the deregulation of c-myc (for example 
LR1, introduction section 1.7 and chapter 5). If any one of these is the
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mechanism by which EBNA-1 acts as an oncogene, then it might be expected 
that deregulated c-myc expression would be routinely detected in tissues in 
which EBNA-1 is expressed. Analysis of the levels of c-myc expression in 
tumour and non-tumour samples from Ep EBNA-1 mice does not provide any
evidence that c-myc expression is consistently upregulated. RNA was 
prepared from a number of different positive and negative animals. It is clear 
that there is a wide variation in the level of c-myc expression in non transgenic 
tissue as well as transgenic tissue regardless of tumour status. This is in 
agreement with published results (van Lohuizen etal., 1989). The RNA slot 
blot may not be a sensitive enough assay to detect subtle differences in c-myc 
expression between transgenic and non transgenic tissues. It may be that a 
relatively small upregulation of c-myc expression (perhaps a two fold change) 
can have a dramatic effect in the appropriate cell type. A comparative study 
of c-myc expression in age matched, strain matched positive and negative mice 
may yield more information, for example by preparing RNA from an entire 
litter of mice sacrificed at the same time. However it might be necessary to 
compare expression in cells which are synchronised with respect to their cell 
cycle stage to detect any deregulation of c-myc expression in cells expressing 
EBNA-1. Alternatively an assay which assesses c-myc promoter usage may be 
useful in detection of deregulation of the gene. In normal cells, c-myc 
expression is tightly regulated. It can be transcribed from either of two 
promoters PI or P2. In fibroblasts and EBV immortalisedB cells P2 is utilised 
preferentially (reviewed in Marcu et al. 1992), in Burkitf s lymphoma cells P 1
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is used at least as frequently (Eick and Bomkamm, 1989). An analysis of c- 
myc promoter usage (for example using an RNase protection assay) in EBNA- 
1 induced lymphomas might provide evidence of c-myc deregulation.
If EBNA-1 acts in concert with c-myc in tumourigenesis, it might also be 
expected to detect an upregulation of c-myc expression in EBNA-1 induced 
tumours. This is not evident from the RNA slot blot results, but again this 
may be due to an inadequacy in the assay. The levels of expression are being 
compared between different tissues, taken from different animals of varying 
ages and genetic background, and so the comparison is not necessarily being 
made between similar cell types. To address whether c-myc upregulation is 
important in tumourigenesis, it might be more valid to compare levels of 
expression between pre-neoplastic and neoplastic tissue from Ep, EBNA-1 
mice.
Although still preliminary, the results from the crossbreeding of Ep EBNA-1
lines with N-myc and c-myc transgenic lines are strongly suggestive of a co­
operative effect between the two oncogenes. The latency to tumour onset in 
EBNA-1 fN-myc and in EBNA-l/Ep-c-mj'c double positive mice is
considerably reduced when compared to mice carrying either transgene alone. 
Induction with pristane appears to have decreased the latency to tumour onset 
in line 26, and also to have led to some incidence of plasmacytoma rather than 
lymphoma. If one of the effects of pristane is to increase the likelihood of a 
translocation involving c-myc occurring in cells of the immune system, then the 
decreased latency to tumour onset may be evidence of a co-operation between
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EBNA-1 and c-myc. Whilst Southern analysis has not detected any 
rearrangements involving c-myc in DNA from pristane injected animals, this 
may be due to a failing in the assay rather than an absolute lack of c-myc locus 
rearrangements. Many of the DNAs used in Southern analysis were prepared 
from tissues (usually spleen) in which the tumour may only have been a small 
part. A genomic rearrangement in a few cells might not be detectable from a 
background of predominantly normal cells. An EcoRl digestion of the DNA 
was used for the majority of Southerns, it may be that use of different enzyme 
digestions would aid the detection of c-myc rearrangements. The karyotypic 
analysis being carried out in Prof. Klein’s laboratory will be important in 
determining whether there are any gross chromosomal rearrangements 
involving the c-myc locus (or other loci) in the pristane induced tumours.
It may be that the enhanced rate of tumour induction in pristane injected mice 
is due to some effect other than, or in addition to, c-myc rearrangements. For 
example it has been found that pristane induction allows the development of 
plasmacytomas in Ep c-myc transgenic mice (in the Balb/c strain background) 
at a rate much faster than in transgenically negative mice (Harris et a l, 1988). 
In the absence of pristane these transgenic mice develop lymphomas 
exclusively. One postulated explanation is that macrophages treated with 
pristane produce IL-6, which is a factor needed for plasmacytoma growth 
(Hirano et a l, 1990, Kawano et al., 1988). In the absence of pristane there 
may be insufficient IL-6 to allow plasmacytoma development. IL-6 transgenic 
mice develop spontaneous plasmacytomas carrying a c-myc translocation
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when bred into a Balb/c genetic background (Suematsu et al., 1992) .Whilst the 
induction of a c-myc translocation may be the rate limiting factor in the 
development of plasmacytomas, other factors have a role to play.
63% (5 of 8) of the EBNA-1 positive tumours analysed by karyotyping have 
been shown to carry trisomy chromosome 15, on which the murine c-myc gene 
is located. Whilst it may be that there is some other locus on chromosome 15 
which co-operates with EBNA-1 in tumourigenesis, it is tempting to suggest 
that the additional copy of c-myc is the essential co-operating oncogene. Three 
tumours from mice doubly positive for the EBNA-1 transgene and the N-myc 
transgene also carried trisomy 15. It could be argued that the deregulated 
expression of c-myc due to trisomy chromosome 15 would be redundant in a 
cell already over-expressing N-myc. However, the N -myc transgenic line used 
in the cross breeding experiment expresses the transgene to a very low level 
and the tumour phenotype is of low penetrance and long latency in this line. 
It is therefore possible that further expression of c-myc is important in the 
development of tumours. Further weight is added to the argument that the c- 
myc locus is important by the observation that none of the line 26fE\i-c-myc
double positive tumours carried trisomy 15. In these tumours the high level of 
c-myc expression provided by the transgene may have supplanted the need for 
trisomy 15 in oncogenesis.
Taken as a whole the evidence to date is strongly suggestive of a co-operative 
role for c-myc deregulation in EBNA-1 induced tumourigenesis.
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The identification of other oncogenes which are able to co-operate with 
EBNA-1 may aid in the understanding of what function EBNA-1 plays in 
tumourigenesis. Using Southern analysis to detect DNA rearrangements of a 
number of known oncogenes (bcl-2, p53, cyclinDl, pim-1) none have been 
detected in EBNA-1 tumours.
The numbers of mice in the crossbreeding with Ep pim-1 transgenics is still 
small and so the results are difficult to interpret, particularly due to the added 
complication of strain background differences. It is clear from the analysis of 
line 26 that the genetic strain background of the mice can greatly influence the 
transgenic phenotype. Line 26 EBNA-1 positive mice that are FI hybrids 
between C57B1/6 strain and FVB strain develop lymphomas at a reduced rate 
when compared to mice of the C57B1/6 background (figure 6.5a and b). For Ep 
c-myc transgenic mice, genetic background has been found to have a profound 
effect not only on the latency to tumour onset, but also on the nature of the 
tumour cells. In some strain backgrounds tumours were predominantly of B 
lymphoid origin; in C3H/HeJ mice tumours were predominantly of T 
lymphoid origin (Yukawa et a l , 1989).
Current results from the crossbreeding of line 59 and Ep pim-1 transgenics are 
suggestive of a co-operation between EBNA-1 and pim-1. The latency to 
tumour onset is reduced and the percentage of mice succumbing to lymphoma 
is higher among double positives. However, the result from the line 26 Ep pim-
1 cross is less clear cut. The latency to tumour onset in double positive mice is 
only slightly reduced when compared to mice positive for EBNA-1 alone,
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although the deaths of the mice are all clustered at an early time point. Only 
through increasing the numbers of mice in this study will it be possible to 
determine if there is some degree of co-operation between the transgenes.
It is possible that the different pattern of expression of the EBNA-1 transgene 
in line 26 and line 59 is a factor in the apparent different level of co-operation 
with the Ep pim-1 transgene. The EBNA-1 transgene in line 59 is expressed 
more widely (introduction table 1.2), including within the thymus. The Ep 
pim-1 transgene alone induces lymphomas of a T cell origin. The more obvious 
co-operation between line 59 Ep EBNA-1 and Ep pim-1 may be due to a
greater degree of overlap in the expression of the two transgenes. 
Determination of the cell type of tumours in the double positives from both 
line 26 and line 59 may provide clarification on this point.
Crossbreeding of the Ep EBNA-1 transgenics to Ep bcl-2 mice indicates that 
there is no co-operation between EBNA-1 and bcl-2. By comparison, there is 
a very strong co-operation between Ep c-myc and Ep bcl-2 in transgenic mice
(Strasser et al., 1990). This is further evidence that the oncogenic effect of 
EBNA-1 is not exerted through deregulation of c-myc (figure 6.19). It may be 
that EBNA-1 expression in a cell provides a similar function to the 
upregulation of bcl-2 to render the co-expression of these two oncogenes 
redundant in lymphomagenesis. It is thought that bcl-2 exerts its oncogenic 
effect through allowing cells to avoid death by apoptosis (reviewed in 
introduction section 1.8b). EBNA-1 may act on some other gene product 
involved in an anti-apoptic pathway. The mechanism by which EBNA-1
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protects from apoptosis may not be through bcl-2. Burkitt’s lymphoma cell 
lines which retain the cellular phenotype of freshly isolated tumour cells 
(group I EBV latency) are sensitive to apoptosis induced by a number of 
triggers(Gregory et al., 1991). Over-expression of bcl-2 in group I BL cell 
lines following gene transfer affords protection from apoptosis (Milner et al., 
1992). However, in this in vivo assay (lymphoma onset), the upregulation of 
bcl-2 is redundant.
A high percentage of the EBNA-1 positive tumours (56%) analysed carry 
trisomy chromosome 10. One potentially important locus on chromosome 10 
is mdm-2 a proto-oncogene which is a negative regulator of /?53. Mutation of 
p52> is found in some Burkitt’s lymphomas (Farrell et al., 1991). Upregulation 
of mdm-2 provides an alternative route to reduce /?53 function. Mdm-2 is 
located on human chromosome 12, and trisomy 12 is the most common 
numerical chromosomal abnormality in human B-cell malignancies (Offit et a l, 
1991).
By analogy with other systems, it is possible to speculate that if EBNA-1 
fufllls an anti-apoptic role in tumourigenesis in vivo, then it may not co­
operate with other oncogenes which fufill the same role (introduction section 
1.8, 1.9). So, EBNA-1 might not be expected to co-operate with other genes 
involved in apoptic regulation (figure 6.19).
The evidence suggests that EBNA-1 co-operates with c-myc in 
tumourigenesis, and may also co-operate with pim-1. The use of murine 
MoMLV proviral tagging experiments (intoduction section 1.6c) may identify
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further oncogenic partners of EBNA-1 (work ongoing in this laboratory).
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Group 1 Group 2
N-myc
c-myc
L-myc
pim-1
pim-2
pim-3
Group 3
' MoMLV- bm i-l \
Figure 6.19
Com plem entation groups in lym phom agenesis. Several oncogenes, p53 loss and M oM LV have 
been grouped according to their ability to synergise in lym phom agenesis in vivo  (review ed in 
introduction section 1.6, 1.8-9). For exam ple m yc  fam ily m em bers can synergise w ith pirn- 1 or 
bcl-2, but p53 loss and bcl-2  do not synergise. Not all com binations have been analysed. Given 
that there is no apparent co-operation betw een EBNA-1 and b cl-2{section 6.6, 6.8), and there is 
m ounting evidence for co-operation betw een EBNA-1 and m yc , EBNA-1 has been placed in 
group 3. (Adapted from W ilson, 1997).
Summary and Future Directions
The incidence of lymphoma in two different lines of Ep, EBNA-1 transgenic
mice is strong evidence that EBNA-1 is an oncogene. However, differences in 
penetrance and latency to onset of disease between the lines lead to a number 
of questions. Influences of the local cellular environment, transgene copy 
number, or mutation of transgene sequences could be contributing factors in the 
different phenotypes of the lines.
In both lines the pattern of transcription of the transgene is complex (chapter 
3 ), however, there are clear differences between the lines. In addition, in both 
lines there are transcripts which may contain cellular sequences. An analysis of 
the transgene insertion sites will be important in understanding the 
contribution of local cellular sequences to the observed transgenic phenotypes. 
Sequences analysis of the inserted transgenes could identify point mutations 
which may contribute to the different expression patterns, or which effect 
EBNA-1 protein activity.
EBNA-1 protein expression was maintained in a cell line derived from a line 26 
tumour even after 12 weeks in culture (chapter 4). Establishment of further cell 
lines from EBNA-1 induced tumours may be valuable in the investigation of 
the role of EBNA-1 in tumour maintenance.
The total level of transgenic RNA is higher in line 26 than in line 59 (chapter 
3), as is the detectable level of EBNA-1 DNA binding activity in line 26 
tumour samples (chapter 5). However, Western analysis has detected more
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EBNA-1 protein in line 59 tumour and pre-tumour samples (Wilson and 
Levine, 1992). Immunostaining of EBNA-1 protein in transgenic tissues from 
both lines at different stages of tumour development may aid the comparison 
of the relative levels and distribution of the protein in each of the lines at 
different stages of tumourigenesis.
The steady state level of EBNA-1 protein may not reflect protein activity. 
The level of protein activity (DNA binding) may be a better criterion for 
measurement of oncogenicity. Therefore, the study of EBNA-1 DNA binding 
should be extended to compare the activities in both line 26 and line 59 at 
different stages of tumourigenesis. It may be that the level of EBNA-1 DNA 
binding activity is enhanced in line 59 tumours. Comparative sequencing of 
DNA from tumour and pre-tumour tissues could identify mutations which 
‘activate’ EBNA-1 in oncogenesis.
Gel retardation assays have identified a factor(s) which bind both to EBNA-1 
andLRl DNA binding sites. Supershift assays using an antibody to nucleolin 
would identify whether this component of the transcription factor LR1 binds 
to both sites.
A number of lines of evidence indicate that deregulated c-myc and EBNA-1 co­
operate in tumourigenesis (chapter 6). Therefore, EBNA-1 may play a direct 
role in the pathogenesis of Burkitt’s lymphoma in conjuction with c-myc.
The crossbreeding of transgenic mice suggests that EBNA-1 and bcl-2 do not 
synergise in lymphomagenesis. In vivo EBNA-1 may have an anti-apoptic like 
activity, which renders the co-expression of bcl-2 redundant in vivo in
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tumourigenesis. Transgenic crossbreeding experiments in combination with the 
use of MuML V pro-viral tagging experiments may identifiy other oncogenic 
partners of EBNA-1, and further elucidate the mechanism by which it acts as 
an oncogene.
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Line 26 x Line 86
m o u se  num ber d a te  of birth d a te  of d ea th Age a t death Phenotype
ill looking, swollen abdomen, LNs and spleen large, liver slighlty large 
white spots on spleen and liver_________________________________,3.7.9526.3.94 464ds EB1+ myc?
26.3.94 26.3.96 730ds EB1- myc?
26.3.94 26.3.96 730ds
26.3 94 EB1 + myc?
26.3.94 EB1- myc?
sacrificed due to difficulty with walking, LNs large spleen 
spots, liver normal size but virtually white_____________26.3.94 ,3.7.95 464ds EB1 + myc?
263 .94 EB1- myc?
26.3.94 11.4.95 381 ds EB1+ myc? massive lymphoma, spleen and liver +++->■, LNs+
Animal was very slow moving, spleen, liver, LNs and thymus appeared 
normal_____________________________________________________26.3.94 17.5.96 782ds EB1- myc?
26.3.94 EB1- myc?
26.3.94 19.8 94 146ds EB1- myc? Thinner than littermates and hunched spleen and LNs slighlty large
26.3.94 15.11.94 234ds EB1+ myc? massive lymphoma, spleen and LNs huge, liver normal-slightly large
Swollen abdomen, massive lymphoma, spleen enormous, liver huge, LNs 
and thymus enlarged____________________________________________29.11.9426.3.94 248ds
tumour in large bowel, thymus spleen and LNs appeared normal, liver 
appeared pale______________________________________________26.3.94 10.5.96 775ds
26.3.94 6.11.95 590ds EB1- myc? swollen abdomen, very fat otherwise normal
animal looked ill. spleen was normal size but had small tumour attached to 
it, liver normal size but abnormal appearance, thymus slightly large26.3.94 264 .9 6 761 ds EB1- myc?
paralysed back legs, possibly due to blocked bladder, spleen, liver, LNs all
26.3.94 12 .12 95 626ds EB1- myc?
left axillary LNs were enormous, other LNs normal, spleen x2, thymus x2,
26.3.94 2 6 .4 9 6 761 ds EB1- myc?
mouse very thin looking, coat patchy & uneven coloured, quite hunched, 
LNs, spleen, thymus slightly enlarged_____________________________26.3.94 2.8.94 129ds EB1+ myc?
26.3.94 EB1- myc?
26.3.94 26.3.96 730ds EB1- myc? normal
26.3.94 30.12.94 279ds massive lymphoma, spleen and liver huge, LNs slightly enlarged
26.3.94 26.3.96 730ds normal
26.3.94
26.3.94 EB1- myc?
26.3.94
26.3.94 26.3.96 730ds normal
28.3.94 EB1+ myc?
Appendix 1.1a
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T ran sg en e  s ta tu sm o u se  num ber date of birth d a te  of death Age a t dea th Phenotype
28.3.94
28.3.94 28.3.96 730ds EB1+ myc? normal
28 3.94 28.3.96 730ds EB1- myc?
unwell appearance, spleen and liver large and mottled, large red mass 
attached to gut possibly lymphoid origin, kidneys slightly enlarged, LNs
28.3.94 17.5.95 414ds EB1 + myc?
paralysed back legs, abdomen swollen, spleen large, liver slightly large 
and mottled appearance, kidneys grossly enlarged and mass below them 
possibly lymphoid or ovary, LNs slightly large________________________28.3.94 7.12.94 253ds EB1+ myc?
28.3.9428.3.94 730ds EB1- myc? normal
23.4.94 23.4.96 730ds EB1- myc?
36 23.4.94 29.5.96 766ds EB1- myc? spleen x10, liver x3, thymus and LNs normal
13.12.94 EB1+ myc?23.4.94 234ds swollen abdomen, huge spleen and liver, LNs slightly large
23.4.96 730ds23.4.94 EB1- myc? normal
EB1- myc?39 23.4.94
20.3.952 3 .4 9 4 331 d s found dead, spleen and liver huge
23.4.94 EB1- myc?
24.4.94 14.2.95 296ds EB1+ myc? swollen abdomen spleen- liver
24.4.94 14.2 95 296ds EB1 + myc? swollen abdomen, spleen and liver gigantic. LNs normal
24.4.9444 24.4.96 730ds EB1- myc?
unwell appearance, swollen abdomen, huge lymphoma, spleen and liver 
enormous. LNs slightly enlarged__________________________________45 24.4.94 13.10 94 172ds EB1+ myc?
46 24 4 94 191ds Swollen abdomen, spleen enormous, liver and LNs enlarged
24.4.94 24.4.96 730ds EB1- myc?
24.4.94 ,24.4.96 730ds normal
24.4.94 21.12.94 241 ds quite fat but otherwise normal
24.4.94 11.4.95 362ds EB1 + myc? massive lymphoma, spleen and liver ♦+++. LNs
16.12.9424.4.94 236ds massive lymphoma, spleen and liver huge, LNs enlarged
24.4.94 24.4.96 730ds EB1- myc? normal
24 4.94 24.4.96 730ds EB1- myc?
24.4.94 1.11.94 191ds swollen abdomen, spleen enormous, liver and LNs enlarged
16.5.9616.5.94 730ds EB1- rnyc?
16 5.94 13.695 393ds massive lymphoma, spleen and liver enormous, LNs enlarged
Appendix 1.1a
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m o u se  num ber d a te  of birth d a te  of d ea th T ra n sg e n e  s ta tu sA ge a t dea th Phenotype
16.5.94 16.5.96 730ds EB1- myc?
16.5.94 7.12.94 215ds EB1+ myc? swollen abdomen, spleen huge, liver huge. LNs slightly
16.5.94 13.10.94 150ds EB1+ myc? Swollen abdomen, enormous liver and spleen, LNs slightly large
16.5.94 7.12.94 205ds EB1+ myc? swollen abdomen, spleen enormous, liver enlarged
swollen abdomen, massive lymphoma, spleen and liver huge, LNs 
enlarged________________________________________________16.5.94 24.1.95 253ds EB1+ myc?
16.5.94 31.1.95 260ds massive lymphoma, spleen enlarged, LNs huge, liver normal
16.5.94 ,20.3.95 308ds EB1+ myc? massive lymphoma, spleen and LNs huge, Irver enlarged
,20.5.94 20.5.96 730ds EB1- myc? normal
20.5.94 EB1 + myc?
2 0 .5 9 4 20.3.95 304ds EBI-i- myc?
20.5.94 20.5.96 730ds EB1- myci
20.5.9620.5.94 730ds EB1- myc?
2.12.9420.5.94 196ds swollen abdomen, huge Irver and spleen, LNs normal-slightly large
20.5.94 20.5.96 730ds EB1- myc? normal
2 0 .5 9 4 13.2.95 269ds unwell appearance, massive lymphoma, spleen, liver LNs all large
20.5.94 20.5.96 730ds
20.5.94 13.2.95 269ds EB1 + myc? found dead, carcass canablised
20.5.94 4 1.95 229ds Enormous liver and spleen, LNs slightly enlarged
20.5.94 19.1.95 244ds massive lymphoma, spleen, liver LNs enlarged
20.5.94 ,4.1.95 229ds EB1 + myc? huge lymphoma, spleen enormous, liver enormous, LNs enlarged
Appendix 1.1a
Data collected on 26/86 progeny. Mice positive for the EBNA1 trangene are labelled as EB1 + 
mye'f Notes in the phenotype section indicate the gross observations made on the animal at the 
time of its death
Appendix 1.1a
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m o u se  num ber d a te  of birth d a te  of d ea th A ge a t death T ra n sg e n e  s ta tu s Phenotype
59/86 1 4.4.94 4.4.96 730ds EB1- myc? normal
2 4.4.94 4.4.96 730ds EB1- myc? normal
3 4 4 94 4.4 96 730ds EB1+ myc? normal
4 4.4.94 4.4.96 730ds EB1+ myc? normal
5 4.4.94 4 .4 9 6 730ds EB1- myc? normal
6 4 4.94 4.4.96 730ds EB1- myc? normal
7 4 4.94 4.4.96 730ds EB1+ myc? normal
8 4 4.94 4.4 96 730ds EB1- myc? normal
9 4.4.94 4.4.96 730ds EB1- myc? normal
10 4 4.94 4 4 96 730ds EB1+ myc? normal
11 4.4.94 4 4 .9 6 730ds EB1- myc? normal
12 6.4.94 10.5.96 730ds EB1- myc? normal
13 6.4.94 17.11.95 590ds EB1- myc?
Back very scarred, possibly due to fighting or mites, spleen, liver, LNs 
normal
14 6 4 .9 4 6.4.96 730ds EB1- myc? normal
15 6 4 .9 4 14.2.95 314ds EB1- myc?
Back very scarred, possibly due to fighting or mites, left S I LN slightly 
enlarged, otherwise normal
16 6.4.94 6.4.96 730ds EB1- myc? normal
17 64 .9 4 6 4.96 730ds EB1- myc? normal
18 6.4.94 15.4.96 740ds EB1- myc? tumour on lung, other tissues appeared normal
19 6.4.94 6.4.96 730ds EB1+ myc? normal
20 30.4.94 30.4.96 730ds EB1- myc? normal
21 30.4.94 EB1- myc?
22 3 0 .4 9 4 30.4.96 730ds EB1- myc? normal
23 30.4.94 30.4.96 730ds EB1- myc? lymphoma evident, LNs huge, spleen x10, thymus x10, Irver normal
24 30.4.94 30 4 96 730ds EB1- myc? normal
25 30 4.94 30.4.96 730ds EB1- myc? normal
26 30.4.94 30.4.96 730ds EB1- myc? spleen x5, other tissues appeared normal
27 21.5.94 21.5.96 730ds EB1- myc? normal
28 21.5.94 21.5.96 730ds EB1- myc? normal
Appendix 1.1b
Line 59 x Line 86
mouse number date of birth date of death Age at death , Transgene status Phenotype
29 21.5.94 21.5.96 730ds EB1- mvc? normal
30 21.5.94 22.4.96 337ds EB1- myc?
Animal swollen. Abdomen blood filled, liver pale coloured, spleen 2x 
normal
31 21.5.94 21.5.96 730ds EB1- myc? normal
32 21.5.94 21.5.96 730ds EB1- mvc? normal
33 14.6.94 EB1- myc?
34 14.6.94 EB1- mvc?
35 14.6.94 EB1- mvc?
36 14.6.94 EB1- mvc?
37 14.6.94 EB1- mvc?
38 14.6.94 EB1- mvc?
39 14.6.94 EB1- myc?
40 13.6.94 EB1+ mvc?
41 13.6.94 EB1+ mvc?
42 13.6.94 EB1+ mvc?
43 13.6.94 EB1+ mvc?
44 13.6.94 13.6.96 730ds EB1- mvc? spleen. LNs. thvmus normal, large white tumour mass attached to liver
45 13.6.94 EB1- myc?
46 13.6.94 EB1- mvc?
47 13.6.94 EB1+ mvc?
48 13.6.94 EB1+ mvc?
49 13.6.94 EB1+ myc?
50 13.6.94 EB1- mvc?
51 13.6.94 EB1+ mvc?
52 17.6.94 EB1- mvc?
53 17.6.94 EB1- mvc?
54 17.6.94 5.6.96 718ds EB1+ mvc? spleen enlaraed (x5). all other tissues appeared normal
55 17.6.94 EB1- myc?
56 17.6.94 5.6.96 718ds EB1+ mvc? spleen enlarged (x3), all other tissues normal
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57 17.6.94 EB1+ mvc?
58 17.6.94 26.4.96 679ds EB1+ mvc?
axillary and lateral axillary LNs were huge (left side), other LNs were 
normal, spleen was slightly large (x2), liver normal
59 17.6.94 EB1+ mvc?
60 17.6.94 EB1- mvc?
61 17.6.94 EB1+ mvc?
Appendix 1.1b
Data collected on 59/86 progeny. Mice positive for the EBNA1 transgene are labelled as EB1+ 
myc?. Notes in the phenotype section indicate the gross observations made on the animal at the 
time o f its death.
Appendix 1.1b
59B Pristane study
m o u se  num ber d a te  of birth d a te  of d ea th Age a t dea th T ran sg en e  s ta tu s Phe notype
59 B 92 23.3.95 17.11.95 208ds EB1-
huge abdomen, m asses  of fluid in peritoneal cavity, spleen 4-5x 
normal, liver 2-3x normal, som e nodules, thymus enlarqed
93 23.3.95 EB1 +
94 23.3.95 EB1 +
95 23.3.95 4 .3 9 6 346ds EB1-
LNs and liver normal, spleen 2x normal, lots of fluid and nodules in 
peritoneal cavity
96 23.3.95 EB1 +
97 23.3.95 20.11 95 211ds EB1-
spleen, stomach and pancreas fused, m asses  of fluid in peritneal 
cavity, liver fused to diapraqm, thymus huqe, LNs normal
98 23.3.95 17.11.95 208ds EB1 +
huge abdomen, m asses of fluid in peritoneal cavity, spleen 4-5x 
normal, liver 2-3x normal, som e nodules, thymus huqe
99 23.3.95 EB1-
100 23.3.95 20.3.96 363ds EB1 +
spleen 10x normal, thymus 10x normal, lots of fluid and nodules in 
peritoneal cavity
101 23.3.95 6.11.95 197ds EB1 +
enlarged abdomen, spleen 3x normal, liver 2x normal, lots of 
nodules in abdomen, very little fluid, LNs 2-3x normal, thymus 
enlarqed
102 17 4.95 22.4 96 392ds EB1 +
spleen 2x normal, bloody fluid in abdom en, liver pale with white 
spots
103 17.4.95 22.4.96 392ds EB1-
animal swollen and ill looking, spleen 4x normal with pale patches, 
tumour attached to liver
104 17.4.95 2 .6 9 7 EB1-
liver slightly large, small tumour attached, spleen 2x with faint 
white spots
105 17.4.95 EB1-
106 174 95 EB1 +
107 17.4.95 6 .6 9 5 40ds EB1 +
Severly injured genitailia due to fighting, spleen 3-4x normal, LNs 
at site of injury large(5-6xnormal), other LNs normal to slightly 
larqe
108 17.4.95 EB1 +
109 17.4.95 20 11.96 EB1 + spleen 3x, tumour qrowinq on liver
110 17.4.95 EB1-
111 17.4.95 20.3.96 338ds EB1 +
spleen enlarged, thymus enorm ous, lots of fluid and nodules in 
peritoneal cavity
112 17.4.95 EB1-
113 17.4.95 10.12.96 EB1 + spleen 3x
114 17.4.95 EB1-
A ppend ix  1.2
Data collected on pristane injected 59B progeny. Notes in the phenotype section indicate the 
gross observations made on the animal at the time of its death.
Appendix 1.2
Line 26 x E^bcl-2
m o u se  n u m b er d a te  of birth d a te  of dea th Age at death T ran sg en e  s ta tu s Phenotype
1 30 4.93 11.4.94 346ds EB1+ bcl2- mouse euthanased, probable lymphoma
2 30.4 93 3 5  94 368ds EB1- bcl2- euttiansed due to slight unwell appearance, normal
3 30.4.93 25.11.93 209ds EB1+ bcl2- found dead
4 30 4.93 2.12.93 216ds EB1+ bcl2- swollen abdomen, enlarqed spleen, liver, LNs
5 30.4 93 29.11.93 213ds EB1- bcl2+
unwell appearance,thin,LNs slightly enlarged.spleen slightly enlarged, liver 
normal colourinq possibly sliqhtly large
6 30.4.93 29 11.93 213ds EB1+ bcl2+
mouse very ill.thin,appeared partially paralysed, LNs sightly enlarged, 
spleen sliqhtly enlarqed, larqe white nodules on liver
7 30 4.93 10.6.93 41ds EB1- bcl2- found dead, carcass cannabalised
8 13 .6 9 3 27.5.94 348ds EB1- bcl2+
massive abdominal tumour attached to gut (mesentenc LN?) spleen 
enlarqed, fluid in peritoneal cavity, LNs sliqhlty biq, liver normal
9 13.6.93 2.8.94 415ds EB1- bcl2- Very fat, otherwise normal
10 13.6.93 24.5.94 345ds EB1- bcl2+
huge abdominal tumorattached to gut ct (mesentenc LN?) liver and spleen 
normal, other LNs possibly sliqhtly larqe
11 1 3 .6 9 3 2 8 9 4 415ds EB1- bcl2+ very fa t, otherwise normal
12 1 3 .6 9 3 14.1.94 215ds EB1+ bcl2-
mouse found dead, externally nothing obvious, spleen enlarged, liver 
enlarqed and discoloured
13 13 .6 9 3 25.7.95 772ds EB1- bcl2+
massive abdominal masses (mesenteric LNs?), spleen 4x normal, liver 
enlarqed,pale, some clearfluid in abdominal cavity, other LNs 2-3x normal
14 13.6.93 28.2.94 260ds EB1+ bcl2- lymphoma, enlarqed spleen, liver and LNs
15 13 6,93 19.7 95 766ds EB1- bcl2-
Swollen mass at neck, pus filled,enlarged superficial cervical LNs, spleen 
3x normal some clear whitish fluid in abdominal cavity
16 13 6.93 2 0 5 9 4 341ds EB1- bcl2- appeared fat and unwell, spleen and LNs 2x normal
17 29.7.93 2 2 .9 9 5 785ds EB1- bcl2+
Box flooded, very ill, very thin, spleen small difficult to find, liver normal 
size apart from uneven nodule on one lobe, large white mass attached to 
qut (mesentenc LN?), thymus huge
18 29.7 93 6 4.94 251ds EB1 + bcl2- Probable lymphoma found dead
19 29.7.93 17.11.95 841ds EB1- bcl2- normal
20 12.8.93 11 4.94 242ds EB1+ bcl2- lymphoma, found dead
21 12.8.93 6.6.95 602ds EB1- bcl2+
swollen abdomen, spleen enlarged, large white mass attached to 
qut(mesentenc LN?)
22 12.8.93 3 5.94 264ds EB1+ bcl2+ Lymphoma, spleen, liver, LNs all huqe, thymus larqe
23 12.8.93 28.2.94 259ds EB1+ bcl2- lymphoma, enormous liver, huqe spleen huqe LNs
24 11.3.94 21.11.95 620ds EB1- bcl2-
liver mottled and enlarged, whitish mass at top of middle lobe, LNs slightly 
larqe(1 5-2x), spleen 2x normal
25 11.3.94 15.11.94 249ds EB1+ bcl2- lymphoma, spleen and LNs enlarqed
26 11.3.94 4.8 94 146ds EB1+ bcl2+ massive lymphoma, spleen, liver, LNs all huqe
27 11.3.94 21.11.95 620ds EB1- bc!2- normal
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Line 26 x Epbcl-2
mouse number date of birth date of death Age at death Transgene status Phenotype
28 11.3.94 1.11.94 235ds EB1+ bcl2- LNs huge, spleen huge, liver normal, thymus huge
29 11.3.94 21.11.95 620ds EB1- bd2- normal
30 4.4.94 23.5.95 414ds EB1- bd2+
mouse found dead, spleen, liver,Lns all normal, haemorrage at neck, 
source not clear
31 4 .4 9 4 4 4 96 730ds EB1- bd2- normal
32 9.5.94 1.11.94 176ds EB1+ bc!2+
lymphoma, unwell appearance, swollen abdomen, greying fur, huge 
spleen, liver enlarqed, LNs sliqhtly larqe
33 9.5.94 9.5.96 730ds EB1- bd2- normal
34 9.5.94 9.5.96 730ds EB1- bd2+ normal
35 9.5.94 3.7.96 730ds+ EB1- bd2- normal
36 9.5.94 1.11.94 176ds EB1- bcl2-
unwell appearance, greying fur. spleen slightly large 1-2x normal. LNs 3x 
normal
37 9.5.94 9 8 96 730ds+ EB1- bcl2- normal
38 9.5 94 7 EB1+ bd2- 7
39 9.5.94 7.12.94 212ds EB1+ bd2+
swollen LNs and abdomen spleen huge, liver enlarged, LNs huge, thymus 
enlarged
40 17.5.95 29.4.97 712ds EB1+ bcl2- normal
41 17.5.95 7 EB1- bcl2-
42 17.5.95 7 EB1- bcl2+
43 17.5.95 21.11.95 188ds EB1+ bd2+
very thin and hunched, spleen 2-3x normal, liver normal size but very 
yellow coloured, LNs 5x normal, fluid filled sac around thymus and 
enlarqed lobes
44 17.5.95 20.11.95 187ds EB1+ bd2- spleen liver and LNS qrossly enlarqed
45 17.5.95 7 200ds+ EB1- bd2+ Animal missinqfrom colony 18 1 96
46 17.5.95 29.3.96 317ds EB1- bc!2+ small swollen mass on head, spleen sliqhfly enlarqed (2x)
47 17.5.95 26.9.95 132ds EB1+ bcl2+ swollen abdomen, massive liver and spleen, LNs sliqhtly enlarqed
48 6.6.95 4.3.96 272ds EB1- bd2- spleen 1.5x normal
49 6 6 .9 5 20.4.96 318ds EB1+ bcl2- found dead
50 6.6.95 7 280ds+ EB1+ bcl2+ animal missinq 25.7.96, survived to march 1996
51 6.6.95 7 280ds+ EB1+ bc!2+ animal missing 25.7.96, survived to march 1996
52 6 6 9 5 19 .296 258ds EB1+ bd2+ bad loss of hair, cervical LNs and superficial inquinal LNs enlarqed
53 6.6.95 18 10.95 134ds EB1+ bcl2- found dead, probable lymphoma
54 6.6.95 7 280ds+ EB1+ bcl2+ animal missinq 25.7 96, survived to march 1996
55 6.6.95 12.12.95 189ds EB1+ bcl2+ LNs grossly enlarqed, spleen 5-6x normal, liver enlarqed
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mouse number date of birth date of death Age at death Transgene status Phenotype
56 6.6.95 17.1.97 EB1- bd2- spleen 3x. thymus enlarged, cervical LN enlarged
57 16 8.95 ? EB1+ bd2-
58 16.8.95 11.6.96 229ds EB1+ bcl2- LNs large, spleen 10x, thymus 5x
59 16.8.95 2 6 4 9 6 183ds EB1- bd2- Liver appeared abormal. thymus slightly enlarged, spleen and LNs normal
60 16.8.95 ? EB1- bd2+
61 16.8.95 30.4.96 187ds EB1+ bcl2+
All LNs hage, spleen grossly enlarged (x20) and infiltrated by tumour, 
thymus enlarqed (x10)
62 17.10.95 17.3.97 EB1- bc!2- normal
63 17.10.95 ? EB1+ bd2-
64 17.10,95 25.11.96 EB1- bd2- spleen 6x. liver sliqhtly larqe
65 17.10.95 ? EB1- bd2-
66 17.10.95 6.6.97 EB1- bd2- spleen 4x, LNs enlarqed
67 17.10.95 6 .5 9 7 EB1- bcl2- normal
68 17.10.95 31.3.97 EB1- bd2- normal
Appendix 1.3 
Data collected on progeny from line 26 cross with Ep-bcl2 transgenic mice (line 85). Notes in the 
phenotype section indicate the gross observations made on the animal at the time of its death.
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Line 59 x Epbcl-2
Mouse Number Date of birth Date of death Age at death Transgene status Phe notype
59/85 1 27 9 94 3 5 96 554ds eb1- bcl2-
Liver slightly enlarged (x2), thymus enlarged (x5). otherwise 
normal
2 27 9 94 20 8 96 692ds eb1- bc!2-
spleen enlarged x7, thymus x5, animal appeared sickly, LNs 
normal
3 27 9 94 11 9 96 714ds eb1- bcl2+ normal
4 27 9 94 11.9.96 714ds eb1- bc!2- normal
5 1 8 8  94 9 500ds+ eb1- bcl2+ animal missinq 25.7.96
6 18 8 94 21 8 96 730ds+ eb1- bcl2- liver sliqhtly enlarqed, otherwise normal
7 16 8 94 9 6 9 5 297ds eb1- bcl2- very fat. spleen normal, liver enlarqed and pale
8 16 8 94 2.8.96 716ds eb1 - bcl2- eye infection, spleen sliqhtlv enlarqed but not infiltrated
9 15.12 94 9 eb1 - bcl2-
10 1 512  94 4 3 97 730ds+ eb1- bcl2- spleen 3x, liver pale
11 15 12 94 11 9 96 635ds eb1- bcl2- normal
12 61  95 4 3 97 730ds+ eb1 - bcl2- normal
13 61  95 16 8 96 587ds eb1- bcl2+ Lymphoma, spleen 10x, liver enlarqed x2 and mottled, LNs normal
14 6 1 95 4 3.97 730ds+ eb1- bcl2- normal
15 6 1 95 ? eb1+ bcl2+
16 6.1.95 5 1295 333ds eb1- bcl2+
found dead, carcass part eaten, large m ass on gut; difficult to 
distinguish gut from mass, LNs ~2x and dark, spleen ~3x
17 6 1 95 2 1296 696ds eb1 - bcl2- spleen sliqhtly large, liver sliqhtly larqe with white spots
18 6 1 95 17.11.95 315ds eb1+ bcl2+ swollen abdomen, mostly fat, spleen normal-2x
19 6 1 95 24 3 97 730ds+ eb1- bcl2- testicular qrowth otherwise normal
20 61 .9 5 ? eb1 - bcl2+
21 6 1  95 22 8 96 593ds eb1 - bcl2- animal scabby (mites'?), tissues normal
22 1 5 5 9 5 12.11 96 545ds eb1+ bcl2- enlarqed LN at throat, otherwise normal
23 15 5 95 17 2 9 7 643ds eb1 - bcl2- normal
24 15 5 95 29 4 97 714ds eb1- bcl2- normal
25 1 55  95 23 1 97 617ds eb1 - bcl2+ sac  due to fighting, blind, other tissues normal
26 1 5 5  95 ? eb1 + bcl2-
27 1.8.95 9 eb1- bcl2+
28 1 8 95 3 3 97 579ds eb1 - bcl2- liver sliqhtly larqe, other tissues normal
29 1.8.95 ? eb1+ bc!2-
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Line 59 x Epbcl-2
Mouse Number Date of birth Date of death Age at death Transgene status Phenotype
30 2 1 9  95 14 8 97 692ds eb1 + bcl2- spleen 3x and almost white, LNs enlarged. Liver sliqhtlv enlarqed
31 21 9 95 6 5 97 561 ds eb1+ bcl2- small abdominal tumour, other tissues normal
32 21 9 95 10 9 96 354ds eb1 - bcl2+ animal appeared ill, tissues looked normal
33 21 9.95 eb1 + bcl2-
34 21 9 95 10.12,96 415ds eb1- bcl2+ spleen enlarqed, with attached m ass
35 21 9 95 1 3 1 2 9 6 418ds eb1- bcl2+ spleen enlarqed
36 21 9 95 eb1 + bcl2+
37 21 9 95 2 12 96 407ds eb1+ bcl2+ normal
38 21 9 95 2 7 3 9 7 521 ds eb1- bcl2- normal
39 21 9 95 eb1 + bc!2-
40 21 9 95 eb1- bc!2-
Appendix 1.4 
Data collected on progeny from line 59 cross with Ep-bcl2 transgenic mice (line 85). Notes in 
the phenotype section indicate the gross observations made on the animal at the time of its death.
Appendix 1.4
Line 26 x Eg.pim-1
M o u se  N um ber D ate o f  birth D ate  o f  d e a th A ge a t  d e a th T ra n sg e n e  s ta tu s Phenotype
26/87 1 2 6 .6 9 4 1 4 2 .9 4 235ds eb1+ pim-
Lymphoma, Lns obvious, swollen abdom en, sp leen  +++, liver 
normal, LNs +++, thym us ++, anim al quite fat, fat deposits  on 
abdominal organs
2 26 6 .9 4 9.6.95 348ds eb1+ pim-
Lymphoma, sp leen  enorm ous, Lns huge, liver en larged , large m ass  
in abdominal cavity (m esenteric LN?) thymic LNs and  possibly also 
thym us enlarged
3 26.6.94 4.7.96 730ds+ eb1- pim- normal
4 26.6.94 1 3 3 .9 6 626ds eb1+ pim- LNs enlarged, liver 2x, sp leen  4x
5 26.6.94 4.7.96 730ds+ eb1- pim+ normal
6 2 5 .7 9 4 24 7 9 6 730ds eb1- pim- sp leen  3x, thym us 3x, liver and  LNs normal
7 25.7.94 24.7.96 730ds eb1- pim- normal
8 25.7.94 20.4.95 269ds eb1 + pim+ m assive lymphoma, sp leen  and  liver +++, LNs +, thym us+
9 25.7.94 1 5 4 9 6 630ds eb1- pim+ normal
10 25.7.94 10.5.95 289ds eb1+ pim+
M ouse found dead , t issu e  badly d egraded , sp leen  and  liver 
en larged  5x normal, but not huge
11 25.7 94 24 7.96 730ds eb1- pim- sp leen  3x, other t issu es  normal
12 2 5 .7 9 4 24 7 9 6 730ds eb1- pim- sp leen  5x, thym us 2x, o ther tis su e s  normal
13 2 5 .7 9 4 2 4 .7 9 6 730ds eb1- pim+ normal
14 2 5 .7 9 4 31.8.95 402ds eb1+ pim- m assive lymphoma, sp leen , liver and  LNs huge
15 2 5 .7 9 4 13.6.95 323ds eb1+  pim+ m ouse very thin, sp leen  3x normal, LNs enlarqed
16 25.7.94 2.5.96 646ds eb1- pim- found dead
17 27.9.94 9.6.95 255ds eb1+  pim+
Swollen abdom en, anim al very fat, sp leen  2x normal and  mottled 
ap p earan ce , liver normal, LNs normal-sliqhtly enlarqed
18 27.9.94 9 .6 9 5 255ds EB1+ pim-
Swollen abdom en, m ouse very fat, sp leen  enlarged , LNs slightly 
large and dark red, thym us possibly slightly en larged  but hard to 
distinguish from surrounding fat
19 27.9.94 ? 600ds+ EB1- pim- anim al missinq 25.7.96
20 27.9.94 21.8.96 703ds eb1- pim- normal
21 27.9.94 18.7.96 721 ds eb1- pim- found dead
22 27.9.94 11.9.95 349ds eb1+  pim- m assive swelling of abdom en, sp leen  and  liver both huge
Appendix 1.5 
Data collected on 26/87 progeny. Notes in phenotype section refer to gross appearance at death.
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Line 59 x Eppim-1
Mouse Number Date of birth Date of death
59/87 4 7.9611 6.94 730ds+ liver and spleen normal, small tumour m ass attached to lungeb1 + pim-r
11 6 94 730ds+
massive abdomen, liver huge and discoloured, spleen enlarged, 
LNs enlarged, some bloody fluid in pentoneal cavity___________11 6 94 31.8.95
11.6.94 26 4 96 685ds eb t + pim- massive abdominal tumour, spleen x3, thymus x2
bad scarring on back, ?mites?, spleen slightly large, LNs slightly 
large_____________________________________________________2 8 6 9 4 2 0 4  95 297ds
28.6.94 2511 94 150ds very fat, otherwise normalebl-i- pm-
9 7 9 4 12 7 96 730ds+
9 7.94 20 6 96 71 Id s liver enlarqed (x3) with spleen enlarged (x3)
Liver slightly large (x1 5) and pale with white spots, spleen 
enlarged with white spots (x4), Lns huge________________2 0 6  969.7 94 710ds eb1+ pim-
9 794 12 7 96 730ds+ eb1 + pm- normal
97.94 12 7 96 730ds+ eb1+ pim- normal
12 7 96 730ds+ normal
9 7.94 1 2 7 9 6 730ds+ normal
Liver enlarged 2 5x, spleen enlargedl 5x, abdominal cavity filled 
with fliud_________________________________________________9 7 9 4 221 96 562ds
25 7 94 24 7 96 729ds normal
16 25 7 94 animal missing 20 5 96e b 1 +  pim +
2 57  94 2 4 7 9 6 729ds eb1 + pm- nomial
animal sickly looking, having difficulty walking, spleen, liver, LNs 
and thymus looked normal__________________________________25.7.94 26 4 96 635ds
Lns and thymus normal, spleen huge (x20), liver normal, large 
abdominal tumour________________________________________19 2 5 7 9 4 3 5  96 642ds eb1+ pm-
21 8 96 730ds+ all tissues normal
9 8 9 4 20 8 96 730ds+ Small growth on back all other tissues normal
9.8.94 21.8.96 eb1 + pim- normal
spleen 20x, thymus 20x, huge abdominal tumour filling peritoneal 
cavity, liver and LNs normal__________________________________9 7 699ds
9 8  94 21.8.96 spleen 5x, small abdominal tumour, LNs normal
11 9 94 11 9 9 6 ebl-i- pirn- normal
2410.94 2011.96 normal
2410.94 20.11 eb1+ pim- normal
2410  94 21 11 96 normal
2410 94 30 10.96 normal
2410  94 2111 96 rectal prolapse othetwise normal
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Line 59 x Eppim-1
Mouse Number Date of birth Date o f  death Age at death T ransgene s ta tu s Phenotype
un-numbered
female 24.10.94 91  95 77ds eb1+ pim+ found dead, spleen, LNs and thymus enlarqed
31 1411.94 17.11 95 368ds eb1+ plm+
hairless mouse from birth, bad scarring on back of neck,?mites?, 
spleen4-5x normal, liver 2-3x normal, LNs sliqhtly larqe and dark
32 14.11 94 9 eb1 + pim-
33 14.11 94 9 eb1 + pim-
34 14.11.94 21 11.96 eb1 + pim- normal
Appendix l.6 
Data collected on line 59/87 prc»geny
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